var title_f36_24_37248="Radiographic features of meningioma";
var content_f36_24_37248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Radiographic features of meningioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 146px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A: Tail sign: tapering dural thickening (arrow) due to direct tumor involvement or reactive change in the dura, is a highly characteristic sign of meningioma; note also the small reactive arachnoid cyst, reflecting the extraaxial site of this lesion (arrowhead). B: Reactive cerebral white matter changes. C: Bony reactive changes: reactive bone sclerosis, reflected in the increased vault thickness (arrows) is seen most commonly in patients with multiple meningiomas associated with neurofibromatosis type 2; invasive tumors such as these can cause problematic extracranial facial masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Whittle, IR, Smith, C, Navoo, P, Collie, D. Meningiomas. The Lancet 2004; 363:1536. Copyright &copy;2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37248=[""].join("\n");
var outline_f36_24_37248=null;
var title_f36_24_37249="Normal versus anomalous pancreaticobiliary junction";
var content_f36_24_37249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Normal versus anomalous pancreaticobiliary junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37249=[""].join("\n");
var outline_f36_24_37249=null;
var title_f36_24_37250="EUS fiducial pancreat tumor";
var content_f36_24_37250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    EUS-guided fiducial placement for pancreatic tumor localization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image of fiducial within the pancreatic tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37250=[""].join("\n");
var outline_f36_24_37250=null;
var title_f36_24_37251="Polypectomy APC Endosc";
var content_f36_24_37251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Argon plasma coagulation following colonic polypectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 183px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAC3AioDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Xq9Y2pcl2GVHXnt/nFRWsQbLduhyvbiuxtdCt4NEgv8AVL42Ud3uFpCkJkkmXBxLjOBHuXaTncD2NZttuyNo2WsjJsbVpbiG2topJriVtkccS7ndj0AA5PNdZqPg3V9G0b7frunLYh5AiR3dykdySD8wW3zubOQfoM9KzPDtzdabFC9si2N9G5lS/gVhdKGXaVD7sBSCf4c89auyMXZ7l5Xku5BukmmYySue25mJJ/PtUrlsbqM2+yJEtNKsfDX2+W9ml1dWCnSo7VtqrkAu8x4BxkgKDnj3reuWstL0i4s76ygXWZFjudPu7K6SaJIXx8tzgnccZKrjPNcW7mV/vODxg44pyAJHsVcAsTwO9TzJdDVQba1Z3Oi32jz3SW93czWnmMI4VSFXEkpICqWYhUUknLHgd6u6trGoadfXul3yrDq9nGkaL5yzpGWG5QrgkEYIyB0PFcJAPMyMIDsI+boRjB+uRU9vuUbNg29Au37v096xfLbY6km5Xex6Y+v6TPFY/ZILiMhP9N+0lSpk29YcHON3Y8Y6VGZ7S+kh2yLBCJFSeeXgQp3kx1cD2rgowGXBbHqMVbMcsGky6mxU2cEy27Hd828ruGEzkrjPI4yMVNuiNYwUFuztTZaZcfboIJlmjWYrbzsoV5lx/rAo4UE5wp6gA96o39g8D3SLBbmW2t1uGurKVSvkngLt67uu9QTnPIrBuIbvS7qCK9i8pprSO8jTcDmGXJVuOhOOnUd6YksuA6MeCNoA6MRQ9GXTb0ad0bUn2nTra7W5+z29xBBFcW1vMMSXwkYgpEqnAx1OcY/OoLCzh1LU7bToRdTzMskht7SPzpwQM58snnnHIOMHPNZX22T99FsjHmSLI/ybHZR95UkH3QwyCcN64rVV7K10S317SZxFqs07WdvpdzKXvLTjiZZU2kjGTuYAAEDB601DmIrVXC677dipfxy+VLY3o+e1kkUNtO7zMgyAswDls5BVyxGOMA1mTWEX2NJFG5G+beTyK3IhbwBTrkmuXtpFNvmNs6GXzXXl2Ln5cgcyAMSBzgAUXE9tJdFb+dtKs5LVp47qC0MjHr5ZkUEglgMNIg25A46mpjeTuthc6UXFrb7jkVgFvH5jLJFdRSJPb3fmMojKdtvQknBDkjbjHOah8Q3OqeJ9cju9QmkvtVvHjtw7KoeVicIDjA7gA4HGK7wx2Wn6da6hbaQzfZba0uPOEpu7RZ5RmQ3quASzKy7UUBeQc9xJoPhvTrzStK1KdhBJcyO9y+pQyR6XMzysPssMgGY2A6OCy8cHjFdKWmjPPnJN3aseZeIfAWp6dpM+oxyWl0ltI0V9BbSh3s3VipDjuOM7lyMEc1w5r2/xtLc6Z4atfDC281hJpss0iRTEfaooZM5iMgAE0B3OAyHDdwMAV4vdwmGQjHBPHH6VtdLQ4+SVrvUrGkpTSVRmFLSVPbRCVsHNJuw0r6EcaPI21FLH0Fe9fBT4Tw6lpr61rtit3POrLptpK37reMHzJgp3Bem0EYPJPGM5fwO+Hf8Awlmr/ar2LOkWfzyQ4+a6YYJiUdSBkbj2BA6kV9j+F9Kt7RVnVEEhXaGVcFQMgIfYA4A7YxUc7b0OmnCMFzz18ifT9LsY10pjY2cBtY2W1SCMBItw+bZgcAjtWzBnYcqVOTwagCRwB1kbMbMCkZH3fpUqlzLlwBHj5fXPvTWm5jK79CSNkZA0ZBU85FOphBJwpK4OTx1qOSTZMuSwG08HG3Pv3zVkJXJ6jlTcpxgN2NJ5ipvLbV/iP+NNDJcxpJHskX7yHPHsaTGk1qVlhmyzsAWZuFDYwPc9zSNaeakojuGj3fL8oG5D7ZqUx3Zef54NrEGL5DlOBnPPzc59KniWMFyioGJy+0ck+9TymntGtUZk9jhBGJJSOhcD5qx5bVdO+YJI67iTIv3lbsWA5Ofoa6vzN/EZOSM5I4FNmtoZ2iaaNHeM7kYjlTjGR6dalwNqeKlDSWxxJ11NOMcd7DcqZsEXEEfnW6tnlcjlfowHtW7DJBfxb4CksbZyQeh9KuXelJJK00Z2SkbWYDPmL/dcdGHP4VzWuaLqdrM974buLeG72rutLhSYZ9p6bhynHAPPbpWco9zsjOhWtZ8svw/4Hr+RZuNLKETRkyYySCOQPT3Fc5qGmKZj8pMb5QjAwD/kV1egazDrUNzGYZLTUrVgl3ZTDDxNjIP+0p6hhwRTbuzVjJtOJSoZosdR/eFZNW2HCcoycam6/r+meT63of2lPI8oyB8nAxztryi804xTTMExhsbxznGDjHtwa+k760DK20lWI6gYINec+J9EWKdnSBhEzMZyVyIlx8r8dFzwSeBXDUlKFTm6HdTqKS5WfM/jDRDYzNdW4zbSHnHG1v6Z/SuTkGCa+gNX0Tabmznj3Kw3BWXIye30I6GvFvEukNpd2VQMbdyfLY9vVT7ivUoz5keRi6PJK62MSiiiug88KKKKAHOhULn+IZFPjHTjNFxJ5szPjC9h6DtVrRoUutTt4Z8+SzfPt67RyaTLgrux13gPwy+pSi8uU3W6tiKNukrev+6D19Tx616VpWjLeafq+sOA+k6JMiX7g8jcM7wP4gvGQOeeAavGxfSNGttsSxS3MSi2iXgqCPl+gAOa9C+H9lL4d8H6rpsEGnXQvZIZF+1Qb1kCqqukq55JCnawz97kcc425nY9J81CmnTV22V4dHW0h0yDy1+2W/mPqE8gBEknBjWEDgRjkgkZxjPOa0b+B73UTFHNsnaILLNt3FGPt356+1JeodG0MRPO82pX8rGJ5W3lSSWZ/wDdXOB+FXXnstFsGnvSQ4xKFT5pJH67QO5Pvx61fNbQxbbSl1C206GQtmOJI4x+5SUBjHICQzb/AO63Hy9sck1YntLeNglyAk7DzRbrGDK4HJKoOW9ePSs6HxGLueFLeOC2iI3SPcEHYW55IOB+Ga51rqK+8Sw2emj7RGpJuXeQLtlBwFkcYOT1CA5xzSdQytJuz0O012/ttOt2e0MN0/kGeOHkNIen3cZAz+QrKtdQ1nUtEtjaWVvHrLTIbiMxloBGG+ZV/izt6dOcc4qK91azNs1tq7NYPLdRfZoVUpOjRY3u7u2PKYqAwAXcCQCTUmn+MJNC8V26QTNqFlFB5N+Lf95IZmKD7RMNuIIUw+WU4PUjvVRu1oYyaS2L7aXqGoeKprCO21V4hbGb/SThYVJwoRz8qtxyuDuxnoDXlmpqBqogbV9Qhlsp5YJ5YXZ3MqHLKULbW5wBghe9em+M/HyR+Nxd+HlW5W209rWO+8wvbPJK6NnCE7wirnsCWIyMV5V4m0T+z/8AVSP5MjG5D+V+8urhhlyiL0yeRgBQPSnJSt7x14SMW9VoYFj4nN3qqTeIYLSSSQiOS/aEo8EYzhdkeFI65wvU5961rfxZAbj7RbIHaJP3izl1aePJHB3FVcD256E1n+G/Ph1GaWF4Pt8kEqxKzoWaTbwdrfe549zxkVzbWVzJbvc/ZpkCuIpiYyArnkKRjg4zWfmdLS2R7tos7arY2t9pErXlm0WCIyCef+eqDlXH/wCrNZOs6fC+p2qziT7HMjRERRGSRJ88NsHJXqDjpXkWj3l5o98NR0y4ks7vDRieFirDPXOOo9jkV6r4e8fz6np1/eeIl0cNbr5SXCMsVyXwNpMOcyJkgFk5B7NTbvoYuLh7xj6l4dkjuHt2AeSP5W2/OCfUEda5PWPDzBJFkiIK9cr09q+htK0iO5tLK6tg0Vwsat5bgrtkxlh8wDKeeVIB9QKyPEHh95rO4OxfMVt4Hb3WiKViPrKbtI+U9UsHs5mGNydVJFYc8W08HjFe0eJfDscqStGC6kZIxyv1/GvLb6weEyMV+RGCbjjqQT/IGmY1qdtUYmOuOwz1ox6kf99VIYSJNqjJPAGKTy/9qP8A76H+NI5y3boJspGuJc+oC7cE9+h9663SPCWq3Oiw61Baf8Sx3kjEzSKAXQcrgnIJ6KMfMemas2Vvo3hiwhkvraHWtXuIg5s3kP2WCNhyJGRg5mHdcqF9SeKyrrU7m6htoZZ5nW2TybfzW3GFM5CJ/dA9BUtW3OyG+hrPb29rlJZoQ2BgK+c8dfWq5e1dSvmIwyN+G71ThSK2zc3pOSNoQElpCKxLu5le/afIVyckL0rOxupvY3isOxmjfbnkBj2/xozLIysibhjGR0JqPSbcX1yC+fLXgA8846/TNdxBZR4CkZO38zj+VYSqWO6jh+dczONEjQSETxuisOC2cEZ9au2syFQUcBweu6uu/s3K7F5Rh3bh8evt9axb7SoUQfuiGLE704YHHQjoR3qVVT3N1hGl7ruVcqy7pHwRkAg9P/rVH5q/Ksn7yPIJQkkNzyPxHHrTbWyYb2kbzCmSyO2Nw9j/ACHU11UFhawae9wsMkRlgWSCXb8s2Wx8nqAQQcVM6yiKMZL4jIlvkkvL25ntyGkwlsHldxBGBgKA3zMAPukn5fcU23e2kixIMfMSXU/MvHGQe2a37eERC58/Mquu1SzfNnHf1HYj0rn7jTtlwREGQ9QEbIz6Uo4jn3NI0uxfmsnWFFuFJVlDDd244APpjBrOdJItxwDkYOTz/wDqp2n3Myp9naeTYpaRIt2VUnuF6DPfGM1fkkjkiXqGKjcfQ45U/T1rW5k4yW5m2WrXtlq9rqlrdzrqNs5kiuS+50Yrt/iyMbeMYxin6TrEFvBdQ39sJ5JG8yCWQeYImJLMQpYA73xuJ3DHRTmmSQ71MkYPI49vyqlKMYWRSQRyOtUtrGE6aTudbb/YvEsUj6hJdNrkl4bt9Uhi+0LbWwXDRvCuGEajBXYDjj7orqPDkMemeE9Ov01tmtrqKWOO8v7cvpl7axzMI7KYN/qHJ5DAgfMQcnFeTafd3mkXv2vT7ie3kwVLxSFSVPVSR/CfSuy8K+KNR0ywltdFuzFazHZLp8qrLbSKckqY2yFBJOSuOvINa05KL1OKtSlU0i7eX9f1uU/inp2qtrFxfasyx3DymNLOS9Nw8KMvmbozwfs7EtsPIBBBNeZX9mJYdy9x8ynqvvXsXie/0648M25trGzmu7jd9ou5JZTc6XNuz5MUbMf3AXO0lip5PBwK4G/tPLclARxzg9Qe1Octb3ClTbhZqx5rIu12X0JFNqe+UpezqeokYfrUFdK2PNejCu3+FPg+68aeIU061PlxKRJc3JGRBEOre5PQDufbNcRX1H+yWjnwhrmAvltfKG4wWYRjaM+gy3B70pbF0o800j3Lwr4bsdOstMtLCD7Nb6WCLQqfmUnO4k/xbsndnqfoMaWr+JLaw1QadYFJdYuvn8oHhVHG9vTj86w/Gni2Dwppn2e2CzavNGTbws2AP9tz2UV4NZeMb2ylmlFyJ9UnlMk16R+8Deinsvt0rGVSNNan0GX5W8VepP4ei7/8DqfTFisdpqFxqGpXAOUCvK7YVcdvTFU9Z+JvhzTJRH9qN02MkW434PpnpmvnUXWs6wA7HULuKVzjYGaMt3HHAPtWnL4X1aHSFvTYzyJ0kSNSXiOeCyjnn2zipWI/lVz1P7BoOSlial+lloj0HxB8Z5mUpoWnrEM/667bJ/74H+Ncbd+OfEGo6pZXF7dXCQW8itMbSPcyRE4d1XnJxn29q562hure9dFikjuYl3MGBR4R/eK9eh9D1rZ0bVp9Et/7U0KMJervt7tpMyKEbGzco+4c5weM4xSjUnPrY9OGW4bDwtQpq76+vm7/ANdDr/ih4hFlb6afDniee6hvsNPaEKxVAuVkztBTkcq3XPAGDXBJ4119MmLV7iLPaNgo+nSrPjHX4tcsNNbcBdW8TJcHH+skJyGB7rjpnkVxcm4Ln5gDxUV604P3Wb5fgIUqPJUV3d7pf5LsdbceOPEdzEIptbvWjHA2yBT+Ywa6Lwt4o1fVL+w0qzDz377nL+cVaYKMnd2GMcnvxXmjytcyKwVVYKEKwoFBAGM4H8Xqep71s+GNYuvD2tW+rafKFuIgUyw3K6H7yMPQ4HTpUU8RO+rNcRg4+yapQXN0Wyv8j1l/iR/Z815bXsl9Bewt5UkDJzG2Ooz17H3B4rpvA3xL0zXZ10+7b7JfHAiMvyrcfTsGz/Dn6V8/+LNdufEGv3OragyfaZlVFWPhERRwqg89ycnuayI7jPDZOcdauWLszzZZBQxFD348s326P9f69T7ZBDdO1MkjV1wR9K8P+E/xMNuV0fxTeO8TOqWl7IdxBJx5cjfUjDH6GvdK6oTjUjdHxGOwNXAVfZ1Pk+5xPiXQ5pbuLVtFdLbXrZTHDI5wsyZyYJP9g9j1UnI7itLRdYg1i1W5WJ7aYHZNDL9+GXo0bjsf5jBHWr1/cLHqUdo5AM6F4xnltpG4Ae2QfxrG1LT5raeS/wBPWV51TZLbqwVbpB2b/bUfdbr2rKS6G1NqrFRno+j/AE9PyfzHajGFuDtGCO39KxdUs0mhdgOChjYZ+8p6qfatK5vIpbgRpJI7NGHBZSCV7j6j061WRiwZScge/wDn2rlqQT0Zu4SjG7PKPFGlvJCqD9xOg2I3JCqDlc+wHFePeKbFLuF4bqMo3PGeQfUf5719J+L7QS6TPKuQ0Q8zj26j8q8O8ZW4nUhAElX5w3quOn9BRCap2iyr+1hZngt1C1vcPFJjcpxxUNX9bYPqczAEA469egqhXpJ3VzxJrlk0FFFFMkcBnAUEk16n8O/DawRi9mjD3Aw/I+6AQenfnH1ri/DemeZcRzTrkYDqPxIz+leyaPiwDiRkX7OguJGDZXhSVG7oRnFRJnfgqV3zM6RWfVPEkkk0vnvDjc+cfvWUbuBwMADgccmvQ9Li2KEdsDq59sf/AK643wJaMttDLcgfaJh50oIwDIeen41peN9ah0rQ54mkdJZwEVI/9ZIpIDBBxk8+o4HUVgmejWs2oLoU7bUYtZ1/V7ppGEsUW21/iiZMfuzwemeW71nXF+unWTXHii+jmvJYjIqRgMQBjPy5Hl7uwJJAycUvhXTo0uY5bVWaB7bDonyRq/OWVecZG3OSec44rM8SQRRQfZLy1MtxM4lthkKHkBwCw67QO54PTPas+Zt+Rz8sZOyZV+2XGvX8EdtaGC2ZPOj3S+TsK8ff6KmcHJAYgcV6ZpOl6dbw2elBLa714kSXhCOIYJ2+5InAZS+DiQnPHJ5rmLCDVrDUFupSbfUDFEZkuCFh81RtDmHAUlVwq89D9K2bV7fUNZ1C6Sci8uYFhuGtJyrKynKkrzkEjABzt9TnFNSWxjUg9k9DnpdGibSINdtLCefT9cZIY5RMZXs51m8vyirNl97Zzjdt2kg4qbwj4cWXxVqWm3Z+0m3T7SptoyzSQMu2Q84bAPyGLkk8gHrV2xjvNPikkuoYrC6ORHJA7QNHvkDOqn5hG0hHzED5s4JHUbGs65d6ujvcpcafGbZp47kfuprN41YvcW6ruMhKsFKbsnHYE10Kotkc9SlK/wCpijw3a3I09tPBmstNWX7TeCdVutQQkgIxYfKsfKgkEkp2wa5i4gkM8trHJfPDLOPJhmxuA2ks2chQMdMZBxyR0ru9a1SXS9RurPU7G7vbbUzFfPBppbz4ZGUYhl2gtDA2A2Ad27fgsCa5WWGK38IMb+6kh1LTJ5oxaXE2HgsZH+5au42vMo2DD8gnkDirabKoT9lbmRz2jWOna5q1zEkdmbW1tTcNPO7QrEEZQRHuzubLAgDAz37m7Noepvey3qXk9xqKR747uOSRZZ4m4G4SYZCRwV56EV2fibRLHTb7TNMubT+ysxl9N2bVlt/K25dWyfMnO9QNpYnoAK09IMumWCXtzGr3suYZNSvJQiPGnKvJIciNckqABu35GOCaxkjrjWTvNa+R4Hf2UlvPNFOpDNkhQMYY+3as10MbIXUb17MOQK9c8f2VrqM2mXWn+ZZ/8JBepaQTXKmKNTuyJM/fCSYwrYBwd2Aa5H4jxWr688dho9voyWTNayWcDbyssbHe0j/xswZTnHTGec4qKdrsmdVSa5FuWPh544u/C97G9xdztpKZD2THehDnLuOrB84O78DkV9JaVf2OuKyGWF5wmZQjDByvDccY5A4zg9a+RbC2e4nSK1Wa5YQPNMsMXMQT7x91AwS/A7Vv+DfFd54ZFrNZMJLWKZikYbAIYZI+h60X7kVcLGrHmhoz0vx7o66JdtdMzBXAiZSvCKTwOOuSa8X8b6G8FzLlcPF8rDuCRn+tfTv2618a6V5siQfbLaNJl2kkYfO0/jgj868u8T6M6XEL3SBPtIfyQSD8w6g+5A6HtzSuzKlPmXJPc+cryApkOvUZAPXHrVTY44HSun8R6cbO9mjAwuSy8Y4rBKcnIH5Ve5zSjyuxsWFtcXen3uqGC5uUgObqYRFo4i5+Uu/bJz1x075pbTyot91cKAqYCIc/vHx0FUdHluZTLa280kcdyAsyCQqkig5AcdwCM81Ld3kM95KLcH7DBlYcnqO5/HFYPud0U72GXNzPcSvcXBy3QccAegHbpWXcM3mksMYOP1rXlnFtcK0sQYoCixzcgHvxntVW6gMth9qikhIQ4eFTh0HADkdwT6dD6URuwk0jd8OzmJn2+mQceteg6MwmMbH5gOSvcfWvL9CnK8A8sCuM9a9C8M+Y4hkCnyyThj/EO+Pxrgqqzse3hXzROxls9xbAOB6DrUb2bLBOrIMSoEchckDgjnsfpWnp5BjETKdx6ZPNXvsoZMhWWMDovc+lc82pWSOmLtozg9R02OCRFt8+XIq+amMjOOjf54pjpcpZxWyz5hhcmBJSzLAO+0E/jgY5rrL6wXy02x5YYwM/07mq8lhbSI+5XMnARs+vtRZ7NltJrUyb0wi1to7cObgESSPIPvL6AA/5NMSxW4jAVtj7McnHze5/rV2DS9kpjQLvfIy7hQPqTQskSRFGAEpVVZD94A9GHuaytKGiJUbKyOSvbJizQBQkkQYk9ww/hyOtLp1wkqmOYBJlIwMfeHrmuguIYnuRGVTEnVTJs3Ac/e7HjjFYlzZRA4dGjwSQxbPHvXRTqhKHOWWs1hk85Rgt0cdVNUbmxBiLxnLq54xjcKsiSaBDFLvmtsZ3qfmB/r9Kn2JJYzOhi8xGEsJDEmdNo+TuM5ycnHcHFdCn2OSdNx3OYuLZkBKjI747VViea1nE8RIk3ehH51211aWN9ov2i0eX+0EkycYEJhPqOu8H+IZBz261z13a7dzhCFz8y5yB6/UVsmcTs9i1ZXUV9ZOxysoADKPTuF9qqCPaqghi4JUdgq44/HNZj7rSVHjZvLBB6/pW6k8dzAsuV8zC7huxj1NVa2w0+jPINWG3VbwDoJnH/jxqpV/XQBreoBen2iTH/fRqhXctjwZ/Ewr6G+Afi6z8F/CzxJq14EklS+C21uTzNKYxtX6dyewr55rX0a5wnkTSEQKxkCZ4LEAce/ApSdlc0oW59TqdV8Ra54i1S6v769ZrqcF5CxKq4ycLjpgcAAenrXR+BNN/t4q7yrDAx8vzXHAfuDXnuqambh2WAssJ6jPWvTf2edUtINev7XUJMCS3Z4hIf3ZYdQ/sRn8a46tPns5H0OU4qUK3LvdM97+E1pJareaXOy/abRwWMLZikQjKsp9cdRXqC6eGffGSjHO4+teHad4itdO8TR3ujGOK2lAWeFCds6jv7OPX0r2nw3rltq0KvDuDYw0b8EVtCKWhWc0a8J+3to1+PmZ2o6SuoxXctxaRmZVMK+eMiVAcjJHIBP5Vwmu6No91peuDUh/ZUFsEaC8kUC4jkbnymKnEsZwMc55I4IFeztGfLPlfKa8e1/4fy3utXMAuZU0+7dpoYuWS2uMffbP8LHjAx+latKxlleLUm4znypar5b/h69fR+ITLIkjAIqmL/W4YMDnuPUfTpmt/RI4vEGkw6FFZ2ba0XVbK6YlGIJ5RyODgZwTk9qzHtI01Saz1BpbMrM0Mo27jG4OOQSOPx6GoJYHgYYJkSTcEkhY/vAvXaeDkenUVxppXdtNv6/rc+9naaSTs90/6381fYhW5ksXns5IYW8t2UkjlXHy7lcc4BzgdKv3Ul5ceFvtkliFsVuBEb5Y8KZiMYZvU457Z468VTEkdvC7SyO9wsgKxkgoqgZ5BznPFakXjG/i8A6j4UV4fsF2zHMibmiDNuZF5xtJyfUZOD0xCkkrN6GeKddRUsPBSd9bu33HKyyKHAUkLnGDz9arSTOrsMYx146VteMtT07WLy1n0vR4NGSC1WKSGCXeJnB/1nQYOOO5PcnArBF0fKMbBXQtvII5Jxjr1x7etcNSyla510K0qlNSnBxfZ2/Q0LWRp7SYsI2hTaj72AyGPHHUj1wDivoj4MfEBdQuZvD2o3Uk3kIp0+5uF2yzoFG5H5OXBzjuVGTzmvmWAHflFZtoJOOcDv06Vu+H9Rktp7j7OsRNzbtbuZUV2Rc5ym77je456elbYau4SSPNzbLYY+k0/iW39an2lPDFdPFKAkgUOmQBnBGCM9unP0qnpGnG20iG0Esr+R8qO+dxUdASfbj8K8l/Z/wDEiHVtd0q+ndZbqZbm1WRy247MOAT/ABcBj65Jr3KvVi1U95H51jaNTA1Hh5bK1vx/zZwOthtMu2vLhlFmAqyZ4MT5wG9wSQDUZyLy4UoASfT+LoR+FbHjWzS88PahsUvdQQsUCn7z4+UfyrjfCOpJqek2sspJk8v9444zJj5uPqK5pqx6dD99h3U6rR/mjTvlDxurYIKkdK8L1y1WSO7hkGJIGIDY5Pf+tesatr8dpew2s6ubhofOZVBwFGct9BjJxnA5NeY6/JFNqkF5buz2dzaeaMZ4JP8Ak81g1zGKpSpptnzp4qga2125ibGRtPHoVB/rWTXR/EJdni29UHIwmP8Avha5yvTh8KPEqO8mwoooqiD0nQIFj1GwiIyiRRbwejLufIP1rtbpR9geFFwt1coqoDyql84HrgcZri9KdftQY/eNuiLnsfm+Ye4rt9LYy6zolqW5JZ5G7vhewrOex6uA7nrOmrtRUjUb8hc9ya8o8QagNf8AFt5doRNa2jtb2kZY7UjQ4Yrju5yc+nFeia7rB8O+EdX1lCgltoD9lVzhWlc7FHvjcTj2rwvwNqdvpGr2EOqMzaUzr5xJ+43UMT6butZqDtoKtVSlY9qSBNKuLe9sJmgh8lJUQyHyzn+/2znjHWsvxZrvmzf2gQ0dsEWB7sNnzZi2GVl6oF6Z9x25rVvvCj6iLibSrxxLcgyfMQIw45yq9t3ryOARivOY31PSdauILi0fdeWjxXUEEgy6tw0isMgup+bHc+lZuN9GZwkr3jqztbfUL7VPD/2K5uo766t5VlF4rZngOcCNgevHRsgkDkGul8Py3DyXE6hFvC4XcpDNIufuuDzz/eNc74W+zSaei28spIufM8nauWkA2q/TIOB8w6A9KttHqtxZeImtInV7RIpJdgVTIXPyiBcbmICjKFlTPPJJrJK8tzRqysdXfNFqVjKZwwtLeZTLA0YZAOm7PUEHgZ/GtWC5We/kjuYrWVoggglibKlP4WY/ptzg1Y0/SJZ7N495LrGu6RePtR7SEdVzz2xUNn4XNswWCYtb3TM+pQEYWZccOO4ZT3zyPStIK25i3B31PPPG2rpbXsWoacRJDDeH7XDHH9oM2VAGRJ8ohXaQMkENkqRmnj7J4jg037fEgu7eZtSuLrUGMscSFWOxSfk8soqqVkKgkYGOtUfE+kXGha3NY6Jk2+rFZ4mEjM1qkYIULJ2Uk5JPygEA8ZNdX4Y0WxsLyLQtLj1LUtO+2DUJpru3aFi6rgxTTFdk0ZLbht4+THzA5ro6aCqNJq1yDwjpEcxF5PeavY6jfXK3Fjc3env5cMKBfNjji3OsXyjClj0bKgCtr4j38lnon2ewkmtXmJii2xhljUHPzEnq2eAMknNbdtaarpFrqXmS3N4128xJaRsAOQECJ9yMqpYbNpDFQSwyapGwsP7N0PThHHJpdnjTnvUcyS28wAVY5Y1yA+TkvnAOegNc9ROezFGo1LmlqeeaO0F3pks9/c3mk6pcn7LqV5I8ZOn2TAlUg3/IFJAZn++ueMkDFmLwJaa819aWF1HaaelvavZmK2USKqKw2l2UNJG78+b0cfSut8T6MlvbrqGiaVHqd6sCyQoI9yzQKeXO7hyATiLOTnIqXw/9iis9El057i70a5syIL6ZQGDMVbaiAblhHzbt3CEIBmri5NWtsEpRjLnT3PnLXtFuNMiE0xXymd4QwyrblONrr/AG528kMAc4rBV2Awx4r2f4qW8I1+B4H2W3lQzXSSxb4YVlYpHc7eN3G7KnjgE1wkPha3Y6lZm4YXdpbm5iEKee06g4wpDYZQPmJHK960udP2eY9T+AGqW1x4atbQyIb21uZo7mIfeEeC0TEdxyeegPpXRePvD32SK91a0ieSKSMSzKOQrAcED6dcV434csJ/DGo/2nbXLJrVpaDULUDabXUbcY82En7ysAeR8wyM19F+D/ABBaeI9GiubVWwFZVDA/KcfMhz94D1pNWd0efKbhPmR8zeOtJ+06aNSgAK7BI4z6jqPUV5h9mLcjoea+nfEmjW8LXNpDGER0cICOBkE8e3PSvnKQCJ2jIOUJXp6VcTabU9UVo44dP8HHUYr63e9vJWtfsqkrPAAM78YwUYcZB68VkWpCptzycdKbcysba2tznagLY+veokbBJ9/Xms2ro1hdSd2bFrqZg03UNOeC2mt7sxszyxAyxFDkGN+qk5IPYioNX1G61SO1N35RFlALaIxwpGdgJI3bQNzcn5jkmqjAK7gurZA5U9cjOKthFkiQLnONuDjls9vbpU3aK5E3ch0yYxS9SAeB7GvcfCFssttFFCAqpGDnOAPUfWvGJrQQRhCQXYEg9Mc969i8AXINiFOBJGAcn6cY9+tceJs2mergm+Vo7RE2kH5VHfitez2yRlY87oxuJ7Dnqay5PlgMn3sqWA7irWmbWniTzRGr5+dunTvXnVKns3dHfGN43LM9uH3gPnB3Bu4PWsqS28iGcBcqSGGPvBu/FbqghsKChAOQ3OaoXMTyGUxEFscKTgnpnH0q3VjKN7miTehkuig7pVwxG0cdT9D3qpPAXj8t42EC5Y3KoGZPlwVGeD165rpba2F6HWUgsGVXK4L574J6HAqlBYyIssQlaRELtFs+UR98gHPPr71HtlFWlubRijnJrIxw3UV6j28scRwAN0pORtKDpkjseOtZ725jnMMir5rRiQAf3T3H8q7CKz/eyTy5dm++38TDHXrxVa+0zdZrMdo3SiM4GSp9M9OQentVRtJXiaSilucveZazgtFANtCSwGwBg59SOo+tV7GJVLwMT5Ujbun3G7kd+fyrp5dLWL9yRsyCwzyDt4PNYmp2ps7u3uIVLgEEr1HX+VXtoYzpqS0LWo2L3dtYwzy3BEEcsVlGJRHCpbBKltp+XIBx0HQYzXN3aSafei3vUkEbYG5wAyNjlTjj1PevVrfTIrnRgpA+XLq4/vY6fj0rmdV0Yz5ykTSsoQmQ4DD+6CfusOoP4VpF1KbTeqPGTg7q1jzrVNPHzbGzH647dqw4Zntrgq24xg7WI7E9q7W7s2tUlgjQ3EzzKi5jO6GLu6kkHJOBgg8Z6VyepRCK6ZjjaSVb0HpXZGdzOUGtTzzWTnV74+s7/wDoRqlVnURjULkf9NW/marV6MdjwJ/EwqWLvjrmoqlh6Gh7Dp/EWotpVy/LBflz65H9K0vD2pyaVqlveRE/u2BZQcZXuKy1ANTxjBrCdmrM9LDuUJqcXqj6Di0N7iC1vNKljn0+8USRuCMoSOVYDuCcZrrfCeq6v4XFpfauJH0KWQRy3OMy2j9gw/uHjrn614j8N/Gs/h25SKZPNsi+QR96LPBx7Y6ivpxNY0jVvCE97YXUE9o8YWaRcHYM4O8dj9azpxV9D6upmCxFOMJRuno+6/ro/wAD0yy1OOeyhuFdJYpQGSSMgqwx1HsaazRXmJUb5G45GDkHvXiFr4gvPhxqqaRPML/w3MnmwKjAtAG5zGc9BnlT68U+H4qquvyTPbhdP2hPKd8t/vADoeeeta+0W0nZnjf2FWbcqOq3T7rt6nofi7wVaa3eJfxC2hvgUWV7i2E6yxj+BhkH2yDkCmaho2nWcNrpT6cXtTuS1zho1YgkrjqrYJ5HBHU5rOHxV8OwJD5lxdOJI9zN5Ocex5/Wo77xxC+taTLZoWW8cWMenXKbZXkkwVnUDJCAdcgZXkHirstWghSx1NKNVNRje19P6/y7HnfxU0rSdANhFp0EUd35UjSW6INnljgFs8k5z1zmvJ2Z/K3HcVQ4BPTJrpfH1xqs3ibVIdanSW+tZ2ikKDCfL02g84wRiuVl2hvn5X1XvXkYualOy6H3mXwcMPFylzO17+uozcGkXzSSoIGMc49BU75ysBjUJGxbIA34PYn6dKhby5H/AHKFFz90nJPvVuyhLxSPGCDGwyT6HjmuZJ3sjqUVa7IJWjFxL9mWVIiTtVzubHoSMA/lTYm+dSrc+9WLm1aEkcdMkjtVaHasybuUyN2D2zyBUu6eo3FI6rwXrh8P+LNL1Zvmht5cygrn5GG0kDuwBOOetfY2nXi3tusqH5WAZSerKRkHHbPpXxhctpEb6o1huntWVEtlusiaMtyWG07SVxjng56Zr3P4LajcavoFlpVxevC2lyJdK1vIN8kWTiKUH+HntzgCvUwk3Tbgz43iTBxrwWJircujv2/4f8zvPF9+2nxsGifbdTwWsBUAh5JGwc+wA5NchY240/WNXtAhht47t3iDDjDIrZ/MmvQfEunrfx2hyVkglEkbdVDAdxXE+O1ZNNacNslR1kO3gSE8bW9sHH1ravZNt9DxMtqRlFU19rf8LP8ArucX8TozH4f1S+UBJIhFLBPn5kbcFk/4CVJB7EcGuIhWdpoZ54kit7iyVrSKPOIkVvLZTn1wG9geK9EuzLeeGgh2h48bywyNhOGU/gcY9qwvEFrHZpBFAAIEDRIoH3Mrnj0Gaxp2bujpxEuSDpve/wCh8zfEtBH40v0ByF8sZ/4AtcvXVfE7/kdb/wCkf/ota5WvRjsj5efxMKKKKZJ3+lzqtzGpzkxIc49Ca9F8EL5utXNwwyYYhCh9O5/pzXmOkNmdB/sL/WvTvh0+bRpGPMkznPtnGKzmj0cNK0C58btQC+HNA0sffurp7t8d0jXAyPTcx/KvJQFcMHAIbPGOua7X4wytJ40trcn5bXTogCTyu9mY/wAxXFop3e+O1XBaHNVfNI7/AMG/ETUdCggtblDf2VunlQhn2yRJnhc/xgehx9a6/QfFOmavJcyXOLeRGU5SMLJ5WSWxk/KR3YZyOOK8ZjBxjPNXod6OsiMUkQ/Kw6j/AD6UpRTCnoe+WsAtoI9VLWyQszFjCP3SnPyuOm4HI6c1i3PlWurWFzcTrEYLrYNyeaY0mb97IidTjjo2ACcDrXMeEdaeGTT/AA8UP2aa7UQW8jkRw5JLDPQgnkDtnFeh6x4atdbmnt7m4Nipj221w4HyRbsuqsePm4DBh05rklBKWux1Rnypp9TsvBFneahpej3WoTBZIrqZnuIzlr1MFIpmwflBXny8bcnOBiulm1Ga01iO0CxtpQixM/PnJITgEDGNpHXJz0wKzdFtJNM0ZLeykEkyKBEpJIA9Pl5xjPAFamlamviab7TawGOC3eS3eeQY46Mqdd4JC/N9305BrWLUndHC92+hnXnh+01CK3uBEiGE+VDGjbY5QTwSBxgj+HoQec1f8OaZHBbSaekjpFBgRhMKYXHUKB8oHTAAxVvQNPW20+W3t9ObTrePcn2HIKlcnBUg4XI5AB4zjAqO31BINITVLecyWIj3Opw0+Bwqhs8nI75z61U46Ec0vhRP4iRniZQizPHH5saElN7ryAWHT1yMflVHwxHYahbLfQw4RpGukjdSgExzvfb0ySThh1yT3revokvtPO5Mkrgow7HqCPXFUXmisYYXkk8sxKfLRVBaRQPT2Fc2qfkXG1tNxNTsBfWyHeqTQSfaLNgoIgkUEZx0J+Y/melcjo9h/ZmoSPZ2xgikUXMyJhIGlJbIC8hFYkMVQZyAWJzWrYauJ5YEPmr9rYybJhtJTuUHtxkdOaz/ABFqdxpniVoGjVbI7ZlknwiBACSyN/eBGMHHWrTkloaQi37rOR+IGj28+p6hNeCFtMvrY5SJzFePchtySf3XC9AmVU55yeK4zVdLm1LxFaR6fbXhaxT7Vf2eopBFHJGxAVlkiG1GYBt0eR3wTXqt1cx67oyCzMUVzewC8t4LuEN8qMMO0R+8oJBx0JI5rLPhhdH1GIQpcmw1OR1kO7M0cz/MzsxGOeo4DDOAcCnCbkrNDnKytzP0PLNU0yXW7Tw3HZadv02e8NtazzzERJC5BMGASybcAjfhuQvPSup+GetHR9e1DS/tKXMVhPJbtKjYjkdT8qr6rtyue5A+ldboFhpvhiSO+0yExRNEbVIgm5rooS0rnJPz7htZmC8+9eV+CLeSMapeNDHY28l7I1taw7vLtnUZypJ3Y4HfnJrdJWOa/M7M9M8fRxx3VvexHMMoO3nHJ56evb8K8GvdID3k7ADDSMenvX0G8T674LmlM2nG/glVhIsu6Cz3YI3DO4uQTjp95TjFeI3ySLfXCgqAJGGG69e/NQmdVDVWPDZCS/fhaBkr1Oc0jYLEgYHYUqkk8DrTNVuW4xnGf6V0mk2jPH9pmUDaoRcKMHB6n36fhWHaW++aEAZLdfwrsnRYraKBeAwDuR0z2rnlLsdlOJieIRtAkbKgJjHoK2PhtrZe/ggkLZUneRgnaBw34Vla7BJqd6LGOa0gkELXBe5mWFSijIUFuCT2HUmuZ0y5nsbmG9g3KYmyGA4Psfw7U5UeenruRDFeyrabdT6QfVGdDDvAlLFUJ53L/jWzoNwqKDK2fk2g9SPp7+9cRo2rrNbXRt1WOHVYYvNI6OU5wgPT5uvuK27Vnube3hspHN05Mjkj5Yox1Hvn9K8CvFv3WfRQ95WWx115dpctth2xhEAJdtobHYf7XtVH7ELmRTO8jBGDhCfkUj29PapIbOQpEXVpEXpGWPY5xntz3rbtrRHffKJEHlHam0kgj1J+99RXA5cqtE0T9mtCLSYWhleVFCFtxKgDAJGPlB4/rVyCyCgCVN5k+ZUJx5eP4nA7HsO9V7Nt0SBI28wAsWJ+UnsvseOavxXIcCZmBYrtYe9RGTvZifN0I/sbt5kvlr8w8sbjna2MjpUflMumSxBXhlbOBtA5A5+ufWtG0kZrmRXB3bAFxyGJ68fh1qxcWYmsXjC7yG3Dtzjr9B6V3U5yh7qREqtnaXkc/Fp7ToyD7mB16tj0NY2s+HZDFutmc4GXB+vau7ht2t48uC2Byx6/lT5Y1lXg8jjPrXXZct1uQ67T02OC8Lz3F3B9ijwm0mMSN90YPIYevpiui1LTYjgxoyn9c/8A1qg0zS/I1DVGUFYzKhUjt8vPH9a3Z/MJAkGSFHzf3vr713U9Yni4t2qXgeZ69o8UscnmL8yjKnHWvNPEVkyRuzbi6ghj7dvxr6BubRZAysuGGDmvNfHGmCKaSSGInzxtZV6HAJ3D3rTkW6FRrc3us+adSOdRuiBjMrcfiarVa1NQmo3SjoJWA/M1Vr0o7Hiz+JhViAKY3JfDAjC461XqxbDg/WlLYqkryJ0FWI15HNRrgjoPWpoQAelc8metSgaFknPFbmjT3FpdboXdGZcMFOAwP8JHcVl2WM46AnOK2oEB8tlyD/KuKc2me3h6Oikt0dhd6pLd2lpY3D+a0CZtpFTBZSclGz6HPPNYE87LK4BbGTimXMUjNHPECFGF9OapTEiZgRjk9Riueq3J6n02Hre5Y7GzvLaLw5eWtzbfar+4dZ7S+jlC/ZRjDRuuPmBIOR78U/Q9Ym0TXbHVkUG7s28yHzQWUnBXB742k1y8M+AAvCZ4z9Ku+estoibGBAADjuRTVV232OpYanOLjLVS3u2/zenyDULiW8vLi4nkeW4nlaaWRzku7HJJ/P8AIVXaFnHG7OKtW9qJ2EbdOpz2Fd74i0+fUbY6t4tup/t8losGnm3txmR0bhHAx8xBJPsc5PShUZVU5FTqxw/LTily7eflZW2+eh5uLeSLy2bepPKnGOPUV1HhtLKLVbEa8ZH0y4k828VQSzjB2j5eeTjpWfpGmJf3zQz3C26opY7yFLY6oucDd6A45rutU0a30jOrWjTm3hjhXTpJRhpTj72eNu3nkZGR0rXD0G/e6f1cjE14L91fV9vw17/5X6FXXfBl/NqGp2ttZRwmytftzWyOXlRW5WPLcs+Mkj0HrxXmdypjk2kk455FdhH4k1K30zULeO+n3XkqyyySHdLuU8FX6qex9a5C92iU7DuXOR/jUYrlbTiPDxrRi1Vaa0tv21/EdErnBIYbwdrcDp1r6f8Agpc2Wp+BdMntAiajpMb2cqE7RuJyC3rng/ia+XbeTZGVHltvYEnHzLjP5Zzzj2r1v4Qte2trfyPuXStahksDN97bcIMIoxwGIYj5sfXPUwz5ZHjZ1QdehvZp/f0f4Nn0foOpRazpSXARkfJjmhkGGjkU4ZGHqDXG+KLL+z/D3lXAnmitHGSH3SNGHBByepAP6V1+jvbGef7M0YRtqgA8uVXBJ9T2/CsD4hXTx+G9faAK08FqZ1DDI+Tk59civTqcs4anxGEk6eJSitLp/wBfecNCwuE1GaJtyXt27xMq7BgHAOO2QAawPE7KLW4kdv8AVuqL7njJrfvVjszJDYsWt0MCo5OQzsm58H0yR+tcn4tkCxqigSHfvYr904Ocj1/+tXPTVkejXXNLTY+bfiapXxtqCnIx5Y5/3Frlq6j4lOX8Z37Elj+75Pf5Frl69COyPnKitNoKKKKZB12kviRT6IP616j4BbZpdso+8y5P415NYMVRznnyv8a9b+H5AWxDHKkqMetZzO2h8BynxBn+0ePtckB3Krxwj22xrn9c1hRZ38cVYvpvtWrapcMcyzX0zk+o3HH8qijX5ua1WxzyvclQcgr0rThGcH2qhD0/QVoW/wA2DntWcmdFOJdkluXs7K1Msj2tg7TW1s33I3c5d1HZif8AIrr/AAf4jmh/syOd7dUsDJ53BFxfGXkvMx+V9p/ibpnvXK26ccn8T6c1b2/NkHnH0z6VLaasypU0z3T4Z6sviOS+tNUgFnP54mha3cqwgRvly/3skjk8ZU4HFdqJXm8QWlz5K3Es0vk3TNlBHbqGKFVOdwLlehHPPbFfPXhfW7jSr2ExXDRG4KwTyNjBTvG5xxGfXrnvXvVhryG2sUjmsg7ghisiusHtherHgAHAHPPQVneSZz1Y8rLvjK9u7zTba1t7lbFZbxYby8jfP2WIct1GN7YVQDyu/POKwdY1GceJNRtI5obmytJI01CJVMTpA8e7fJKQFCxjc4Izv+71U1uW9ook1HS4VW2+1ztdSTxnL73xvIYHhyOmOAMDmuZ17SXgu9KnaHSl+y3byeRMNkTnkKkcm04kckMVwT8pHPWqT7mUWt+h3miG6MZM9wLiJtpimWPpGcBQwzkyHOS2AuCOOKyfFGjXup6nYtAY1MQD28b5U28oPMrkZ3jGBsBUNzuJzxoJeyfZWn01rVWDQyTefG6yrF/ErIBuL7Q23IGSenrd0y5l1C8nnP7qNJPKSF0ZGKY+8c9c8EccdM5zSaT23BRcNbHOWXhueaC6m1B2utRnkZWuZSRsjVsrgfwEdcLxye1VviHoh16NYDeu0bIbZoMDZGWHLscZAwMEdCDj3ro/EEl2LG/hjaO3WOMyw3Tz+WikdVdsHYPfnjPTFcBb6ymoeHBcfar3T9Pm1BNJNnEQbhrgOVdGkOSVJ5DLhgvOfSYU7dTVNv3jzzxTL5njGC6vYJ7rTbVUiggEn2eW3RFwHiK/MIiQG5DFhVzwj4t1Cx1jSX1G8/te6luts7XM+3YJeCYVzgIOAM4B9ia77xvpCzedY6VBGrXdxFPIsY8uOQIvPnk/fBwuPcDGa5P+y7+2ttT0bdAP7VUy3N1Mv70uQAdpJ2qcKOcc4p8xc5QnFdzplk0/VvEvijTbYW9o6yrLfTGPAnRRzGSTtY8/MoGOeSa5bW9Hk0vRr+Czf7RqV3cDUZJJI9qjoiLhcbV6AD9MV1Ws2FhpelWipHPcRNs2RQKpKyqPmLOf4H43E5yeRTdbttRs/BOu32q24hbyrcvJE6ubrDAiNMchBkKCeT1qruxzxgviiZvg27GkxSm7C/Y/LaVo3Ubc4+9wOT9eleZ3OjT3dzLceRMPOcyYHQZOa9CFpeTaXrFjHukhKFwSSzCIjd5XqDnvnse1WLK+tjZW5dVLeWucY64pJ3LhPkuz4t5BIzVi2GXTp1qIKWOSD+VWYFOSQMY9qcnodlNanSeH44xctI7EAseT2HqRXQqglmZTgEnoT36DNc9awuoXAxg5H410Gg3jabqlteSRRSeU5+WdPMikDDB3A9eDx3B5FcXNdnowXLG5wfi2RpNfuVb/AJZbYePVRj+YNZx8xY8EuFz05xn/ABp2oyb9UupVJOZWIJOT145pks0s8jPNI8judzFjnJ9a9C1lY8e922egfDyeS7txA7EmzbKH0RjyPz/nXv8A4Z00fZGIUqiKFCcZyfX1NfPvwYHm+NY7UkDzreTG44GVG7+lfT3hxlezMxLCWR/un0x96vnswSVWz6n0uDq3oJdjUtbGKNU8zG/AOBzj2q6q722oxKrwCeKktowqFznPTFX47Xy4g4XdvGQew9q85TinZkVK1nqYNxpUTSF4yYy38aHBNUPsO9Wt5toPRZQPm9x/9euykt8RBmHzHsKxtStXwAqnPUEetOUY35ol0MS5aNjILSMtHOnyTBSp459/5Vb0qUSTXVuzAsqqSDx8p9/wqgt4wyI1Mj7cbMgFj7Gq13LFcW9kJYVnhvLlYbuEuVNqgO7zHHUgEDjoR14zXRTqRlJMVWMnF839dTqJDCsRcvtUMIy3QAtgBSexORj61k3cP2XLgAIpyAegq7axyag+otqD3Lwvdjarzbo7hYwpSRVH+rUkfdGMlcnOaTVSvmWsRDE3M2wfQckn8q9OrTi1ZHFh5yTtIfbaf5VrGWyd/JJ55PrVLULdBlgxG0Y2jofeuxtEEluEYfdHSsXWLKTzh9lxz1U9PzreEbLQ4/ac83c5o46t0X35ArkvFNl57QoME79ykDHJ6iumSTbeTxOCHwMqe3FZuq/vHswowiSbpj3aP0HvmrRKThM+LPEKhNf1NQMAXMox/wACNZ1bvjpUTxt4gWLHljUJwuPTzGxWFXetjzpO7bCrVqMqfrVWrll9w/WlPY1wyvURaRc96tQoS2FyTz+VRRjj8KsxKwbjr61xzZ71GBpWajI5PXGM10mmxh8K5J49R1rn7MIs3O4x542jn2610+inM0ZIOBjgcZ5ril8R72HWljTs/wDR3khkG6GX5H7kDsR7is/X9PNu5MZDADnHTnoR9a6S7hDSPLn5c5+UYrF1CYpHGXBeBPlbH8I7A+3vTlrHU76MrM56FskDBIz93PWtyMh4UhjJclt2MZIyP6VilVWZ9n3c8H27VteH5Ggkby03Skqw2qTIqr8xI9jjn2FYQ+Kx6tJ2hc9D8D+FZBf2k940GLl1WOMOCzYO4/RhjoOcV6zBZW2rkiPehtJ3lRyrKyybSNyg9WAPB6V51pnjfSf7CuTcoIdQhxcBCWAumByFQpyrfp2ORW9oPjhtZ8VpprW8MLNCZIJ7eUS+Ww+ZgWwO3HAxmvXp+zikos+ZzCOJqylNq3Lf+vPT+uh5HoWg3uvz3K6bC1xsBkkY9V5wN3oxPb1z2FeuReG7vQtAt7u9tLXXNRsU3/ZZm3qkI5KRsf4l5JGMHBFelpaQ2sU80MMcM1xzNJGgV2PqSOpqrrVlGdCuXlVI2it3maVgCAVUkZzRSoqHzOPEZ3LESUbWjf5+f9LU+Tr+9T+27u6W2t/JnZmFuM+WgcdF5yMZyPSorKxTWtWFhpiTFpUPk+ZgsXAyd7cBVxkluwFT6tJNdfY9QK7ppYv3gEW0KwOBjB5OMV1Hwx0YwzDWrtY/JvbW5s7dZJAhaTG1nXJC4AYD5j1PANedGDnV5Xtv959Xia3sqN472t93r/Vjzsq0cxD8j+FgeGGeq+o4PNfQvww8QWHh34d2GlmIG+v1luiwAI84yhdj56OF2nB7DivHLTT7jVvE1tahGcI6W0cM0oi/doMCPeRhScYB9TXpVvokui3NpZLKZHn824nsjiGQR4Um3nbO6YjIAdeMqQBzWuGg1J222PKzKNOs4Uq2+/3f119LnpWgarILm1gszAlz9oRXhnyGeJtwLoDypOCcdSF5q344litdVaC4kl/061YJGsRO+Rf4lPTgYypxwcjJGK43wvHenwyNf8v7NrEl4tvYC7GftQ3jnA5Hy71HoFyeK6nVr19X1nTdae0vLez0+V4YobkKonLrh5NoJJAAwPXJNdVlFNPU+crU1HE80NldP1XT7/17Hn+v3r2/h21dHYyrPGVHHzgDJXB4P0I61neI3itdMsmjxvdQW77zjNR+JifN0yzaR3C3DM7nqw3ZB9uMD8KjaOXVdQtYZf8Aj1t4zHuIBA9B/wDXrGMnextio2971Z83/EFHj8V3Yk+8VjbrnqimucrtPjCuz4hamoGABFgf9slri69COyPlKrvNvzCiiiqIOktBlCP+mf8AjXq/hCTydLaSP/WW9s8ufdUJGPyry6wj3RN/1y/xr0zQGEfhzUJCcA2UuR0x8hrOZ2UXaFzgbMZtYGJyXQMxz3zk1ajUE5Pfio7JSLaFSOVUCrcceGyCMdRgVr0MluLGoViQfx9avWw3AYAx0qvGg9etX7VcnBPJOenb0rN6nRAvxAbsHGdo+n0qwmfbPXNEQVc9M49KVSD0H4EVBt0JgVAxhTnj1q9a6hdWaYtyrkLgRS5K/TPUD8aoYGfvdPSpSwwAMHHHpT9SJbHtOheJ01+ws49FleO9CbBbyMvnK6jJAH8QxnBI6VoXfiVNYkRLpbgTwbWEQQxgzI25GAPXkAYPy++K8Ect56zW8klvdRsGSWFyjqR0IYcg+9dTYeL72/1OCPW7shUjMbh+UZgMAjGShPHA+UnniplTucjpo9ZvdcCa9NcaXcPFeNaeUbR3G2ObO5mIztJ5HJyvHB5NdhpuoSLBcxxrFcyW7KoSN+SSNzsSeAeSdpPbrzXkkS22r6NZ6tCHbT7tRBLZ3IVJQ6NhGixkg8HkE57Ada7O+1mG18RadpkcW2xFv5u4/IjyhuUeQcJhRu5+8Tjtis7NSu2DXMrdjovFJF/YWsMDWRMtxHMgnAfzUQ7n2r/ewODzjrXBaolxJfpBYRpayTGWQSW0REkU4cmUwKTlZJI2bDn5cghjg4rvrLUkurNZU2SW/MscrAAMuT8uOowPzxWHf6ZDdHUpbaedE1RQGuEfAjxgYGeFJHHQmjntK/QISaXLsZHhvTZLnT9aja3ZJNQLbB9yYIFClpQDhZg+/O046YNZ89hBeTtBHaxSmWERJJLI5OEBXJPB3devrWr4gRT4hieN5LZ3ULJC7i5tHVP4QrfccjqVw23nmseGaTVY5pbGC4nS4aNkhUFVwpKsYhuLBON2cnPPAAqpLqifaN7m5pdrb31i8ktu0JFobEor7IsKeBGOgb1br0qOR5dS+Gu+5uWLQytJtRAokWNyQhPY4GMjqevFVfFGoTRRtptk++AmKO3SOMDdMerF+pA5yBWdB9nXX9T0q9iGoXyJGxWE4jUcZKAnhfbrnNC1jYVna5t6G1ufCtxqKqircQFjn7xBBwM+vauRiuJhEgaNVYKARg8V017JNLbGCRdtur5ZfX0Fcw+Nx69a1hGyJit7nyAnQ4/nWtptm0sygjIPOM1lxryOvNd7oFmPLQnsMsP6Vy152Wh7OHhfcZHAMleVPbmplV1G1QTtOeeo5/nWu0AjD/KSCMrigxEBbjDK5TAz3HrXGpHo8iUTy3xBb+RqUxQYRmyKoR4zk9K67xHZmQuwGdpxXIurRMVYV6VKfPG3U8TEUXSnfodJ8PL5bHxxos8jlYxcqjn0VvlP86+t/B8beTI86F5/MZBEjcKQf14FfE0DBWLZYEcrj1HSvtP4fatNc6Hphs0hD3USXDysm7buTBUHPXIPHP0rw89i0oyR6GXVZOnKC9f6+49J0+3t5YxIgZmYknIwBWgFZwfkCgH5f8arWT7iCo2kAcCtJAFU8cetfPJc71OOtN82pTuIm8uMDBx1PrWZqVuwjLHPT+Efxdq6EcdKr3EYKSHOFxg1o3KKumKlWcWjzW/tX+3JdxsQ0Z+ZPY9xTpObgPEpBbr71ta9afY7ncmdqgMzHoAeMn0GawpjLG7Nbx7yDiSPOCAe49qaqNO7Po6VX2kFJG1oWpx3RdIpM+WSrg8YI7VuQoLuWEIpIibfz647Vw+oMVi01bYYltJCFZf4oyMbD6jPPNeg+G3WS0Vx1GAT717mDrqr7p52Nj7OPtIo1YuZUTGPlzx6VRuI5DKwhULKvzAnkH8K1SmHV0HTgj2pl84WIMOWY7QK9RI8ONSz0PMvEIWLWllUETSrsdc8+7fris87JU/dEHYNrEd//r1q+J7OSXUXuFOS67NwOe+QK5eyuvsHiufSZcAPCsufTPWqsd0oqUdN0j5H8egDxz4hAAAGoXGAP+ujVg1v+Pl2+OfES+mo3A/8iNWBXatjyHuFX9OXKN9aoVo6YcI3+9UVfhOrBK9VGjtUP+7Jxgcn9asRLlgc/maiiBJOc5q1H8rd+PauCbPpqMC5ajawIPf1ro9JcKRjk8c5zXPWpw4POAea6HSCoddwIFct/ePUp6I6h5d9uRu59c1m6hCAjbcGOVSGGc/nVyQ+VGrZ4bqP6U7KTQkAkkjAFVc15rHFXUT2N15bklGG6Nv7y+v4VqaZLZpGJZ5pBMsiFVU7d6Z+dQ38JK8Dim60PMgaFydyEsjeh9PoawYpmQYYEYPNQ42d0dFHE29yTPRvEOm3MmtvaabZmKGZo3soncvJiRQQgfo2DkVJ4Y07xHYa7Yy6LbXi6hbyeWXWHKxk53Kd3ynIzxXLaLr09nqGnvP5tzaWsokW3aQgH12nqv4V7dp3jCPxhpl5pmiQahp15HErQ3EsnmrAdwwxKjkcYyexrppqFSV07PsGJr1IU1FR5o9W/wBbu7/rU9XtJZv7MDTKGmYDB34RfRjxx34rgPEWreI9TsdZ0qz0+DUo4oGtdVUMCEeQEqIsYLYTBOecnnpXoGjNPJZ2yamsSXflKkvlPlWfvIPQHriqmn2As7/Vb5HuEvNTYtK2/cV8sbUKqflGBn6136tHxtGrGlKTlBPtfbf8rX+djx3S7G4Xxz4X8OeI0g1ELYjKmIhNjKdnmf3ih4z9BUPiHwHd2+jRyWtslvd2kkgS037jdQ5+WRgDtWTHVe4x3rstJe80myjvNRuUvbm+EiLdToUYRq+7DDtk4IAwata3rAiks2luZdOmS4EjQTBS88a9Fx/cJ5JyDxWfsk0fQLE141Yuna3ls2r30+bT07eRzHw58Ozv4OlvXjSS/wBXY/uLzIi8uNsL5n8QYMNwAweOa2tH8K2+reK9Uax06WHSYrD7A8zyvHDcXJOXEaZ3CNfvcEfNVHU/GV2jwW8FrFFPdmYxTCTebcKB+8dD0zkYDda9P8BXllfeHNPuLSZ5IRFtLytlw4PzB/Rs9R70KEbKK6HDmFfEUYutLeTe3/A9El138jH8YaXNp3gG7H2x3v8AT7BkTUHTDqOBIygdNyjGBVm4IuvDFvLAGKRWrPEX6hRGcE0fFDUmGkjRrARzatq37mGKQAqsQI82Z88BFU9T3IFTLFFb2kNk7OUaJraNpCcH5MDc3UZxwfWlJa2ueXSqylRUpb3b/D/O/wCJ4ZeTfbJ9AmBJFwqyBum75Bnj1zXVadZJbWf2mYOkEUgluJUj8xhEo3Mqr/ETjAx0zmuRt2ka58MQyo8cunkrMh+8Qh2EnHf36GvTo5JDPp+l6akZub2baGdsLHEFLu+ByxAGAB3I7ZrCMddDuzKdnrsfH/xfmF18Q9VulSKOO5Mc8UUUolWJHjVlTcOMhSAQOhyO1cZXdfG3SU0P4na1YQyRSRRtGyPGgQMrRqwOF4H3u3FcLXox21PlZtOTa2CiiimSdxpUJaJgByYv8a7vR1afwpeRqcM9q3OO+OlcvoMWXiGOqD+tdr4SjBs7mL+EeaoB+hqHudVFXg0cRAubeM9MgGp0Xax6gjinaen+iREnJCn8cEipguDg8jvmtd0SlrYaqnHXgnA96uW5KjOSD2x1/wD1VXVc4J4IHPHarkeFU5yCOQMfzrNnRFl+DAUjoT0Hpxz+tSYzjDYz39Kg3/uiVbDfw8Z607zBkgEe/pUI0bsTO+3cf7opWcnnkjAP0qp5uSQGBBqZXwSvBXpg/wBapIzcurJ9xJIJ5x17mojG8kickZYDIOMVIo55wS3T2+tTJHlfYdRVIzkXtC1i8srxDaOZUt5C4Q8K+0/fUHv1wRXfSXM7XUb332+1SUGWPEW6K5GORKVJCEcEbvqK81WOSNldGwy/dOM4FeqeDPF1s+kLaXD/AGa+jMasDnEyg8kep7c1M4JmMpSj8J1fhPVo59Ol8yVPtNyd005lRoVVeCwYYBHQZ71y0Hi8aZdPaWl25tp7k3EUxgz5hUcxNn7qsR97HPrWprep20MGqRwxWIs3QuU2AEkcjgdcH0ridPkGozXE+pb45zGkvzxkCWMDnb/c+h64rNRS0J1d5Mk8S+Kl8Q2UEN/EoEU4uWiUFEZwflVsckDp6mn6J4lis76KePynuZM7ctsVR32r2wO3eszyVutQtTgSEI2cD5Sf4cCrSxK7taOiz7EDyDaG3OOc59f5VdklYt22OjvtReCPTNR+zvcJasbuV4ZVSSbGdgbIwu3dxjnFYngyee31jVtXvJlZjEWaXkIpJysW48sffqe9dHrXkSWwSZgC8KjdjG5cdCK5t5jPbW1u/liC2QRLGgwpwep9TQkJe8rM7SPUUvNMjucbGmHmCM/w5HT9awGKFjz3qj9rk4UEDAIOD1qPzB3ZfzrWKJ5Utj5YReRkjHFej6IA1uD/ALIXpXA+UybMjk8jmu90Un7Em0nc2CQTXk13ex9BQW5q3qhlaGNvnAyoPBx9PrU7rut8kEAAY45HrT3RXlibaDK2VU9wo9far3hbRdT8YXl1baFFFI9tavcFJpdhfbJs2AY6k5wTxXPGLk9DpqVYU43m7I4O9tvNeSMEiPoT0wO/NcRqkBSdmUYIY4Nel3xV4Z5rRlWRRjnkbj/PBHPvXLeL1sbjVJJNItp7azaNQsc8m994HzsT6E5IHaumjPlkc2IiqkU1qn1ONVmaQFzk9K+u/gDKt94C0OU/KITLbMM5yUYkH8mxivkqeB0fIUivqT9mGZb34fTWcboLi21Zicn7iPGp3H2+UiufOoqeGuujRxYRulNxfY91sZo4rwW4bdIVLrx8u33rTtplmglkJA8uXyjnjn/Jqj9kQy/uZMgfKnPIHcZqfQre5m0SdryONLiWaSRVGSFw2Ez74UE/WvBwNCVWUoLVpP8AL/OxNbka5vQuTRvKvlo5Q5BYjrt7gUrlpN2BtiIAVcc8dzU9su/zCT0+X8cUm3KqE69wa7Pq81ST/mv66af13OTm6HP6xZifzY3JWKVQNpGQPb3rl7zTDYrJiVn7Dd94j29vrXbargIpx8ynI+vaubnjeaQl8s5OSTXl1Iu7SPYwVaSjvoYQUzbUwqluOf510XhG8DSSQvwUbay+h7GqkunFlLgkEDsOlZ8czWOsQTMD8xEcg9Qeh/Ou/AylSnaSOuvy16bij0tZGV3BPyqOBWfdSRQwqqfKuWYLz3zz+eafAzSRbgxz0ye9VtSPmqAR8mRuXufTB7CvpIs+fUEpGQ0JaF5GBGW+RT7V534vtDb+NrO/UEILUCTH8RzxXqEkfmcZwMdj0rhPFMIm8TeW2WAtB8o7DdzVbnTSlaR8Y+OGL+NNeZvvG/nJ/wC/jVh1teNQR4x10HqL6f8A9GNWLXYtjy5bsK1NHRZMq8ixgk/MwJA49vyrLrT0rOxsf3v6VFX4TpwKvWRqwKRjOelWY196ZChI6Hpz9KtQqWPQ15k5H1tJJImt0O/jPBAz6Vv6Smxee3es21tyxGCc545/nW5p9mNm9sjYOc+vb+VZpXdzo5rF7exUfxL2pYbiNflI5GeR29qY6+e0jxr5QBJ2A9KoJExclwQB2z1/GhoqMrkt3AbsSFFO1GBL4+uBXP3dmwJZV59ADzXWwSlIfs0xxEzByO2cdafcWkbkkZH9D/hVWuVbocNDHKVeSNGZEG5n5wOfWvWfgX40t9BlvNM1FVjtL5vNF0Blo3A+6w/uEfka4lGmsFeKGGOWPdv8qUbkLdBx/Ksy3t3iMrRFlEDZmjZvniJPGfUe9CbpvmRfJGtH2U9mfa9pdQXNvDLausqvjbIuGDenNc5438b6VpGnxK18q3TTpi3IILw7gH5YdBycj0wK8B8K+Jb7RY2klF01pKN2YpjHjb344buOKoahPL4gnZrayMV1K222tYGaV7gM3CqWOFA5P9K7PrHu3jucEcnp06nNUldL+tdz2PxB8RdJvrfULcLcXVldRTK/mQbGii8ohGyTyxfBHTjmuGktZPEerLfazdy2ukwaVBNqEzMFbzSnKAHhd5AOOfXvUFh4atdI36p4ivF1RLODdLaQlkhimGAsUzn/AFnPBVR2pPClne6zqsst2jXVxKDI8b/MT82clR8ox/epSm5WUl/X9fqduGpUqabpXVur/wAvTr6PUy/FsK21xHPp161zbX8EZtHMHliQLkGKZc53Lxz0NegeC7ldWWeOxso44plt55LCVmKQXKHa1wpXn5lHyg9xyMVUfwy8l017c2sX9mpIRLZJLukbYD5Z3t2yc4HGOtdR8P8ARW0zTJA0m83k32iWUDlyBgAH09jwO1EU1LyDFVIOlq7tf1rbS6NcaJFq5c39xLdR+eJJLiQ/vJdhzHESP4QRk464FbmozM80Uu7CqSWc9uO341FbMMKZF2opyyLxk9Kh1ENPIokJUN1xxuHb8aqR4c3zT12R5bpxR/iDBEFZUujcIqsepPOPxwTW7q1wV0+PTpMGOW4jgubhmKNbWmd0rbx8y/Ku3j154rJtBAPHOi3eQsH2mZQ3QMRGRjPuRU/jS6kstTsodPXfqDwlIoyflWUnmRz2Cg/0rKLs9TbEQVSSi+3+Z80/FvW4fEXxF1vUrRi9nJMEt2KhcwooROB/sqK4+ut+KemR6N42vbGJxKIkh3yBcCRzEpZse7EmuSr0E7q58nUjyzcV0YUUUUyD1vw7EGmhHrGD+prsNCUwXlzGuBl9v/fQrk/DZ/fQ/wDXMfzNdrEix6kpKgLKqlscZ2+v51DOmi7KxxfkCCWSAAqInZSMdOelG0gcjnqcmrmob21C7Mhy7TFvw7D8qjB65/A9606AmuZoq4Ktjg+tWEX95sfgn2x+dCruU/3s1KOCXPGfXtSsa6jmJXBKdByKhyx4B5IzipZDu3Z7dfaoeDwOSATn1PalYLvYaG+gxUyH5sYJAOaiJG7KnipJJo7a2muJeUiUscewzVWRGprRKxw3XPBwKmglQEKXUu5IVQcsxHUAdSfpXp+k+BLaLwV4ctptN0671/VIftV/qN3B5ot4GG5ginHIDKqr0zzXbeAvC9roDy3Yhnv7mcgG6virzpGowiA4wFA7D16mqUG1dHHUxkIux4BGVeFWjZXjJIypyAR1H19u1NDFXDrkEckivXPjF4TtZfD+oeINNtVstatIllk8jiK8VTl1ZOm7bnDHmvGlb7QkckKuY5ceWFUsWyM4AHJOOcCjla3LhVVVXizbi1rzdsFxym3ClTyK6HSHsp7xbd7iQQXBLOtscknH3ip6gHkjNecXqqFIDqVI4ZD/ACNaOm60iW5t7pUik3KVuYwQWxzhj2J6ZHWolDqX5M6PxFNaaQUiF01ze7SbaS2jZY5CM5yx+6R0x37Vm6RrE0U0N26lZYwQy5woH09fer8KLd2M93qFvDFBAgaW9jnMoK9lVT/GfQdMZrnLm7haVYoSBCX2u5PLD19qVrlrVHd6vcXV99lvLhFSML5apGMLGp5Aqt5qRKuTn+97GsN9auZraO1eYtBbnKgcDjpn8KkhnaQDcR7U1ESlZWNtJQwBxjnGKiMi56N+VQwZIXcRknirAC4HI/KtFE53M8CuYQ6g/NkdPpXR6K4ACMCDxjjpXNWUyyeZFIzBkX5cDO5vQ+n1rb0eQCTDev0rxJx0PpqMrOx2CL50Kuo+bnP09abYExSth5I3eNoWaNipeM9UJHVTxke1QwS7HX5vl6EHsP8AP86sxYkdXTnB4rn2OhNNWZnX0ZW3KxoI1RscAAKM8Aelcxf6ds3kfMFIBO04GRwD+Vdk8Zy+G3Bjnb2X8aqalEwgkSNi8LMrsmfkZwMBmHcjJGaEVLscVcaUhVcLgc84969k/ZbddP1XxPZFWMcywlVxkHrn+deaShACVPHTBP6/SvQPgFqC2niPX7XKJcS2aXUB/jJjbDKp9MEkj2qMY5Sw8kv61OOdNJ3Ppy1aMHhgnQIAc7/f/wCvWhbN5dp5MbEAE4c9eTmuY0m/S9itpQFjlX70Q9B6exrcinVmynfqQa+dw2KlRvy6Pb7/AOvI4a9Jp2ZrWxUArwCTn60yQgOwBAINUQVMkbkZZCSpJ6GkleOKSabADPgyN64GBxXryx8ZUFBrVP8AA5FS1EupY5J1iBZZcbg442/jVWO03qJH6nIb1z6n61NFGQ8ocfNLiQg9lHTPvU8LbU4OCeeT/nmsKVP2lTU6ObkVolaW1VIySMHHNcX4pj8m2aUkkx52jv6/zFd3cb2TeqM2TggDGPfBrhPG7YsnzztJbg9RXo1YKMdDswMnKVmdFod6z6PbSkk+ZErcc9uadNOQN3O3rgVz3hadm0ayiB5CDB/DpXRRRRi1IX3J55zXo0n7iOetFQmyO1Z5AWP8XpXH615g8bySOFNuYEjjGeWYk5z6e1dipWLe+eMjHP8ASuF8ZXYGqQOrBZEfAA64I4+vrWqJo+9OyPjXx2NvjfxAp4xqFwP/ACI1YVbvjpg/jXX2VtynUJyD1z+8asKuxbHmS3YVsaKgeJ8/3v6Vj10HhqPfBKRjhx356VliHaDZ35Yr4hJ+ZrQR8BTnp0xWhbQcEnqOny0kEYMgBx09a27OzLEErlAcHJry1eTPqdloNsIuQyrwOc47VvEoLEiIbmIHyjtTNFhREZm4csQAelXREiK/ljapIziqtYuMlIZZQIsBUqSzEAtjr9anubNDHKCASFyP/rVFbMTMUIJB5XB7D1rQlZWhUBuwwfT1/CpbNfhZy0EDyX4hbIQ5D4HI/wA+laSeYshhb58ZCSdMVYvYPIu1nUDcSA2D/D/jVzTbVL3V7C0hK+ZezeRGXOEDkZ+Y9qqL1HUlaPMyjDpa3F0lvKG8pnUO69Tk8/l611R8H6e72TSyXErWbZiL7Cdv9w/L8y+xz1Nel6P8O5rXStQl1q4g08vEvkfYhvaFsHJcsMOc4xjHfNefeNJZ9N1bVdChlZ5bExrLOuAXWRcr06NjqPp61dWnUS5tkfHYjE43HV4RwsuT5/jt08mzo9PuYbtbh4re3uYywgby0VgjAYA64BHNYfhnQLVL+C+imS5Nqzqt/CuBcuQ24hRwkiZxkcV53p99d+FNYN9bsVhbmRR0ZR3I/n3r0K58RrBp9vPaW63VnOCYvLcRmLd94nHU1tSkrWZ9JhqFSjT5OZyfVv8Ar7v8zE16+uLvwjAt5eRSXlo62dpbLHtLZb5VPYsACzOfXHWum8ParoWiatDJoUayabeWix/aFz5puNxDxsO7ADIA4xXmPieykv70XNtJtD4AUNxx/dHdvU12/wAALzS7DVdcj1O/26ikIRYJFyCBklk7b+g6jrinzNS2N68lCm27tdl/wF8zav2vfEWo3c2lNPYabGhgjBG15nz88pH8OOgXvzXa2JWOOKCHJgjUKnHbHOfqa4zwPfm7imvZUaC3klYxxu+TEmeELdz6+la7a8Uty8rLFtzlxgAj1H8sU13McRe3ItkdDd3SxgrFhSM8jpWNc3Mt5N5EEjBG+WR1OSo7qvuentWUNX3xuBvIQbMnqzH09etdNosKx2bskY3MdgB/PJ/Gk32OR/u1dnLeL7aDRYfCohjEdtbagZCmfujy2A5PX8e9c7ayXWp6lcXEe0312iiGSTlYbdPmwB1LO3Xtiuh+Kls97babpUDHzzcCWTB5245x7AZqgpjghubxQVggQxwYGMqByfzzUJaj50qV3u7nzZ8W7j7V47v5TtBMcIYLyAREgI/MVx1dP8SG3+Mb5h0IjI/79rXMV3w+FHzFf+LK3dhRRRVGR6x4ak/f2/PHlj+Zr0O6UG0hmABKD8wa8k8PXe2e35/5Zj+Zr13TnFzprISfu9T2qWaQdjndYizLHIB1XBx61mBT0B/Gtm6IeFgxO4Hp3rOVQQexq1saPcjVepI5PeiQ/fABPNOkYKpGTgDOagfBPJIyMjpxSSNFewkxyxzyVHXoM+1RNuQJk9fSpMZXk9R29aYG9CTjgg9KpITfYQLzgfh7VYCRPbSJcpvh2N5qgdVxzj6ioQQMYJJx19TmrllkuATw3GfzBqrEpn0f8H7O4fwtaXusyC51K7giXzAQVWFMiNBjgkA8nuck816ZDAoA+XtXn3wCbzvhP4YY8lYHRiRjpIwr0sdKqcraI8unS5pOUjK1SzdrWXyEiaUrhVkztb2OO1fLniHSr3wT4pfTbR5bRUZ7zTJI3BdEbhwDjgru257jpX1wRkYrxb9pHQCdAsvEdqnzabL5d4VHLW0hAOf91trZ7c0QnzLlZcaSpz5lt1PBZoljiVU4UZIUdOTk/qaoTsR8oHXoR3rVvF2uV/jzjA7/AErPREEglcnOTgdv85zStY7nrsMjixAigbUzvwOBu6Zx0z71bj2qOmfxqpvJYYJwOAP61KsgBHPr05qR7Iv2smGwOOa1rSTsM/U1iQMWZRnkdgPzrTspM45BzTW5nLY37T7o5PpzWoi5UEIcY9KydPcOCQR1GB3roEjOxeD0q7GDZ8+6daIt2+7r1JNb+gX1npGufatQ0tNTijt3hhtXbKNO5CxykH7wBbG3rnmsG1uQ291GQWweOv8A9erkoSVPMddzBvkYn05B9iDzXjRdnc+hlFSjynSXWnX/AIY1f+wNZRV1Wzto3lKuHBDdGz3POD9PxqeKTkbTtGe3an2U2r+O9X0fR9Osbe91i0juLmW7aXZLdsyqrSzuRxjACj2Fc9aagZInaI8oxjIIwQwqK1NJ80dmaYes5Lkm1zI3pZkUARnnG38KiOXVkyTg81ktPkNk85xnnmpra6bB3Y31zbOx27oyNQSRpbjyZERxkIXHGe34VsprFnoXi/TNb8MJfR21rFGJ4rpg8jErtnA9UIPH6YGKrXUIZJpQB8hB+oNWPDnhy41t9Ra3uNPs7LT1Vrm6v5/KVAQSNo5LdDnA44rZRco8qW5y1VFPnk/69D6V0WWH7Ok1rJ5lu6h43/voRlTXTae55KjAPIXPArwb4UeJI7DTNB0u8vraYXbzpbRIxEtkqknZMTwVY8rjBGQOc17hpF7HcIGQADtxivmK+CdGpyP5DqS9pDmRvYVlxIAwI+6fSopzubjoRwM8E0qyKZDnGMYNVTcnIDAfKeOK1pYVtpM4Iwdy7O6LCUj3eZIR97qD6D171chUBgSBlmwuOw7/AK1ktMGILD5zypUcqfUfhWvaTAAbwqkjjFe5QpRjsZVYuMSS/AMJyeD39K8x+Ikot7SO2UEyzSMcDkgEZJ9q9C1G+VM7m2oFJJNeNeOdTa6uGkC5QrthUg+vU/WniZxUbdWdeW05J3ex0Hg+Yf2ZAq5ZsDDdj7iustm2BwScE5B6/wCea4bwfKqWcMTFSETawzyCOgNdRc3RUKqHl+Gz/CM8V1UVaCMcX8bQ+9uQLqJBgRiTax/2u1eWeOL15dd05UBBWWXIHJ6EZPp3rt9ZvXYQRl+YmURjOAP89zXlyC58R+Idf1exureCz0iJnluZv+PeIDBEZPXJG5sgH25rpjG+iM6M40k5y6Hzh4tQJ4q1hAAAt5MMDt85rJrZ8ZuJPF2tusTwq97MwikOWQFycE+orGrqPObu7hXVeDUZlcAcF8dPauVrsfhzcwDUWtJuJJPmjJ7kDp9axrq8GduXSUa6bO4tdMRcb1JO3jkj6GtvSdOSUiKVjgjqP0pGj2KBjnHFXtPYROm8YYjGa4LWPqOa8dDNgjIuLi2dSJIjzjpzRbh42w5Zh6H0rRvkS31CO6IBVxscd29KtJpRu7d5YGGU6n+mKmRSdkmyjJCJGWRHKtgjPqKkgLFNrnjPpVe4gubGZDKh8rnLjpToJFuHJjYBT+tQ7o6E7rQmuwoA2E5ORg9KktwtosZlA2zEKG7M2RjHv0qJtvmDAyo5pZJEdEZlDbGDDP8ACQcgj055pJjvpZHokWu6/o9lHotvDdaS9yGMbzxFnWP+OQbs/Kuck9vyrnZUsGtYrPT5IJ7e3DL9tgDf6Yx6yOW5buAfSsRvE2p3+rTXM2pXs05t2tjNJIM+USCUGAMAkc45OOTTEvGtg+5CQTnC/rgVpObelzlp4ZxfM0k/L+rhqFlHO++4JIB9MgjHFcyL2XRrto4CrQMDmNuV9yP89a6LU7+KKwe4lkVQPfhvxrM0zSGvpG1LVvMgs2jzFGRh5M8biD0H60RvY1vysw31q81EyWVghVpYysZj/wCWeTkknsPU1o6Yq2awxWStEI8LdyBiVuT1Ab1UnnFXLgqyNFZRLFFnoi44Hv1xTYlWGL5hwB90dSf8ateZUp636m3BqE7zeZNMzGRg5VhgccdPQVa+0rcNvmkztxhD6D07AVh73ZkVEwB0zyT6CiKQh3YjL4CBm4wc8D9elao55SbOy0C6+2Xdwzllt7cAIM53MT6+39K7611EyRW1pbgPLINsYHQ+rn2ryOG8Sz/cIrOytsKL1kbPPHp/Su68MLfRQXutXEbSXnkkQWy8LsAOFUDpk8cUJ3Zz16a5eeRt6pZM7yzSnzJWUDzcA8Z5AHbNcd4gmFtZsV+Ys4jRN3LDI7+teh+IbeC18AwNFq6R6hdMtxHfOhkiLY3OGAHEAUMD/dGCTmvKNThfVbyC9zJp/hS3iZ7XcM3F4ACZJEGOE6dRkoeK1jA8p4tOLb0SPnfx9Kkvi7UGjZ2UMF3PjJwoHOCR+RxXPVs+L57S68SX1xpsXk2Ur74kLZIUgYzzwe+O3SsaupKx5E5c0mwooooJN7SbrZPAwPQf1r2Dwtf740Bf5cV4Tay7JU5r0XwjqXllFY9x3oGjutWh8q8HP7uU7gcfnWRG2Cykjr1x2rcuCLqyGzl1wy+1c1M5iuMA8r1B4p9TW+lySXq2MHP8qg3jJ6AnvQ04JA55Pf1qKSQb2PPXimUmSAKVwpOc5/D0prfMVzj09Mio45cNkDHY4pxccEZ600NkyoA4I+ZOxNWrZCJEyRkHn35/SqkTkhUbtwOcD8a1LIoZQVOSBnJ7Y6n8s00V01PpL9noIfhLoiqcyRmZZRjo/mvkV6VXmv7O8RT4U6ZMCfLuZZ548nOFaVsV6VSqfE7HBT+G4VDeW0N7aT2t1EktvMjRyRuMq6kYII9CDU1FQaHxVqujy+HtW1LRLobbnTrholG4t+5YlonBPJBQgZPPBFZVyjNJv28EZAHFe5ftFaDDY6lpXimKMhLhl0zUNiZyCSYZCe2H+XJ7MB6V4xqO6KeaJhgo204P3WHpXQ/eVzSlLTlMtASxzgD1NTIyng9uhz1qtI7Fj0UHqOgoVtrDBzzknsayZbsaSSbFwNoq/ZnCHcR6iseEKcljx6GtXT3GVY7jgcUyWdTocYVVMgG772D2P0rcEzYGNmPrXP2EuD/tH9K6CPaI1BbkAdXUfpW0Tjm9T5i0jUDOCsrOWA5UNjdxjP5Vu20wVtsnPA79a4WG4aEAxqocNu39/p9K3LW/8zy3K/dIJHt6V5FWlZ3Wx7WHr86s90dCt/c2V3NLp08sLToYJ3hcoZEPWMkdQfSp2kAGYlwcD5FGMY6fpWcsqoeSCjPu9gPWpAzRSjdu2yEbWAzgelc0rs7o2WqL9vcpMyqFkIVtzqgJYoOWwB6DPPQd6nkleC8limt5oGRtwjmUrIqHkBgcdQRzjB7VR0++uNKvxPY3EtvPKjWzyRABmicYdeQeD0zVvVr+71a/m1DVLqa71CXaJZ5mDM4UYUcADgegqeWKj5lqc3L+6benWF1rV7dWejW8t7cQW5upY4cF/KBC5UH7xyw+UVUtpjGxjngLG3YoS6YeJh1BUjII7jtWLDuWUbnkRwQQyEg/gQQfwqwly6OTIT85LOzZJY+pPUn61SSsHNK7vsatzarcw5R/3hOWOfyPsRXV+FvGep6KPJupXZIwQJSC7HPQOO+P7wrkbedC6tu+Y/e5q1NcyAOU2sGXlMdvaonRjNWkio1NdD3HQPHZvzGEENzIyZDQuW6dtvUEe9aVjrQ1S4gaSQ7SS2wHo3+1XzTFeXFtfJc2bz29yvKywnDqfTPcVs6d8QNSWS3GozK8kPyxTgbW5OSOOCPrXNPCSg7x1NIVqbdnZM+r7J28tDg7pBlyD93Ht3q+qLFGDuxu+YvjnPrXkPhj4q2EkSjU451OBteJN4B963rj4qeHhAZRJqDyAHaiWpBY+nXAHvXRTelmclXD1ebRaHU6pJEtvI8zCCHDPI8jY24HUntxXiE+onVdRN1FueGQhIBnGIgeOPc1F4y8aan4sm+yRRGy018b7ZXDtKfR3HG32HFM0aMxSBm5Yndnr83t6DHas6sOZ7HTTXsoe9udlYSNaM8lqFMzIVijY43cZ59AME1rTatbz3SPauWtjGoDkcs4++wPZe2D6ZriLq4cu825RsG9gD146e2eaq2+sbZUmc7Ui52YGT6D2+tddJye6sjlq0lPW+pqfEPW3sbO5kgVDKkR8tnPyBsgc4715xrXinTfBOj6nJoP+mX/AIksxbyx6hEgltFBO9wE+QqxPyg8/Lu6cHF+IHiPdEGlwzCUskLdGPv3wK8svLqa8uZJ7hy8shyzH/PSu6mrannYpqMfZELsWcsxJJOST3ptLSVqcQU+J2jkV0Yq6nKsDggjvTKKAPYvC/iEa/YKZGC6hEAJ0/v/AO2PY9/Q/WuhnfbbfLyNvJPb1rwjStQuNMv4ru0fZLGcj0I7g+oPSvVtM15NYtQ9om1mG10JyYz3B9R6GuCvR5XdbH0mXY32q5Jbr8ToIplurQLM+WXo3c1e0q5k8n5Sdyv8xzyfTFc2rPGyupOzOM4rSsZXiIY/d78dB0rmeh7DSa0PQ9K8UGOy+x6jbWl7Yqxk8iWPBfnp5g547cfWsh4/CtymsXc8d5olzK+dPtrb97DCu3kyN0JY5yucDjb3rCklXL7ARGQCpPP4fWlZjd4y24qoAB44qlNpWOX6vFS5o3Xp/ViO80+aDQ49StNQtp5GkCjS+TdqC2N3TGO/0xVrWvDuu6a8ENzZRq06hk2yDJzzSSWzRbGjZl9ah3XFrCptbtwA3CMCwH4mlZG0ZSWz/D/IqHSr7LIbKQngHDgH6Vam0vVpIhI7WtvHnB8yXcQMY6Lz+FWP7Uv4t7Pc28jkdWXBX2z0H8+elNu7zUvLC4gkQ4wNpH/AT/jQ00Uqjl1RmLYWdtOJLgPqNzGSUV/liT6J0z7nNWtQnu9QnPmFpGYj5QMKv1qOW61FYWUWUS4bOVG7HsPeq1rfajaPM0ls8csgAAk6sO2B70ty1yrVbm3aaFcyDDHacbiAOvFUtftDpyQeaMCYkqo5IA9f6Ve0/Wb+JiskTuQ2CDyfxputR3GrbJ7sHYvIH9PfFXBpGLjJy1ehi2cN5etvtgEiyQWcH5yB90ep57VPoum6jqWoLBZtHGsZzI4IfyP989Ax5wvWtjTLae5AtoGEFpCu2S5Hcnkxx/7RHU9BXRS3FnpWmEwolvaxvwEHVvU+rH1PJrVSuZzVnZbjdE8O2VhAwd2ub2YmPzXOCR1yo7V3enW8enrH9oJ+VQwVeMt6/X9K5bw9HNcmLUL1Qkki5iiGf3aHkfU4HPpV6/1Q6lezQaeV8oArPcHDLCSPuAfxMfy9eeKpI56zlL3b+pJDJJ4s1JrG8XbZKy3bWzE7b2NSQEJPCQh8bj/y05AB5J8X+PPjxr1IdO0lo2sDKWF4ihPtQjYhVEfaJDkKejEZHQ12vjLxlZ2fhKXT5jIfDlhbvawIs4aae6GQsMgbLBAMn2TGOor5j1vUrnVtQkvbwqZJDgBFCooAwFVRwFAwAK6qasj5/F25yi7FmZiSSTnJ702iitDkCiiigAroNBvDny84kHT/ABrn6fDI0UiyRnDKcg0Ae2eHdVyixvwR7VFr2DdSSQHKkemM+tcjoWoR3MCuMBx95c/dP+ea6BLhZARKcjuM0NO9zWLTK+4kdeMHGRTkk4PPB7YqCdTFK3PyHp9KjDjAGOP6/wCcVTLRa34+UdMdhQkx6EdwelQK+QQADximu4BHAJ7/AP1qExmjE3QEjn261qwPlnBORKhQ7RjIPynHvWBbOZGRIxl2IAUdSa07SQmWNQArbwMenIqkxvRH1V+z/eG6+E+iI775LRXtGOAOY3ZRwOnAHv616JXmH7OK/wDFsLeTjM15dSHn1lbr+Ven0qiSk0jipu8VcKKKKgsyPF2hweJfDGqaLd48m+t3gLEZ2kjhh7g4I9xXytbeFPEN1Y3E0mkmSTT2e0vZvPiRVlh+V2wzBmyBu4Hevrm5naF4FEEsolk2FowCI+Cdze3GOPUV88/H/wAMw6d4qtb+3tYJIPETpC4eEHyr6IZikz2DrlWHfaPetab+z3BXTujyJ0jmhhuIG3QTLvRtpAYH0zVRxtbDd+nHNbWs3qXckQFusMioTM4fc1xISN0jcBV9AiAAD1rn55ArcHPtnrS2OndE6OAyjvWlaTFAMYx0+lc/5qo2D1HHWo73WEsraSaQ5VcYUHlj6ChGcnodHrXimHQLMTkq91ICttGeQD0LsO4Hp3P414xcXM1xPJNPNJJLIxd3ZiSzE5JJ9ak1C9n1G5kubltztwBn7oHQD2qpn3qJScjNRS1GVLDK0bgj8RRRSauEZOLujZtbkNDjsa2LKdGxDKu9SMY9M96KK4KkUmezTk5RTYy+hktAkuS0GcoQeeKuRSCdOoDD58miismlZGyk9RQXLKCMPkkEHg4q7FmN1HG09jzmiipiNvQesMM0uMGNscbT0qw0E8eQjpMu3POQeKKK0TIUU9SOKV1K+ZFtJH97PXtVGZoWL/uyOaKKozm+VFWe6ktyJLdnUdGAbg/hXU+C86tAn22Z1MgcxgdCFwO3Q0UUprS5dCclKyeh3EUNrbYaJNgXr35qt9uWO7d1OFUAAjPbvRRUxZ0pXuUNW1hSm1dxOCAo4DH3rm9e1cWcJE5+TaJZNoOc9l/zxRRXRBXOSrJwWh5Zq+oS6nfSXM3G4/KoPCjsBVGiiutHiybbuwooooEFFFFABWnoGqyaTqCTrlo+jpnGR/jRRSaUlZlwnKElKO56baXSXKKyt821XAAwNpGQf16VpRXJhCb8Mjg4NFFebKKPrsPUckrmkCstuCmQrdAetOWZrMrIIhIwIIUnhvQH2zRRWEX7zR0NnS3dg0mp3VlZTRXYhjVrh41MaKxwxRQ2CcetaXhY2OlWcya1oUmqXiTNMl/HcBGjU9AY2O3K9sBh360UVtGTi3Y4Kr5oqEv6+40R42S+1WaxufCulS6BcXC3L6e+DOGUlmuGbGxm6HbnooANZXiXWdL1ptTu7bTEge6ljfTbuIbP3YxvaWPOCxwQMDpjoaKKt1HKOprSwdKnNOKtt1/rsZk3kmQgFkXr8tRPbRyXAmxyg7elFFcr0Olrl2HJbJJdLKWYIOCAev1pMJd3Uyh2FpEAX28GRjxtHoPWiinEO5YD4WJY12Rxjy1C8YHbHv71FFMk14j3K+Za2ozHC3Id88yEfoM/XFFFaxdrEdGzQi1G41mR1aSSO23bAyt85A61Qm1hL201aw0Yi10/SbV729kGVd4wOREcH94c5BYYz1oorpp62v1ODEzcKc2vsrQ+e/GHiObxDepIY47e0gQRwW8YwFAGCzf3nbqzdz7AAc9RRXWj5ybbd2JRRRTICiiigAooooAt6deyWNwJYzkdGXswrsrS+EsQeMkqwBGRyKKKaZUS2tzujYty3SoS+ATycDk/jRRQ2arcRZec84P/ANcGnLIS+OeAPpRRQ0O+thYpWVwQSv8Adx1P+f61q6dODPGrfLlhk4zxmiihMvdan1D+zJdi4+G0kAPNpqNzBjnj59wH5MOletUUVU3eVzjiktF5hRRRUDCuc+IWgt4l8G6rplv5a3k0D/ZZJEVhHNtO1vmBxzxnqATiiimnbUD4pmu/NghldQkpBWWJc4idSVKAknI+Xrk1m3NxgD6/rRRWs3qbLaxm3GomIykHC7SGJGeO9crqV/LfSAucRpwi+lFFZN9CJFQEijJooqRI/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: A large sessile polyp is seen in the sigmoid colon. Middle panel: Following snare excision, the base is oozing blood, and residual adenomatous tissue is vissible at the inferior margin (arrow). Right panel: The argon plasma coagulator has been used to fulgurate the base and remaining adenomatous tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Cohen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37251=[""].join("\n");
var outline_f36_24_37251=null;
var title_f36_24_37252="Laryngoscope incorrect motion";
var content_f36_24_37252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incorrect laryngoscope motion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When performing direct laryngoscopy, do not \"lever\" back on the handle, as in the photo above. This impairs the view and can damage teeth. Instead, pull in the direction of the handle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Orebaugh SL. Direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37252=[""].join("\n");
var outline_f36_24_37252=null;
var title_f36_24_37253="Brugada ST patterns";
var content_f36_24_37253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patterns of ST segment elevation in brugada syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three distinct types of ST segment elevation have been described. In type 1, the ST segment gradually descends to an inverted T wave. In type 2, the T wave is positive or biphasic, and the terminal portion of the ST segment is elevated &ge;1 mm. In type 3, the T wave is positive, and the terminal portion of the ST segment is elevated &lt;1 mm. Arrows denote the J-wave. Calibrations are given.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Wilde AA, Antzelevitch C, Borggrefe M, et al. Eur Heart J 2002; 23:1648. Copyright &copy; 2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37253=[""].join("\n");
var outline_f36_24_37253=null;
var title_f36_24_37254="Microbiology and epidemiology of cryptococcal infection";
var content_f36_24_37254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology and epidemiology of cryptococcal infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/24/37254/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37254/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37254/contributors\">",
"     John R Perfect, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/24/37254/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37254/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/24/37254/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37254/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/24/37254/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcosis is an invasive fungal infection due to Cryptococcus neoformans or Cryptococcus gattii that has become increasingly prevalent in immunocompromised patients.",
"   </p>",
"   <p>",
"    The microbiology and epidemiology of Cryptococcus species and cryptococcosis will be reviewed here. The clinical features of cryptococcal infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Taxonomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcus neoformans and C. gattii are basidiomycetous, encapsulated yeasts. C. neoformans and C. gattii can be subclassified into four serotypes and two species with two varieties. The serotypes are based upon capsular agglutination reactions and are designated A, B, C, or D. Serotype A and D cryptococci were previously classified under the species neoformans. However, it has been proposed that the serotype A cryptococci be considered as a separate variety based upon genotypic differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/1\">",
"     1",
"    </a>",
"    ]. Serotype A cryptococci are now considered variety grubii; serotype D are classified under the variety neoformans and they are divided into four molecular types (VNI, VNII, VNIII, VNIV). Serotypes B and C are now considered as a separate species called Cryptococcus gattii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/2\">",
"     2",
"    </a>",
"    ] and further divided into four cryptic species identified by molecular types (VGI, VGII, VGIII, VGIV), and several subtypes.",
"   </p>",
"   <p>",
"    The significant differences in the ecology and epidemiology of the two species are discussed below. The clinical presentation of cryptococcosis due to the two species is generally indistinguishable, although one study suggests some possible distinctive features that are described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle of C. neoformans involves asexual and sexual forms. The asexual form exists as yeast and reproduces by budding. These haploid, unicellular yeasts are the only forms of C. neoformans and C. gattii that have been recovered from human infections.",
"   </p>",
"   <p>",
"    The sexual (perfect) state of C. neoformans and C. gattii has been observed only in the laboratory. Sexual structures have not been found in nature, but apparent sexual recombination events have been detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/4\">",
"     4",
"    </a>",
"    ]. The yeast forms can exist in one of two mating types designated a and alpha. Coculture of yeast of each mating type on certain agars can result in conjugation that produces the sexual state. Conjugation between the alpha and a types results in the formation of the teleomorph, which consists of dikaryotic hyphae that contain clamp connections.",
"   </p>",
"   <p>",
"    Some of the hyphae develop into specialized structures called basidia. Meiosis occurs at the terminal portion of the basidia resulting in formation of uninucleate basidiospores. These spores are initially unencapsulated, but can quickly develop capsules when released from the basidia. Budding may begin after encapsulation, thereby completing the life cycle.",
"   </p>",
"   <p>",
"    In contrast to the classic sexual cycle that occurs between alpha and a strains of C. neoformans, strains of Cryptococcus gattii in the Vancouver Island outbreak described below were created by recombination events between same sex (alpha-mating) parents, which may have increased their virulence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Epidemiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Growth and identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. neoformans and C. gattii produce white, mucoid colonies on a variety of agars that usually become visible to the naked eye within 48 hours (",
"    <a class=\"graphic graphic_picture graphicRef75483 \" href=\"mobipreview.htm?17/15/17663\">",
"     picture 1",
"    </a>",
"    ). The identification of C. neoformans and C. gattii in the clinical laboratory begins with isolation of a urease-positive, encapsulated yeast. Further confirmation can be achieved with biochemical tests contained in commercial kits and by detection of the enzyme phenol oxidase, which is solely produced by C. neoformans and C. gattii. However, most clinical microbiology laboratories do not stock the expensive agars required for detecting this enzyme. Most laboratories use a variety of sugar fermentations contained in commercial kits to identify the organism. C. neoformans can be separated from C. gattii by growth features on canavanine-glycine-bromothymol blue (CGB) agar or by molecular tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histologic identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The yeast form of Cryptococcus can be identified in histopathologic specimens using methenamine silver stain. Mucicarmine stain highlights both the yeast form and the capsule and is specific for Cryptococcus (",
"    <a class=\"graphic graphic_picture graphicRef82930 \" href=\"mobipreview.htm?37/56/38792\">",
"     picture 2",
"    </a>",
"    ). The Fontana-Masson stain reveals melanin contained in the yeast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Capsule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polysaccharide capsule surrounding C. neoformans and C. gattii can be visualized in a suspension of India ink when examined under the microscope. The capsule appears as a clear area amidst the ink particles (",
"    <a class=\"graphic graphic_picture graphicRef63752 \" href=\"mobipreview.htm?8/63/9213\">",
"     picture 3",
"    </a>",
"    ). The thickness of the capsule can vary, but can comprise more than 50 percent of the diameter of the yeast cell in some isolates.",
"   </p>",
"   <p>",
"    The capsule has antiphagocytic properties and is an important virulence determinant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/6\">",
"     6",
"    </a>",
"    ]. Mutant cryptococci that are either hypocapsular or acapsular are less virulent in animal models than encapsulated strains, and undergo increased phagocytosis by white blood cells in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. neoformans and C. gattii strains can undergo phenotypic switching with prolonged in vitro passage, and one group has demonstrated this phenomenon in vivo in mice, resulting in increased virulence and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/9\">",
"     9",
"    </a>",
"    ]. In this model, phenotypic switching led to changes in the polysaccharide capsule, which further reduced alveolar macrophage phagocytosis and promoted a more vigorous inflammatory reaction that was destructive to lung tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Melanin production",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the enzyme phenol oxidase in C. neoformans is unique among members of the genus. This enzyme catalyzes one step in the conversion of phenolic compounds to melanin. A wide variety of phenolic substrates can be utilized by the cryptococcal phenol oxidase, including catecholamines, such as dopamine and epinephrine.",
"   </p>",
"   <p>",
"    The phenol oxidase enzyme may be an important virulence factor for cryptococcal infection. Cryptococcal mutants lacking phenol oxidase activity are avirulent in animal models and are more susceptible to antibody-mediated phagocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phenol oxidase may promote virulence via one of several possible mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High level of dopamine in the central nervous system may serve as a substrate for melanin production by the organism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/11\">",
"       11",
"      </a>",
"      ]. In addition, the ability to degrade catecholamines may protect the yeast from toxic effects of catecholamines in the central nervous system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Melanin is an anti-oxidant that is produced and accumulates in the cell wall where it may protect against attack by immune effector cells and oxidative products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ECOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant differences in the ecology of the two species of Cryptococcus account for the distribution of infections due to these organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     C. neoformans var grubii and var neoformans",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. neoformans var grubii and neoformans have been found in soil samples from around the world in areas frequented by birds, especially pigeons and chickens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/14\">",
"     14",
"    </a>",
"    ]. This fungus has also been isolated from roosting sites of pigeons and in association with rotting vegetation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The basis for the association of pigeons with C. neoformans var neoformans is uncertain. Pigeons do not become infected with C. neoformans in nature. The organism is probably inhibited within pigeons by their elevated body temperature (over 40&ordm;C). Pigeons can, however, harbor the yeast as saprophytes in their gastrointestinal tract.",
"   </p>",
"   <p>",
"    The role of pigeon guano in the pathogenesis of human infections is obscure. A history of intense pigeon exposure is only rarely elicited from patients with cryptococcosis. In addition, outbreaks of the disease have never been traced to pigeon roosting areas. It is possible that pigeons come into contact with C. neoformans var grubii and var neoformans by eating contaminated vegetation. Human infection may result from a similar exposure to contaminated vegetation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     C. gattii",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. gattii has been cultured from river red gum trees (Eucalyptus camaldulensis) and forest red gum trees (Eucalyptus tereticornis) in Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. These trees are exported from Australia to various parts of the world, and strains of Cryptococcus gattii have been recovered from river red gum trees in San Francisco [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/18\">",
"     18",
"    </a>",
"    ]. C. gattii has also been recovered from some trees native to Vancouver Island, including Douglas fir, alder, and Garry oak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/19\">",
"     19",
"    </a>",
"    ]. C. gattii has not been cultured from bird guano.",
"   </p>",
"   <p>",
"    An outbreak of C. gattii infection occurred in Vancouver Island, British Columbia beginning in 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Between 1999 and 2007, 218 individuals in British Columbia were found to have C. gattii infection, and cases continue to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Most of the patients have been immunocompetent and have had pulmonary involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. Additional cases have been identified in Oregon, Washington, California, and Idaho [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/22,25-28\">",
"     22,25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infections due to C. gattii typically occur in apparently healthy hosts; they have also been reported in patients with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/29\">",
"     29",
"    </a>",
"    ]. Immunologic containment of infection by the immune response is likely responsible for a higher incidence of cryptococcoma due to C. gattii than to C. neoformans. Therefore, CNS infections due to C. gattii are associated with more neurologic complications and a delayed response to therapy than infections due to C. neoformans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15210?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Pathogenic species'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcosis occurs worldwide. An epidemiologic analysis suggested that there are a million cases of cryptococcosis per year worldwide, with around 700,000 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of patients with cryptococcosis are immunocompromised due to one of the following conditions (listed in order of decreasing frequency):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AIDS",
"     </li>",
"     <li>",
"      Prolonged treatment with glucocorticoids",
"     </li>",
"     <li>",
"      Organ transplantation",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Sarcoidosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An incidence of 4.9 cases of cryptococcosis per 100,000 population was found in both San Francisco and Atlanta in 1992 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/31\">",
"     31",
"    </a>",
"    ]. Underlying AIDS and African-American race were independently associated with cryptococcal infection in these cities.",
"   </p>",
"   <p>",
"    Cryptococcal infection is the fourth most common opportunistic infection in patients with AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Approximately 6 to 10 percent of patients with AIDS in the pre-HAART era in the United States and Europe were diagnosed with cryptococcosis. The number of cryptococcosis cases has declined since the availability of HAART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/34\">",
"     34",
"    </a>",
"    ], but this infection is still a relatively common AIDS-presenting illness. The rate of cryptococcal meningitis in patients with AIDS in sub-Saharan Africa is 15 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, despite the finding of this fungus in pigeon guano, direct transmission from pigeons to humans has not been reported. However, one case has been documented of transmission of C. neoformans from a pet cockatoo to a renal transplant recipient who developed cryptococcal meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/35\">",
"     35",
"    </a>",
"    ]. Spread of infection from person to person has not been documented. Interestingly, cryptococcosis is very uncommon in children, even those with AIDS. The reason for the reduced incidence in children is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathogenic species",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. neoformans is the principal pathogenic member of the genus, and has a worldwide distribution. The serotypes of C. neoformans in cases of cryptococcosis vary according to geographic location and whether the patient has HIV infection as a predisposing condition.",
"   </p>",
"   <p>",
"    An extensive review of 725 clinical isolates of C. neoformans obtained from around the world prior to the AIDS epidemic found that C. neoformans var grubii and C. neoformans var neoformans accounted for 80 percent of isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/36\">",
"     36",
"    </a>",
"    ]. The majority of cryptococcal isolates from patients with AIDS have been var grubii, but in certain locales, C. gattii infections have been observed in HIV-infected patients.",
"   </p>",
"   <p>",
"    Isolates of C. gattii have been found most commonly in tropical and subtropical areas, such as Hawaii, Brazil, Australia, Southeast Asia, and Central and sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], and in temperate areas that include Vancouver, Canada, and the northwestern United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/19,22\">",
"     19,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A series of 133 cases from Australia occurring over a 10 year period suggests some possible differences in the clinical illness caused by the two species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C. gattii infections primarily occurred in healthy hosts, whereas 90 percent of C. neoformans infections occurred in immunosuppressed hosts.",
"     </li>",
"     <li>",
"      C. gattii frequently caused focal CNS and pulmonary disease primarily in immunocompetent patients. (However, in a study of 176 cryptococcal isolates from AIDS patients with meningoencephalitis in sub-Saharan African, C. gattii was isolated in 13 percent of patients from Malawi and Botswana [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37254/abstract/38\">",
"       38",
"      </a>",
"      ].) These results show that C. gattii can infect HIV-infected individuals in certain geographic areas.",
"     </li>",
"     <li>",
"      Isolation of C. neoformans from blood and urine was associated with significant immunosuppression.",
"     </li>",
"     <li>",
"      The mortality among patients with C. neoformans var grubii and var neoformans infection was high, but this was most likely due to the severe underlying diseases found in the infected patients.",
"     </li>",
"     <li>",
"      Infections due to C. gattii were more likely to present in an insidious fashion and to be associated with neurologic complications, such as hydrocephalus and cranial nerve deficits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryptococcosis is an invasive fungal infection that has become increasingly prevalent in immunocompromised patients and is a major pathogen worldwide. &nbsp;(See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptococcus neoformans and Cryptococcus gattii are basidiomycetous, encapsulated yeasts. C. neoformans can be subclassified in two varieties (var grubii and var neoformans) and C. gattii into four cryptic species. &nbsp;(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Taxonomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The life cycles of C. neoformans and C. gattii involve asexual and sexual forms. The asexual forms exist as yeasts and reproduce by budding. These haploid, unicellular yeasts are the only forms of C. neoformans and C. gattii that have been recovered from human infections. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      C. neoformans var grubii and var neoformans have been found in soil samples from around the world in areas frequented by birds, especially pigeons and chickens, and in association with rotting vegetation. C. gattii is associated with certain species of trees in nature. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'C. neoformans var grubii and var neoformans'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'C. gattii'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryptococcosis occurs worldwide. The vast majority of patients with cryptococcosis are immunocompromised due to one of the following conditions (listed in order of decreasing frequency): AIDS, prolonged treatment with glucocorticoids, organ transplantation, malignancy, and sarcoidosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An outbreak of C. gattii infection, which began in Vancouver Island, British Columbia, Canada in 1999, has spread to the northwestern United States, and cases continue to occur. The majority of patients have been immunocompetent and have had pulmonary involvement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/1\">",
"      Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 1999; 37:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/2\">",
"      Kwon-Chung, KJ, Boekhout, T, Fell, JW, Diaz, M. Proposal to conserve the name Cryptococcus gatii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetiadae). Taxon 2002; 51:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/3\">",
"      Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/4\">",
"      Saul N, Krockenberger M, Carter D. Evidence of recombination in mixed-mating-type and alpha-only populations of Cryptococcus gattii sourced from single eucalyptus tree hollows. Eukaryot Cell 2008; 7:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/5\">",
"      Fraser JA, Giles SS, Wenink EC, et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005; 437:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/6\">",
"      Eisenman HC, Casadevall A, McClelland EE. New insights on the pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Rep 2007; 9:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/7\">",
"      Kozel TR, Gotschlich EC. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol 1982; 129:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/8\">",
"      Chang YC, Penoyer LA, Kwon-Chung KJ. The second capsule gene of cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun 1996; 64:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/9\">",
"      Fries BC, Taborda CP, Serfass E, Casadevall A. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest 2001; 108:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/10\">",
"      Salas SD, Bennett JE, Kwon-Chung KJ, et al. Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med 1996; 184:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/11\">",
"      Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 1986; 51:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/12\">",
"      Polacheck I, Platt Y, Aronovitch J. Catecholamines and virulence of Cryptococcus neoformans. Infect Immun 1990; 58:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/13\">",
"      Wang Y, Aisen P, Casadevall A. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun 1995; 63:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/14\">",
"      EMMONS CW. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg 1955; 62:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/15\">",
"      Laz&eacute;ra MS, Pires FD, Camillo-Coura L, et al. Natural habitat of Cryptococcus neoformans var. neoformans in decaying wood forming hollows in living trees. J Med Vet Mycol 1996; 34:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/16\">",
"      Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 1990; 28:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/17\">",
"      Pfeiffer TJ, Ellis DH. Environmental isolation of Cryptococcus neoformans var. gattii from Eucalyptus tereticornis. J Med Vet Mycol 1992; 30:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/18\">",
"      Pfeiffer T, Ellis D. Environmental isolation of Cryptococcus neoformans gattii from California. J Infect Dis 1991; 163:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/19\">",
"      Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 2004; 101:17258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/20\">",
"      Stephen C, Lester S, Black W, et al. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J 2002; 43:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/21\">",
"      Hoang LM, Maguire JA, Doyle P, et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004; 53:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/22\">",
"      Bartlett KH, Kidd SE, Kronstad JW. The emergence of Cryptococcus gattii in British Columbia and the Pacific Northwest. Curr Infect Dis Rep 2008; 10:58.",
"     </a>",
"    </li>",
"    <li>",
"     BC Centre for Disease Control. 2007 British Columbia Annual Summary of Reportable Diseases. file://www.bccdc.org/content.php?item=33 (Accessed December 30, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/24\">",
"      Galanis E, Macdougall L, Kidd S, et al. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis 2010; 16:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/25\">",
"      MacDougall L, Kidd SE, Galanis E, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 2007; 13:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/26\">",
"      Upton A, Fraser JA, Kidd SE, et al. First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak. J Clin Microbiol 2007; 45:3086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Emergence of Cryptococcus gattii-- Pacific Northwest, 2004-2010. MMWR Morb Mortal Wkly Rep 2010; 59:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/28\">",
"      Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/29\">",
"      Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000; 31:499.",
"     </a>",
"    </li>",
"    <li>",
"     Park, BJ, Wannemuehler, KA, Marston, BJ, et al. Refocusing on a re-emergent disease: Global burden of cryptococcal meningitis among persons living with HIV/AIDS. Inters Conf Antimicrob Agents Chemother Abstract M1848, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/31\">",
"      Hajjeh RA, Brandt ME, Pinner RW. Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Epidemiol Rev 1995; 17:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/32\">",
"      Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/33\">",
"      Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/34\">",
"      Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003; 36:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/35\">",
"      Nosanchuk JD, Shoham S, Fries BC, et al. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med 2000; 132:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/36\">",
"      Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984; 120:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/37\">",
"      Morgan J, McCarthy KM, Gould S, et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis 2006; 43:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37254/abstract/38\">",
"      Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J Infect Dis 2005; 192:888.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2448 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37254=[""].join("\n");
var outline_f36_24_37254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Taxonomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Growth and identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histologic identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Capsule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Melanin production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ECOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      C. neoformans var grubii and var neoformans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      C. gattii",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathogenic species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2448\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2448|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/15/17663\" title=\"picture 1\">",
"      C neoformans Sabourauds agar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/56/38792\" title=\"picture 2\">",
"      Cryptococcus lung histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/63/9213\" title=\"picture 3\">",
"      C neoformans india ink",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15210?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis and disseminated infection in HIV seronegative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_24_37255="Betaxolol (systemic): Drug information";
var content_f36_24_37255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Betaxolol (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/33/18965?source=see_link\">",
"    see \"Betaxolol (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7995913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kerlone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7995918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Beta-1 Selective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7996038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hypertension (labeled use), coronary artery disease (unlabeled use):",
"     </b>",
"     Oral: 5-10 mg/day; may increase dose to 20 mg/day after 7-14 days if desired response is not achieved",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7996039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypertension: Oral: Refer to adult dosing. Initial: 5 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7996040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Initial dose: 5 mg/day; may increase every 2 weeks up to a maximum of 20 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Initial dose: 5 mg/day; may increase every 2 weeks up to a maximum of 20 mg/day. Supplemental dose not required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustments are not routinely required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7996084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerlone&reg;: 10 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kerlone&reg;: 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7995916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7996048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Absorption is not affected by food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7995941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Management of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8436669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of coronary artery disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7995910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Betaxolol may be confused with bethanechol, labetalol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7995969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (6% to 8%; symptomatic bradycardia: &lt;1% to 2%; dose-dependent), chest pain (2% to 7%), palpitation (2%), edema (&le;2%; similar to placebo)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (3% to 10%), insomnia (1% to 5%), lethargy (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2% to 6%), dyspepsia (4% to 5%), diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (3% to 5%), paresthesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (2%), pharyngitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antinuclear antibody positive (5%), cold extremities (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Acidosis, allergy, alopecia, ALT increased, AST increased, amnesia, anemia, angina, anorexia, arrhythmia, arthropathy, ataxia, atrioventricular block, blepharitis, breast fibroadenosis, bronchitis, bronchospasm, cataract, cerebrovascular disorder, conjunctivitis, constipation, cough, cystitis, deafness, depression (&lt;1%), diabetes, diaphoresis, dreams abnormal (1%), dysphagia, dysuria, emotional lability, epistaxis, erythematous rash, fever, flu, flushing, hallucinations, heart failure, hypercholesterolemia, hyper-/hypotension, hyper-/hypoglycemia, hyper-/hypokalemia, hyperlipemia, hypertrichosis, hyperuricemia, impotence (1%), intermittent claudication, iritis, labyrinth disorder, LDH increased, leukocytosis, libido decreased, lymphadenopathy, malaise, menstrual disorder, MI, muscle cramps, nervousness (1%), neuralgia, neuropathy, numbness, ocular  hemorrhage, oliguria, peripheral ischemia, Peyronie&rsquo;s disease, pneumonia, psoriasis exacerbation, prostatitis, proteinuria, pruritus, purpura, rash (1%), renal function abnormal, rhinitis (1%), rigors, scotoma, sinusitis, stupor, syncope, taste abnormal, tendonitis, thinking abnormal, thrombophlebitis, thrombosis, tinnitus, tremor, twitching, thrombocytopenia, vision abnormal, vomiting, weight gain/loss, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7995965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to betaxolol or any component of the formulation; sinus bradycardia; heart block greater than first-degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7995966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; however, betaxolol, with B",
"     <sub>",
"      1",
"     </sub>",
"     selectivity, may be used cautiously with the lowest possible dose (eg, 5-10 mg/day), availability of a bronchodilator, and close monitoring; if a dosage increase is indicated, administer in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular insufficiency: Use with caution in patients with cerebrovascular insufficiency; hypotension and decreased heart rate may reduce cerebral blood flow.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate and/or mask signs and symptoms of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may potentiate myasthenia-related muscle weakness, including diplopia and ptosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis but cause and effect has not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in severe impairment and in patients on dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, ischemia, and/or angina exacerbation. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F7995993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7995994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7995998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid bayberry; blue cohosh, cayenne, ephedra, ginger, ginseng (American), gotu kola, and licorice (may worsen hypertension). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may have increased antihypertensive effects).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7995942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7995963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic were effects were not observed in animal reproduction studies; therefore, the manufacturer classifies betaxolol as pregnancy category C. Betaxolol crosses the placenta and can be detected in the amniotic fluid as well as umbilical cord blood. Measurable concentrations of betaxolol can also be found in the newborn blood and urine. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Following maternal use of betaxolol, the beta-blocker effects may persist in the neonate for several days after birth. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. The half-life and serum concentration of betaxolol immediately postpartum are not significantly different than what is observed in nonpregnant women. Betaxolol is currently not recommended for the initial treatment of hypertension in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7995964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10546209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Betaxolol is excreted into breast milk in amounts which may have a pharmacologic effect in the nursing infant. The manufacturer recommends that caution be exercised when administering betaxolol to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7996086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Betaxolol HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $123.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $186.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Kerlone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $156.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $235.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7996050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, pulse; baseline renal function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betac (BG, KP, MY, SG);",
"     </li>",
"     <li>",
"      Betarun (TW);",
"     </li>",
"     <li>",
"      Kerlon (IT, NL);",
"     </li>",
"     <li>",
"      Kerlone (AT, BE, DE, FI, FR, GR, KP, MY, PH, PY, TW);",
"     </li>",
"     <li>",
"      Lokren (BG, HN, PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7996023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively blocks beta",
"     <sub>",
"      1",
"     </sub>",
"     -receptors, with little or no effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7996025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to multiple metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 14-22 hours; prolonged in hepatic disease and/or chronic renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1.5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;80%, as unchanged drug [15%] and inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 40(7):1366-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/12383588/pubmed\" id=\"12383588\" target=\"_blank\">",
"        12383588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;ACC/AHA 2006 Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac Surgery: Focused Update on Perioperative Beta-Blocker Therapy. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 47(11):2343-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/16750714/pubmed\" id=\"16750714\" target=\"_blank\">",
"        16750714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul AB, Wetterslev J, Gluud C, et al, &ldquo;Effect of Perioperative Beta Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial. DIPOM Trial Group,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006, 332(7556):1482.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/16793810/pubmed\" id=\"16793810\" target=\"_blank\">",
"        16793810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redelmeier D, Scales D, and Kopp A, \"Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2005, 331(7522):932.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/16210252/pubmed\" id=\"16210252\" target=\"_blank\">",
"        16210252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong DG, Spence JD, Lamki L, et al, &ldquo;Effect of Nonsteroidal Anti-inflammatory Drugs on Control of Hypertension of Beta-Blockers and Diuretics,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1986, 1(8488):997-1001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Raymer K, Butler R, et al, &ldquo;The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Am Hear J",
"      </i>",
"      , 2006, 152(5):983-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/24/37255/abstract-text/17070177/pubmed\" id=\"17070177\" target=\"_blank\">",
"        17070177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8976 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-8C22B84DCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37255=[""].join("\n");
var outline_f36_24_37255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995913\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995918\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996038\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996039\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996040\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682290\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996084\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995916\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996048\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995941\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8436669\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995910\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995969\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995965\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995966\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995993\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995994\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995998\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995942\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995963\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7995964\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10546209\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996086\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996050\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961958\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996023\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7996025\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8976|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/53/4950?source=related_link\">",
"      Betaxolol (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/14/21732?source=related_link\">",
"      Betaxolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/33/18965?source=related_link\">",
"      Betaxolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_24_37256="Hymenolepiasis nana eggs";
var content_f36_24_37256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Hymenolepiasis nana eggs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A-D) Eggs of",
"    <em>",
"     Hymenolepis nana",
"    </em>",
"    . These eggs are oval and smaller than those of",
"    <em>",
"     H. diminuta",
"    </em>",
"    , with a size range of 30 to 50 micrometers. On the inner membrane are two poles, from which four to eight polar filaments spread out between the two membranes. The oncosphere has six hooks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Hymenolepiasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/hymenolepiasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/hymenolepiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37256=[""].join("\n");
var outline_f36_24_37256=null;
var title_f36_24_37257="Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children";
var content_f36_24_37257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/24/37257/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37257/contributors\">",
"     Andrea T Cruz, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/24/37257/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37257/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/24/37257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37257/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/24/37257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1060361588\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacteria (NTM) are a miscellaneous collection of acid-fast bacteria that are widespread in the environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/1\">",
"     1",
"    </a>",
"    ]. They have been isolated from numerous environmental sources including water, soil, food products, and domestic and wild animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2\">",
"     2",
"    </a>",
"    ]. Nosocomial transmission has occurred with medical equipment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 130 species of have been identified, not all of which have been documented to cause disease in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. NTM pathogens are classified as rapidly growing or slowly growing (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"mobipreview.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    ). Rapidly growing species grow within seven days and include",
"    <em>",
"     Mycobacterium fortuitum, M. abscessus,",
"    </em>",
"    and",
"    <em>",
"     M. chelonae",
"    </em>",
"    . Slowly growing species require several weeks to grow and include",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC),",
"    <em>",
"     M. marinum,",
"    </em>",
"    and",
"    <em>",
"     M. kansasii",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=see_link&amp;anchor=H2#H2\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NTM can cause a broad range of infections that vary depending on the particular NTM species and the host. In children, NTM cause four main clinical syndromes: lymphadenopathy, skin and soft tissue infection (SSTI), pulmonary disease (predominantly in children with underlying pulmonary conditions), and disseminated disease (predominantly in children with immune compromise).",
"   </p>",
"   <p>",
"    This topic will provide an overview of NTM disseminated infections and bacteremia in children. NTM lymphadenitis, SSTI, and pulmonary infections in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13994?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7722?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial skin and soft tissue infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/282?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial pulmonary infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22091078\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC) is the most common cause of disseminated nontuberculous mycobacteria (NTM) infection in children without central vascular access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In children with indwelling vascular catheters,",
"    <em>",
"     M. mucogenicum",
"    </em>",
"    and other species that are ubiquitous in water supplies have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology, culture requirements, and methods of speciation for NTM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=see_link\">",
"     \"Microbiology of nontuberculous mycobacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22091092\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the true burden of nontuberculous mycobacterial (NTM) infections in children are unavailable; in part because NTM infections may be asymptomatic and because NTM infections are not communicable, reporting of NTM infections is not required in the United States or many other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2\">",
"     2",
"    </a>",
"    ]. Nonetheless, the overall prevalence of NTM disease appears to be increasing with time (possibly as a result of enhanced detection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disseminated NTM is rare in immune-competent children. In a prospective surveillance study, only 3 of 192 children with confirmed or probable NTM infection had disseminated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/20\">",
"     20",
"    </a>",
"    ]. Two of the cases occurred in immunocompromised children with intravenous catheter-related bacteremia. Most case series of disseminated NTM describe disseminated MAC in children with acquired immunodeficiency virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, with the advent of highly active antiretroviral therapy, the incidence of disseminated MAC in HIV-positive children has declined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/11,23,24\">",
"     11,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NTM are transmitted through environmental sources. Water (from both natural and treated sources) is a common reservoir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/12-14,25-29\">",
"     12-14,25-29",
"    </a>",
"    ]. Aquatic transmission of NTM is facilitated by the formation of biofilms, which permit survival under a variety of environmental conditions and, through detachment, allow dissemination of large numbers of organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25288?source=see_link\">",
"     \"Pathogenesis of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The respiratory and gastrointestinal tracts are the usual portal of entry for disseminated disease. However, direct inoculation may occur. NTM bacteremia in pediatric oncology patients has been reported after flushing central lines with tap water and when inadequate chlorination allowed proliferation of NTM species in water from hospital faucets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060363832\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of nontuberculous mycobacteria (NTM) bacteremia or disseminated NTM disease in children have been reported among children with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital defects in interferon gamma and interleukin (IL)-12 synthesis and response pathways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/31-35\">",
"       31-35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chemotherapy for malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Solid organ or hematopoietic stem cell transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/36-39\">",
"       36-39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intravenous catheter (particularly in immune-compromised patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/10,20,40,41\">",
"       10,20,40,41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Advanced HIV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/11,21,22\">",
"       11,21,22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564807774\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated nontuberculous mycobacteria (NTM) disease occurs almost exclusively in immune-compromised children. Clinical features are nonspecific may include fever, weight loss, sweating, diarrhea, generalized lymphadenopathy, generalized cutaneous lesions (",
"    <a class=\"graphic graphic_picture graphicRef86162 \" href=\"mobipreview.htm?35/46/36581\">",
"     picture 1",
"    </a>",
"    ), diffuse abdominal tenderness, and hepatosplenomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2,22,23,38,42-44\">",
"     2,22,23,38,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms and signs reflect the major sites of involvement (eg, bone marrow, lymphoreticular system, gastrointestinal tract, lungs). Skin lesions may be the first manifestation of disseminated infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with HIV-infection who have recently initiated antiretroviral therapy may present immune with reconstitution inflammatory syndrome. (See",
"    <a class=\"local\" href=\"#H1590633237\">",
"     'Immune reconstitution inflammatory syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is little information about the presenting signs of disseminated NTM in children. However, in one series of 20 HIV-positive children with disseminated MAC, all 20 had persistent failure to gain weight, 18 had anorexia, 18 had abdominal",
"    <span class=\"nowrap\">",
"     pain/tenderness,",
"    </span>",
"    and 16 had persistent or recurrent fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/22\">",
"     22",
"    </a>",
"    ]. Fourteen had all four symptoms, and six patients had at least two of the four symptoms. Nine had intermittent diarrhea, three had persistent diarrhea, five had night sweats, and three had joint pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060365934\">",
"    <span class=\"h1\">",
"     LABORATORY FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings of disseminated nontuberculous mycobacterial disease are nonspecific and may include normocytic anemia, elevated lactate dehydrogenase, and elevated alkaline phosphatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/23,46\">",
"     23,46",
"    </a>",
"    ]. Bacteremia may be intermittent and low grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2,44,47,48\">",
"     2,44,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22091180\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated nontuberculous mycobacterial (NTM) disease should be suspected in immune-compromised children with skin lesions or nonspecific symptoms and signs (eg, weight loss, abdominal pain, fever, etc) without other plausible explanations.",
"   </p>",
"   <p>",
"    Definitive diagnosis disease requires recovery of NTM from blood, bone marrow, liver, visceral lymph nodes, or other normally sterile body site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/45,49,50\">",
"     45,49,50",
"    </a>",
"    ]. Culture is essential to differentiate NTM from",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    , determine which species of NTM is causing infection, and perform drug-susceptibility testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 90 percent of individuals diagnosed with disseminated",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC) have positive blood cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2\">",
"     2",
"    </a>",
"    ]. Multiple blood cultures may be required because NTM bacteremia can be intermittent and low grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/44,47,48,51\">",
"     44,47,48,51",
"    </a>",
"    ]. Mycobacterial blood cultures are collected in special media, different from the media used in standard bacterial blood cultures, and must be specifically requested. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with suspected disseminated NTM and two negative blood cultures, diagnosis of disseminated NTM disease may require tissue specimens from involved sites (eg, bone marrow, liver, lymph node) for culture, acid-fast stains, and histopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2\">",
"     2",
"    </a>",
"    ]. Intrathoracic, intraabdominal, or retroperitoneal adenopathy may be accessible through fine-needle aspiration.",
"   </p>",
"   <p>",
"    Histopathology demonstrating acid-fast bacilli (AFB) or granulomas supports the diagnosis of disseminated NTM disease in children with negative blood cultures. However, these findings do not distinguish NTM from",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    , and the absence of these findings does not exclude NTM disease. In one series of immune-compromised (non-HIV) adults with disseminated NTM infection, only one-half had biopsy findings consistent with mycobacterial infection (eg, granulomas), and AFB smears were positive in fewer than 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590631880\">",
"    <span class=\"h1\">",
"     POST-DIAGNOSIS EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacterial (NTM) bacteremia in immunocompromised children should prompt evaluation for disease at remote sites; this may include computed tomography of the chest, abdomen, and pelvis. In a small series of pediatric oncology patients, four of five children with vascular catheter-associated NTM bacteremia had pulmonary nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22091215\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of disseminated nontuberculous mycobacterial disease in immune-compromised children includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disseminated fungal disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/6/25703?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical features and diagnosis of candidemia in children\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nocardiosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16489?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical manifestations and diagnosis of nocardiosis\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Actinomycosis",
"     </li>",
"     <li>",
"      Miliary tuberculosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Metastatic disease (in older patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histopathology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microbiology studies are needed to differentiate among the possible etiologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564807864\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590632016\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of disseminated nontuberculous mycobacterial (NTM) in immune-compromised children should be undertaken in consultation with an expert in infectious diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2,8,43\">",
"     2,8,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If bacteremia or disseminated infection is associated with a vascular catheter, the catheter must be removed. It is rare to clear NTM bacteremia with the line in situ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are reports of isolated cases of NTM bacteremia being successfully treated with removal of the vascular catheter without antimycobacterial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/14\">",
"     14",
"    </a>",
"    ]. However, given the potential for development of pulmonary nodules or other signs of disseminated disease in asymptomatic immunocompromised children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/36\">",
"     36",
"    </a>",
"    ], we suggest antimycobacterial therapy in addition to removal of the catheter.",
"   </p>",
"   <p>",
"    Treatment for disseminated NTM infection or bacteremia is usually divided into two phases. The initial phase is more intensive and usually based upon the most likely susceptibility patterns. The continuation phase is less intensive and may be tailored according to susceptibilities, if susceptibilities are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590632073\">",
"    <span class=\"h2\">",
"     Antimycobacterial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1845298317\">",
"    <span class=\"h3\">",
"     Antimicrobial susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC) is the most common NTM species associated with disseminated NTM disease in children. MAC is generally susceptible to macrolide antibiotics with good correlation between in vitro testing and clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     M. mucogenicum",
"    </em>",
"    is another potential cause of disseminated NTM among children with indwelling vascular catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In vitro,",
"    <em>",
"     M. mucogenicum",
"    </em>",
"    is usually susceptible to macrolides, carbapenems, fluoroquinolones,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and aminoglycosides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590633266\">",
"    <span class=\"h3\">",
"     Initial phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with disseminated NTM disease or NTM bacteremia, we suggest therapy with",
"    <strong>",
"     at least three",
"    </strong>",
"    drugs to which the isolate is susceptible (or likely susceptible if susceptibility studies are pending) for the first one to two months or until clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic improvement is noted. A typical regimen may include (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"mobipreview.htm?8/4/8271\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A macrolide (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/13/6357?source=see_link\">",
"       Ethambutol",
"      </a>",
"     </li>",
"     <li>",
"      A rifamycin (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/31/12792?source=see_link\">",
"       rifabutin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"     Amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26917?source=see_link\">",
"     streptomycin",
"    </a>",
"    , or a fluoroquinolone may be substituted for the macrolide or added as a fourth drug for patients who develop breakthrough MAC while receiving MAC prophylaxis or for patients in whom there is concern about macrolide resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized controlled trials evaluating therapy for disseminated NTM in children. In randomized and observational studies in adults with HIV and disseminated MAC, multi-drug regimens that include macrolides have been associated with clinical and microbiologic improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Monotherapy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    reduced bacteremia, but nearly one-half of patients developed clarithromycin resistance, so monotherapy is contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/57\">",
"     57",
"    </a>",
"    ]. The addition of rifamycin to multi-drug regimens that do not include macrolides is associated with shorter duration of bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/58\">",
"     58",
"    </a>",
"    ]. Although this benefit is not clear in macrolide-containing multi-drug regimens, the addition of rifamycin appears to be associated with decreased development of macrolide-resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1845298724\">",
"    <span class=\"h3\">",
"     Continuation phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continuation phase usually begins after one to two months, when the child has demonstrated clinical improvement. The child is transitioned to two drugs, based upon the results of susceptibility studies. If possible, the two-drug regimen should be entirely oral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590632894\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total duration of therapy usually is 6 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590632935\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590633258\">",
"    <span class=\"h4\">",
"     Drug-specific effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimycobacterial agents that are used to treat disseminated NTM and NTM bacteremia often are difficult to tolerate and some have important toxicities. Important adverse effects include (but are not limited to) ototoxicity and nephrotoxicity with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26917?source=see_link\">",
"     streptomycin",
"    </a>",
"    , optic neuropathy with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/13/6357?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and hepatotoxicity with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    . The adverse effects of the agents used to treat NTM infections are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=see_link\">",
"     \"Aminoglycosides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30757?source=see_link\">",
"     \"Ethambutol: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1514?source=see_link\">",
"     \"Azithromycin, clarithromycin, and telithromycin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24998?source=see_link\">",
"     \"Rifampin and other rifamycins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19142?source=see_link\">",
"     \"Isoniazid: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common adverse effects of antimycobacterial medications are provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"mobipreview.htm?8/4/8271\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It may be challenging to determine which medication is responsible for a given reaction because treatment of disseminated NTM requires multiple medications. The medical comorbidities of children predisposed to disseminated NTM infection further complicate the issue. Children with comorbid medical conditions may require additional medications (eg, antiretroviral therapy) that can interact with antimycobacterial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/16,59\">",
"     16,59",
"    </a>",
"    ]. They also may have baseline hepatic or renal dysfunction, which may decrease medication tolerance.",
"   </p>",
"   <p>",
"    Most adverse effects are monitored clinically by assessing the patient for symptoms (eg, dizziness, vomiting, etc). However, specific parameters should be monitored as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/15/35056?source=see_link\">",
"       Azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      &ndash; Periodic alkaline phosphatase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) during the first three months of therapy. Baseline electrocardiogram to evaluate for prolonged QT interval is suggested before the initiation of therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/31/12792?source=see_link\">",
"       Rifabutin",
"      </a>",
"      &ndash; Periodic white blood cell (WBC) counts.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"       Amikacin",
"      </a>",
"      &ndash; Periodic amikacin levels.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/32/29188?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      &ndash; Periodic blood counts.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      &ndash; Periodic blood counts.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       Linezolid",
"      </a>",
"      &ndash; Periodic blood counts and eye examinations by an ophthalmologist.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/13/6357?source=see_link\">",
"       Ethambutol",
"      </a>",
"      &ndash; Periodic eye examinations by an ophthalmologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children receiving",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    , a macrolide, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/13/6357?source=see_link\">",
"     ethambutol",
"    </a>",
"    , we suggest baseline laboratory evaluation as indicated above. Thereafter, the need for subsequent laboratory evaluation should be driven by symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    examination findings; scheduled laboratory evaluation may not be needed unless patients are receiving other marrow-suppressive or potentially hepatotoxic medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590633237\">",
"    <span class=\"h4\">",
"     Immune reconstitution inflammatory syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune reconstitution inflammatory syndrome (IRIS) refers to clinical worsening while receiving effective antimycobacterial chemotherapy and is well described in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/60\">",
"     60",
"    </a>",
"    ]. IRIS can result in worsening of existing symptoms (paradoxical IRIS) or new onset of opportunistic infections after immune reconstitution (unmasking IRIS). The most common symptoms of NTM IRIS include fever, abdominal pain, subcutaneous nodules, and suppurative lymphadenitis.",
"   </p>",
"   <p>",
"    One series reported NTM-induced IRIS in 9 (5 percent) of 153 HIV-infected children 2 to 26 weeks after initiation of antiretroviral therapy; MAC and",
"    <em>",
"     M. scrofulaceum",
"    </em>",
"    were the most common isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/61\">",
"     61",
"    </a>",
"    ]. Another pediatric series documented IRIS from a number of causes, mycobacterial and otherwise, in up to 20 percent of HIV-infected children initiating antiretroviral therapy; IRIS was associated with malnutrition and high viral loads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although IRIS has been associated with death (primarily from rapidly enlarging lymph nodes causing airway compression or expansile central nervous system lesions causing brainstem herniation), most IRIS cases are mild and can be managed with nonsteroidal antiinflammatory medications or glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1326137755\">",
"    <span class=\"h2\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who are treated for disseminated NTM infection have improvement in fever after two to four weeks and improvement in symptoms after four to six weeks of initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/43\">",
"     43",
"    </a>",
"    ]. However, clinical improvement may be delayed in patients with extensive disease or advanced immunosuppression. Patients who do not have clinical improvement after four to eight weeks of initial therapy should have NTM blood culture repeated. Clearance of NTM from the blood may take up to 12 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1845299856\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure is defined by the absence of a clinical response and persistence of mycobacteremia after 8 to 12 weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children with treatment failure, susceptibility testing should be repeated on the NTM isolate and a new treatment regimen instituted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/43\">",
"     43",
"    </a>",
"    ]. This regimen should be determined in consultation with an expert. It should include at least two drugs to which the isolate is susceptible and were not previously used (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    , quinolones,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/18/26917?source=see_link\">",
"     streptomycin",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22091280\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354087\">",
"    <span class=\"h2\">",
"     HIV-positive children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prevention against",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC) is recommended for HIV-infected children with low CD4 cell counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/43\">",
"     43",
"    </a>",
"    ]. Given the variation in normal CD4 cell count by age and that disseminated MAC has been seen in young children with high CD4 cell counts, prophylaxis is recommended for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Children &lt;1 year: &lt;750",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"     </li>",
"     <li>",
"      Children 1 to 2 years: &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"     </li>",
"     <li>",
"      Children 2 to5 years: &lt;75",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"     </li>",
"     <li>",
"      Children &ge;6 years: &lt;50",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before initiation of prophylaxis, a blood culture should be performed to exclude disseminated MAC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/8\">",
"     8",
"    </a>",
"    ]. Primary prophylaxis usually consists of a macrolide, either [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/8,43\">",
"     8,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/15/35056?source=see_link\">",
"       Azithromycin",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 1200 mg) orally weekly,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/37/30297?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 500 mg) orally twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients unable to tolerate macrolides,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/31/12792?source=see_link\">",
"     rifabutin",
"    </a>",
"    is a less effective alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/8,63,64\">",
"     8,63,64",
"    </a>",
"    ]. However, it should not be used until",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    disease has been excluded (because monotherapy with rifabutin could lead to resistance).",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    should be excluded by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (or interferon gamma release assays in children &gt;4 years of age), assessment of",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    risk factors, and for children with acid-fast bacillus-smear positive respiratory specimens, polymerase chain reaction for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    In randomized controlled trials in HIV-positive adults with decreased CD4 counts, the incidence of MAC bacteremia was reduced in patients who received MAC prophylaxis with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/31/12792?source=see_link\">",
"     rifabutin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/65\">",
"     65",
"    </a>",
"    ]; subsequent trials comparing macrolides and rifabutin found macrolides to be superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary prophylaxis may be discontinued in children &ge;2 years of age who have been stable on antiretroviral therapy for at least six months and have sustained CD4 cell count recovery (&gt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for children two to five years of age; &gt;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"     <sup>",
"     </sup>",
"    </span>",
"    for children &ge;6 years of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/43\">",
"     43",
"    </a>",
"    ]. There are no recommendations for discontinuation of MAC prophylaxis for children younger than two years of age.",
"   </p>",
"   <p>",
"    We suggest that children with HIV infection who develop disseminated MAC receive lifelong MAC prophylaxis. However, some experts suggest secondary prophylaxis can be discontinued in children &gt;2 years old who have completed &gt;12 months of therapy for MAC and who have had a sustained (&ge;6 months) CD4 cell count recovery (&gt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for children two to five years of age; &gt;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"     <sup>",
"     </sup>",
"    </span>",
"    for children &ge;6 years of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/43\">",
"     43",
"    </a>",
"    ]. Should virologic failure or decline in CD4 count ensue, secondary prophylaxis should be re-initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354137\">",
"    <span class=\"h2\">",
"     Other immune-compromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether immune-compromised children who do not have HIV infection should receive prophylaxis for MAC depends upon the underlying disorder.",
"   </p>",
"   <p>",
"    Given the low incidence of MAC in pediatric hematopoietic stem cell transplantation recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/66\">",
"     66",
"    </a>",
"    ], prophylaxis is not routinely recommended.",
"   </p>",
"   <p>",
"    Use of macrolide prophylaxis after lung transplantation is controversial. There is evidence that long-term macrolide usage decreases intracellular killing of mycobacteria within macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/67\">",
"     67",
"    </a>",
"    ]. However, pre-existing",
"    <em>",
"     M. abscessus",
"    </em>",
"    lung disease in cystic fibrosis patients has been associated with disease recurrence post-transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22091287\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morbidity and mortality for disseminated nontuberculous mycobacterial (NTM) disease is substantial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/22\">",
"     22",
"    </a>",
"    ]. The outcome often is related to immune system recovery (eg, initiation of antiretroviral therapy in HIV-infected children or reduction of immunosuppressive regimen in organ transplant recipients).",
"   </p>",
"   <p>",
"    After the advent of advent of highly active antiretroviral therapy, the incidence of disseminated NTM infection among children in the Perinatal AIDS Collaborative Transmission Study declined from 1.3 to 2.0 cases per 100 patient years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37257/abstract/11\">",
"     11",
"    </a>",
"    ]. Fewer opportunistic infections were associated with increased survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22091294\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disseminated nontuberculous mycobacterial (NTM) disease and NTM bacteremia occur in children with congenital or acquired immunodeficiency. (See",
"      <a class=\"local\" href=\"#H22091092\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1060363832\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <em>",
"       Mycobacterium avium",
"      </em>",
"      complex (MAC) is the most common cause of disseminated NTM infection in children without central vascular access. Among children with central vascular access,",
"      <em>",
"       M. mucogenicum",
"      </em>",
"      and other species that are ubiquitous in water supplies have been reported. (See",
"      <a class=\"local\" href=\"#H22091078\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical and laboratory features are nonspecific and may include fever, weight",
"      <span class=\"nowrap\">",
"       loss/failure",
"      </span>",
"      to gain weight, night sweats, generalized lymphadenopathy, skin lesions (",
"      <a class=\"graphic graphic_picture graphicRef86162 \" href=\"mobipreview.htm?35/46/36581\">",
"       picture 1",
"      </a>",
"      ), abdominal tenderness, diarrhea, hepatosplenomegaly, anemia, elevated lactate dehydrogenase, and elevated alkaline phosphatase. Skin lesions may be the first manifestation of disseminated disease. (See",
"      <a class=\"local\" href=\"#H564807774\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1060365934\">",
"       'Laboratory features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive diagnosis of disseminated NTM disease requires recovery of NTM from blood, bone marrow, liver, visceral lymph nodes, or other normally sterile body site. Mycobacterial blood cultures are collected in special media, different from the media used in standard bacterial blood cultures, and must be specifically requested. (See",
"      <a class=\"local\" href=\"#H22091180\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of disseminated NTM is usually undertaken in consultation with an expert in infectious diseases. If NTM bacteremia or disseminated disease is associated with a vascular catheter, the catheter must be removed. (See",
"      <a class=\"local\" href=\"#H1590632016\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that disseminated NTM disease be treated initially with at least three drugs to which the isolate is susceptible (or likely to be susceptible if susceptibility testing is pending) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Appropriate drugs may include macrolides,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/13/6357?source=see_link\">",
"       ethambutol",
"      </a>",
"      , rifamycins, aminoglycosides, and fluoroquinolones (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"mobipreview.htm?8/4/8271\">",
"       table 2",
"      </a>",
"      ). The initial regimen is continued for one to two months or until there is clinical and radiographic improvement. (See",
"      <a class=\"local\" href=\"#H1590632073\">",
"       'Antimycobacterial therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1590633266\">",
"       'Initial phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial treatment phase is followed by a continuation phase. We suggest that during the continuation phase, children with disseminated NTM infection be treated with two drugs to which the isolate is susceptible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If possible, both of these drugs should be administered orally. The total duration of therapy is 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H1845298724\">",
"       'Continuation phase'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1590632894\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimycobacterial prophylaxis may prevent disseminated NTM infection in immune-compromised patients. We recommend prophylaxis against MAC for children with HIV infection and low CD4 counts (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest that children with HIV infection who develop MAC receive lifelong MAC prophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22091280\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survival of disseminated NTM disease is enhanced by immune system recovery (eg, initiation of antiretroviral therapy in HIV-infected children or reduction of immunosuppressive regimen in organ transplant recipients). (See",
"      <a class=\"local\" href=\"#H22091287\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/1\">",
"      Fraser L, Moore P, Kubba H. Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review. Otolaryngol Head Neck Surg 2008; 138:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/2\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/3\">",
"      Bolan G, Reingold AL, Carson LA, et al. Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J Infect Dis 1985; 152:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/4\">",
"      Celdr&aacute;n A, Esteban J, Ma&ntilde;as J, Granizo JJ. Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair. J Hosp Infect 2007; 66:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/5\">",
"      Ferguson DD, Gershman K, Jensen B, et al. Mycobacterium goodii infections associated with surgical implants at Colorado hospital. Emerg Infect Dis 2004; 10:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/6\">",
"      McNabb A, Eisler D, Adie K, et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol 2004; 42:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/7\">",
"      Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Diseases caused by nontuberculous mycobacteria: (atypical mycobacteria, mycobacteria other than Mycobacterium tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.759.",
"    </li>",
"    <li>",
"     Mycobacterium. In: List of Prokaryotic names with Standing in Nomenclature. file://www.bacterio.cict.fr/m/mycobacterium.html (Accessed on July 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/10\">",
"      Cruz AT, Ong LT, Starke JR. Mycobacterial infections in Texas children: a 5-year case series. Pediatr Infect Dis J 2010; 29:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/11\">",
"      Nesheim SR, Kapogiannis BG, Soe MM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 2007; 120:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/12\">",
"      Fleming GA, Frangoul H, Dermody TS, Halasa N. A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water. Pediatr Infect Dis J 2006; 25:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/13\">",
"      Livni G, Yaniv I, Samra Z, et al. Outbreak of Mycobacterium mucogenicum bacteraemia due to contaminated water supply in a paediatric haematology-oncology department. J Hosp Infect 2008; 70:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/14\">",
"      Shachor-Meyouhas Y, Sprecher H, Eluk O, et al. An outbreak of Mycobacterium mucogenicum bacteremia in pediatric hematology-oncology patients. Pediatr Infect Dis J 2011; 30:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/15\">",
"      Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/16\">",
"      Chesney PJ. Nontuberculous mycobacteria. Pediatr Rev 2002; 23:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/17\">",
"      Grange JM, Yates MD, Pozniak A. Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases. Arch Dis Child 1995; 72:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/18\">",
"      Pham-Huy A, Robinson JL, Tapi&eacute;ro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health 2010; 15:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/19\">",
"      Vu TT, Daniel SJ, Quach C. Nontuberculous mycobacteria in children: a changing pattern. J Otolaryngol 2005; 34 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/20\">",
"      Blyth CC, Best EJ, Jones CA, et al. Nontuberculous mycobacterial infection in children: a prospective national study. Pediatr Infect Dis J 2009; 28:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/21\">",
"      Horsburgh CR Jr, Caldwell MB, Simonds RJ. Epidemiology of disseminated nontuberculous mycobacterial disease in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1993; 12:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/22\">",
"      Hoyt L, Oleske J, Holland B, Connor E. Nontuberculous mycobacteria in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1992; 11:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/23\">",
"      Horsburgh CR Jr, Gettings J, Alexander LN, Lennox JL. Disseminated Mycobacterium avium complex disease among patients infected with human immunodeficiency virus, 1985-2000. Clin Infect Dis 2001; 33:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/24\">",
"      Tumbarello M, Tacconelli E, de Donati KG, et al. Changes in incidence and risk factors of Mycobacterium avium complex infections in patients with AIDS in the era of new antiretroviral therapies. Eur J Clin Microbiol Infect Dis 2001; 20:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/25\">",
"      Mangione EJ, Huitt G, Lenaway D, et al. Nontuberculous mycobacterial disease following hot tub exposure. Emerg Infect Dis 2001; 7:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/26\">",
"      Falkinham JO 3rd. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011; 17:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/27\">",
"      Stout JE, Gadkowski LB, Rath S, et al. Pedicure-associated rapidly growing mycobacterial infection: an endemic disease. Clin Infect Dis 2011; 53:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/28\">",
"      Lee WJ, Kim TW, Shur KB, et al. Sporotrichoid dermatosis caused by Mycobacterium abscessus from a public bath. J Dermatol 2000; 27:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/29\">",
"      von Baum H, Bommer M, Forke A, et al. Is domestic tap water a risk for infections in neutropenic patients? Infection 2010; 38:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/30\">",
"      Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol 2005; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/31\">",
"      Holland SM. Interferon gamma, IL-12, IL-12R and STAT-1 immunodeficiency diseases: disorders of the interface of innate and adaptive immunity. Immunol Res 2007; 38:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/32\">",
"      Marazzi MG, Chapgier A, Defilippi AC, et al. Disseminated Mycobacterium scrofulaceum infection in a child with interferon-gamma receptor 1 deficiency. Int J Infect Dis 2010; 14:e167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/33\">",
"      Tsolia MN, Chapgier A, Taprantzi P, et al. Disseminated nontuberculous mycobacterial infection in a child with interferon-gamma receptor 1 deficiency. Eur J Pediatr 2006; 165:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/34\">",
"      Koscielniak E, de Boer T, Dupuis S, et al. Disseminated Mycobacterium peregrinum infection in a child with complete interferon-gamma receptor-1 deficiency. Pediatr Infect Dis J 2003; 22:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/35\">",
"      Vesterhus P, Holland SM, Abrahamsen TG, Bjerknes R. Familial disseminated infection due to atypical mycobacteria with childhood onset. Clin Infect Dis 1998; 27:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/36\">",
"      Wei MC, Banaei N, Yakrus MA, et al. Nontuberculous mycobacteria infections in immunocompromised patients: single institution experience. J Pediatr Hematol Oncol 2009; 31:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/37\">",
"      Nicholson O, Feja K, LaRussa P, et al. Nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplant recipients: case report and review of the literature. Pediatr Infect Dis J 2006; 25:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/38\">",
"      Lau SK, Curreem SO, Ngan AH, et al. First report of disseminated Mycobacterium skin infections in two liver transplant recipients and rapid diagnosis by hsp65 gene sequencing. J Clin Microbiol 2011; 49:3733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/39\">",
"      Singh S, Yosypiv IV, Iorember FM. Disseminated mycobacterium avium complex infection in a pediatric renal transplant recipient. Clin Pediatr (Phila) 2012; 51:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/40\">",
"      Thorell EA, Sharma M, Jackson MA, et al. Disseminated nontuberculous mycobacterial infections in sickle cell anemia patients. J Pediatr Hematol Oncol 2006; 28:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/41\">",
"      Rodgers GL, Mortensen JE, Blecker-Shelly D, et al. Two case reports and review of vascular catheter-associated bacteremia caused by nontuberculous Mycobacterium species. Pediatr Infect Dis J 1996; 15:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/42\">",
"      Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clin Microbiol Infect 2009; 15:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/43\">",
"      Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/44\">",
"      Friedman BF, Edwards D, Kirkpatrick CH. Mycobacterium avium-intracellulare: cutaneous presentations of disseminated disease. Am J Med 1988; 85:257.",
"     </a>",
"    </li>",
"    <li>",
"     Tebruegge M, Curtis N. Mycobacterium species non-tuberculosis. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.786.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/46\">",
"      Gordin FM, Cohn DL, Sullam PM, et al. Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation. J Infect Dis 1997; 176:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/47\">",
"      Parent LJ, Salam MM, Appelbaum PC, Dossett JH. Disseminated Mycobacterium marinum infection and bacteremia in a child with severe combined immunodeficiency. Clin Infect Dis 1995; 21:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/48\">",
"      Hanke CW, Temofeew RK, Slama SL. Mycobacterium kansasii infection with multiple cutaneous lesions. J Am Acad Dermatol 1987; 16:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/49\">",
"      Pacios E, Alcal&aacute; L, Ruiz-Serrano MJ, et al. Evaluation of bone marrow and blood cultures for the recovery of mycobacteria in the diagnosis of disseminated mycobacterial infections. Clin Microbiol Infect 2004; 10:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/50\">",
"      Rose PC, Schaaf HS, Marais BJ, et al. Value of bone marrow biopsy in children with suspected disseminated mycobacterial disease. Int J Tuberc Lung Dis 2011; 15:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/51\">",
"      Horsburgh CR Jr, Selik RM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis 1989; 139:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/52\">",
"      Lai CC, Lee LN, Ding LW, et al. Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan. J Infect 2006; 53:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/53\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/54\">",
"      Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 173:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/55\">",
"      Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999; 28:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/56\">",
"      Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/57\">",
"      Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994; 121:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/58\">",
"      Sullam PM, Gordin FM, Wynne BA. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group. Clin Infect Dis 1994; 19:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/59\">",
"      Haas DW, Koletar SL, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009; 50:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/60\">",
"      Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/61\">",
"      Puthanakit T, Oberdorfer P, Ukarapol N, et al. Immune reconstitution syndrome from nontuberculous mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection. Pediatr Infect Dis J 2006; 25:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/62\">",
"      Wang ME, Castillo ME, Montano SM, Zunt JR. Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru. Pediatr Infect Dis J 2009; 28:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/63\">",
"      Havlir DV, Dub&eacute; MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/64\">",
"      Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000; 181:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/65\">",
"      Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/66\">",
"      Unal E, Yen C, Saiman L, et al. A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2006; 12:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37257/abstract/67\">",
"      Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011; 121:3554.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14425 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37257=[""].join("\n");
var outline_f36_24_37257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22091294\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060361588\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22091078\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22091092\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060363832\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564807774\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060365934\">",
"      LABORATORY FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22091180\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1590631880\">",
"      POST-DIAGNOSIS EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22091215\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H564807864\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1590632016\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1590632073\">",
"      Antimycobacterial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1845298317\">",
"      - Antimicrobial susceptibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1590633266\">",
"      - Initial phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1845298724\">",
"      - Continuation phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1590632894\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1590632935\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1590633258\">",
"      Drug-specific effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1590633237\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1326137755\">",
"      Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1845299856\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22091280\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354087\">",
"      HIV-positive children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354137\">",
"      Other immune-compromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22091287\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22091294\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14425|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/46/36581\" title=\"picture 1\">",
"      Disseminated NTM skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14425|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/0/3085\" title=\"table 1\">",
"      Mycobacteria classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/4/8271\" title=\"table 2\">",
"      Treatment NTM children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/6/25703?source=related_link\">",
"      Clinical features and diagnosis of candidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16489?source=related_link\">",
"      Clinical manifestations and diagnosis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/2/30757?source=related_link\">",
"      Ethambutol: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41943?source=related_link\">",
"      Isoniazid hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/44/19142?source=related_link\">",
"      Isoniazid: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13994?source=related_link\">",
"      Overview of nontuberculous mycobacterial lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/282?source=related_link\">",
"      Overview of nontuberculous mycobacterial pulmonary infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7722?source=related_link\">",
"      Overview of nontuberculous mycobacterial skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25288?source=related_link\">",
"      Pathogenesis of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_24_37258="Uremic toxins";
var content_f36_24_37258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uremic toxins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/24/37258/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37258/contributors\">",
"     Raymond Vanholder, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/24/37258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37258/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/24/37258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/24/37258/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/24/37258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uremic syndrome can be defined as the deterioration of multiple biochemical and physiological functions in parallel with progressive renal failure, thereby resulting in complex but variable symptomatology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Normally, healthy kidneys excrete a myriad of compounds. Uremic retention solutes accumulate in the patient with chronic kidney disease (CKD), including the patient with",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    stage 5 disease or end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/8\">",
"     8",
"    </a>",
"    ]. The retention of these solutes is directly or indirectly attributable to deficient renal clearance.",
"   </p>",
"   <p>",
"    These retained solutes are called uremic toxins when they contribute to the uremic syndrome. Only a few solutes have an established role. Apart from inorganic compounds, only a few compounds conform to the strictest definition of uremic toxins. However, this does not preclude a potential role for various other retention solutes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uremic toxins can be subdivided into three major groups based upon their chemical and physical characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small, water-soluble, non-protein-bound compounds, such as urea",
"     </li>",
"     <li>",
"      Small, lipid-soluble",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      protein-bound compounds, such as the phenols",
"     </li>",
"     <li>",
"      Larger so-called middle-molecules, such as beta2-microglobulin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Views on the uremic syndrome and several uremic solutes have changed substantially during the last two decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. The current state of knowledge about the biochemical, physiological,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical impact of those compounds is presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SMALL WATER-SOLUBLE COMPOUNDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Urea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the extensive number of studies addressing the role of urea in the uremic state, only a few have reported well-defined adverse biochemical or physiologic effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urea inhibits Na-K-2Cl cotransport in human erythrocytes, as well as a number of cell volume-sensitive cellular transport pathways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/10\">",
"       10",
"      </a>",
"      ]. The Na-K-2Cl cotransport is a ubiquitous process that serves numerous vital functions, including cell volume and extrarenal potassium regulation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11657?source=see_link\">",
"       \"Chapter 12B: Renal potassium excretion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urea inhibits macrophage-inducible nitric oxide synthesis at the post-transcriptional level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As the most important osmotically active uremic solute, urea may provoke dialysis disequilibrium if the decrease in plasma concentration of urea during dialysis occurs too rapidly. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13125?source=see_link\">",
"       \"Dialysis disequilibrium syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urea is a precursor of some of the guanidines, especially guanidino succinic acid, which induce biochemical alterations by themselves. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Guanidines'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      With increasing renal dysfunction, increasing amounts of cyanate are spontaneously transformed from urea. The active form of cyanate, isocyanic acid, carbamylates proteins, thereby affecting their structure and function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been hypothesized, however, that the possible toxic effects of urea are counterbalanced by the simultaneous retention of methylamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The apparent low degree of toxicity of urea is corroborated by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lack of correlation with symptoms of the uremic syndrome after addition of urea to the dialysate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The missing impact in the HEMO and ADEMEX studies of an increase in urea removal on outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Marker of dialysis adequacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urea is unequivocally recognized as a marker of solute retention and removal in dialyzed patients. The degree of urea clearance also clearly correlates with clinical outcome of patients undergoing maintenance hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, urea kinetic modeling is one of the principal tools to currently estimate and (if necessary) correct the dialysis dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, high blood concentrations of urea may not necessarily correlate with poor outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High serum concentrations of urea due to adequate protein intake that are compensated by adequate removal may be relatively harmless, as compared with high urea levels due to inadequate dialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low urea levels related to low protein intake may negatively correlate with prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also unclear whether the kinetic behavior of urea is representative of the behavior of other uremic retention solutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/20\">",
"     20",
"    </a>",
"    ]. Data suggest that the dialytic removal of lipophilic protein-bound compounds, as well as that of several other water soluble compounds, is different from that of urea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The validity of urea kinetic modeling has principally been tested with the small pores found in older dialysis membranes. Since the removal of urea is adequate with such membranes but the removal of larger molecules is absent or low, the clearance of middle molecules may not be clearly represented by urea kinetic modeling. Therefore, some investigators have asked whether there should be a search for marker molecules that are representative of large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipid-soluble compounds. Findings consistent with this view include overall survival advantages for those enrolled after greater than 3.7 years of hemodialysis treatment, cardiovascular survival advantages for the entire group of hemodialysis patients treated with large pore dialyzers, and a survival advantage for patients with a lower B2-microglobulin concentration, irrespective of the membrane type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/15,25-27\">",
"     15,25-27",
"    </a>",
"    ]. However, these results were from secondary analysis of the HEMO-study and need to be confirmed in prospective sufficiently powered studies.",
"   </p>",
"   <p>",
"    In the randomized controlled Membrane Permeability Outcome (MPO) study, the group on high flux membranes with larger pores had a superior removal of larger molecules as illustrated by lower predialysis beta2-microglobulin concentrations over time compared with the group on low flux dialyzers with smaller pores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/28\">",
"     28",
"    </a>",
"    ]. Although removal of small water soluble molecules as estimated by",
"    <span class=\"nowrap\">",
"     Kt/Vurea",
"    </span>",
"    was the same for the two membranes, survival was significantly better in patients with serum albumin &lt;4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    which is the patient group for which the study was originally designed, and at secondary analysis, in diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, as urea removal has been related to survival, urea kinetic modeling should continue to be used as a baseline parameter for the study of dialysis adequacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Guanidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guanidines are a large group of structural metabolites of arginine. Several of the guanidino compounds modify key biological functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guanidino succinic acid and guanidinopropionic acid inhibit neutrophil superoxide production [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guanidino compounds exert both pro- and anti-inflammatory effects upon leukocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guanidino succinic acid, gamma-guanidinobutyric acid, methylguanidine, homoarginine, and creatine induce seizures after systemic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cerebroventricular administration in animals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A mixture of guanidino compounds suppresses the natural killer cell response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guanidines cause structural damage to proteins by",
"      <span class=\"nowrap\">",
"       deamidation/isomerization,",
"      </span>",
"      which in turn reduces the binding of homocysteine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nitric oxide and guanidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not observed in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/35\">",
"     35",
"    </a>",
"    ], most investigations have found that nitric oxide (NO) synthesis is inhibited in patients with ESRD. This may result in vasoconstriction, hypertension, immune dysfunction, and neurologic abnormalities.",
"   </p>",
"   <p>",
"    Although arginine (which is also a guanidino compound) markedly enhances the production of nitric oxide (NO), some of the other guanidines, as arginine-analogues, are strong competitive inhibitors of NO synthase. Asymmetric dimethylarginine (ADMA), which is significantly increased in ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/36\">",
"     36",
"    </a>",
"    ], is the most specific endogenous compound with inhibitory effects on NO synthesis. In the brain, ADMA causes vasoconstriction and inhibition of acetylcholine-induced vasorelaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/37\">",
"     37",
"    </a>",
"    ]. It has also been implicated in the development of hypertension, adverse cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/38-41\">",
"     38-41",
"    </a>",
"    ] and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .) Administration of ADMA to healthy volunteers resulted in an increase of vascular resistance and blood pressure in a dose-related manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/41\">",
"     41",
"    </a>",
"    ]. It was also demonstrated that ADMA increased vascular stiffness and decreased cerebral perfusion in healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/42\">",
"     42",
"    </a>",
"    ]. It has been suggested, based on solute dialysance data, that ADMA was protein-bound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in symmetric dimethylarginine (SDMA), the steric variant of ADMA, is more pronounced than that of ADMA but, until recently, this compound has been considered biologically inactive. However, SDMA was linked to an increase in reactive oxygen production and an inhibition of NO-synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/44\">",
"     44",
"    </a>",
"    ]. Subsequently, SDMA was associated with an increase in free radical production by leukocytes; this effect was attributed to an increased calcium influx via store-operated Ca",
"    <sup>",
"     2+",
"    </sup>",
"    channels (SOCs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/45\">",
"     45",
"    </a>",
"    ]. In an extensive study that evaluated a panel of guanidino compounds on several cell systems involved in vascular damage, SDMA most consistently induced pro-inflammatory effects in various types of leukocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Removal of guanidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The generation of the guanidines synthesized from arginine in the proximal convoluted tubule, such as guanidinoacetic acid and creatine, is depressed in ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/46\">",
"     46",
"    </a>",
"    ]. The reported concentration of guanidinoacetic acid is not elevated among uremic individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/7\">",
"     7",
"    </a>",
"    ]. On the other hand, the synthesis of guanidino succinic acid, guanidine, and methylguanidine is markedly increased, which appears to be due to urea recycling. The reported concentrations of guanidino succinic acid and methylguanidine are increased in uremia compared with normal concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/7\">",
"     7",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef85916 \" href=\"mobipreview.htm?18/13/18652\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Dialytic removal of the guanidines, despite possessing a low molecular weight, is not consistently comparable to that of urea. Many of these compounds display different intradialytic behavior, suggesting a pluricompartmental distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/24,47\">",
"     24,47",
"    </a>",
"    ]. In the absence of protein binding, this behavior points to a retardation in the transfer of these molecules from inside to outside of cells. Based on kinetic modeling calculations, these findings have been confirmed from direct estimations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/23\">",
"     23",
"    </a>",
"    ]. Further mathematical analysis revealed that increasing dialysis time was the preferred strategy to improve removal of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/5/31826?source=see_link\">",
"     guanidine",
"    </a>",
"    compounds that had larger distribution volumes (such as methylguanidine for example), whereas more frequent dialysis preferably impacted upon compounds with a smaller distribution volume (such as guanidino succinic acid) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/48\">",
"     48",
"    </a>",
"    ]. Optimal results were obtained with a combination of daily and long slow dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Removal of ADMA is less dependent on renal excretion than on metabolic transformation which is inhibited in renal failure. Enhancing metabolism might decrease ADMA concentration. Proof of principle is suggested by studies that showed that genetic overexpression of the ADMA-degrading enzyme, dimethylarginine dimethylaminohydrolase, was cardioprotective in mice following heart transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/49\">",
"     49",
"    </a>",
"    ]. Furthermore, since the transmethylation reaction catalyzed by this enzyme is stimulated by lowering homocysteine levels, ADMA concentration was decreased by co-administration of intravenous methylcobalamin and oral folate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/50\">",
"     50",
"    </a>",
"    ]. These data illustrate how uremic solutes may influence each others&rsquo; concentration, and how removal depends not only on renal function and dialysis, but also on metabolism, which can be influenced externally by administration of drugs, vitamins or nutritional additives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oxalate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive oxalate retention is uncommon in dialyzed patients, except in primary hyperoxaluria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/51\">",
"     51",
"    </a>",
"    ]. In this disorder, production is increased due to genetically mediated alterations of oxalate metabolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among ESRD patients without primary hyperoxaluria, serum oxalate concentrations are increased approximately 40-fold, compared with healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/52\">",
"     52",
"    </a>",
"    ]. Secondary oxalosis in such patients is characterized by the deposition of calcium oxalate in multiple tissues, which was mostly observed in early renal replacement therapy with inefficient dialysis strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, such findings may be seen among those with excessive intake of oxalate precursors, including ascorbic acid, green leafy vegetables, rhubarb, tea, chocolate, or beets. In addition, those with inflammatory bowel disease are at risk for this complication.",
"   </p>",
"   <p>",
"    The role of pyridoxine (vitamin B6) in uremic oxalate accumulation remains a matter of debate. In rats with renal failure, pyridoxine depletion results in increased urine oxalate excretion and depressed renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/54\">",
"     54",
"    </a>",
"    ]. In hemodialysis patients, pyridoxine at 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    causes a decrease in oxalate concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/55\">",
"     55",
"    </a>",
"    ]. However, such high doses of pyridoxine may induce gastrointestinal intolerance.",
"   </p>",
"   <p>",
"    Dialytic removal of oxalate is similar to that of urea and, therefore, is relatively easy with any of the classic dialysis strategies. However, since removal is lower than in healthy controls, serum concentrations remain higher than normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Phosphorus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high serum concentration of phosphates is clearly related to pruritus and hyperparathyroidism, both manifestations of the uremic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/57\">",
"     57",
"    </a>",
"    ]. Phosphorus excess also inhibits 1 alpha-hydroxylase and hence the production of calcitriol, the active vitamin D metabolite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/58\">",
"     58",
"    </a>",
"    ]. Phosphorus retention also alters polyamine metabolism by causing a decrease in intestinal dysfunction and proliferation of intestinal villi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least in animals, phosphate restriction has an attenuating effect on the progression of renal failure. The results are less compelling in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/60\">",
"     60",
"    </a>",
"    ]. However, dietary phosphate restriction reduces PTH levels over a wide range of serum calcium concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/61\">",
"     61",
"    </a>",
"    ]. In observational studies, high serum phosphorus is linked to mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/62\">",
"     62",
"    </a>",
"    ]. The same applies also for low serum phosphorus, very likely because low phosphorus is an indicator of inadequate nutritional status.",
"   </p>",
"   <p>",
"    Blood phosphorus concentration is the result of protein catabolism and protein intake as well as of the ingestion of other dietary sources. Restriction of oral protein intake increases the risk of malnutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/57\">",
"     57",
"    </a>",
"    ], which can be avoided by the administration of oral phosphate binders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26822?source=see_link\">",
"     \"Chapter 6G: Calcium and phosphate metabolism in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of the latter, however, is often insufficient, especially in subjects with high intake. One major effect related to hyperphosphatemia is the increase in serum Ca x P product resulting in Ca deposition in the tissues, especially the vessel wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/62\">",
"     62",
"    </a>",
"    ], which is a negative prognostic factor in patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/64\">",
"     64",
"    </a>",
"    ]. Of note, however, Ca x P product was abandoned by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on Chronic Kidney Disease",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    Metabolic Bone Disease",
"    <span class=\"nowrap\">",
"     (CKD/MBD)",
"    </span>",
"    as it was considered a mathematic artifact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/65\">",
"     65",
"    </a>",
"    ]. This does not exclude the individual roles of both Ca and P in vascular disease of CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/65\">",
"     65",
"    </a>",
"    ]. Application of calcium-containing intestinal phosphate binders may decrease P, but this effect may be counterbalanced by a rise in Ca.",
"   </p>",
"   <p>",
"    The newer generation of phosphate binders, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     Sevelamer",
"    </a>",
"    and Lanthanum, provides one of the solutions to this problem. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Dialytic removal of phosphate is unpredictable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/22\">",
"     22",
"    </a>",
"    ] and often followed by impressive rebounds, which is due to the release of intracellular phosphate stores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/66\">",
"     66",
"    </a>",
"    ]. Slower dialysis techniques may allow a better control of phosphate levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .) In a study strictly controlling all other dialysis parameters, for example, an increase of high-flux dialysis duration from four to eight hours was accompanied by a time-dependent rise in phosphate removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic acidosis can contribute to some of the abnormalities in end-stage renal disease. Metabolic acidosis can cause muscle wasting and bone mineral loss and, in children, impair growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=see_link\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although serum creatinine is a marker for renal function, only limited data suggest that this substance is associated with adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/4\">",
"     4",
"    </a>",
"    ]. These effects, such as chloride channel interference, are only reported at creatinine levels not observed with chronic kidney disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Polyamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyamines, which are measured at increased levels in uremia, may contribute to anorexia, vomiting, and adverse central nervous system effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROTEIN-BOUND COMPOUNDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     P-cresol and p-cresylsulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;P-cresol, a phenol with a molecular weight of only 108 D, has been considered the prototype of lipophilic uremic protein-bound toxins. Because of their strong protein binding, their removal by classical dialysis is hampered, with removal of small water-soluble molecules being completely different [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/21,70\">",
"     21,70",
"    </a>",
"    ]. It is therefore conceivable that alternative removal methods (eg, adsorption or convective transport) should be developed before adequate elimination of these toxins can be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, evidence underscores conjugates of p-cresol, p-cresylsulfate and p-cresylglucuronate, and not p-cresol are present in the blood of patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/70,72\">",
"     70,72",
"    </a>",
"    ]. Previous repeated measurements of p-cresol were related to the fact that most determination methods applied strong acidification for deproteinization, a measure resulting in deconjugation of p-cresylsulfate and p-cresylglucuronate by hydrolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Since this hydrolysis is conceivably proportional to the quantity of conjugates available, former p-cresol measurements as well as estimations of protein binding are likely proportional to what would have been found by direct measurement of the conjugates. However, this issue needs further exploration.",
"   </p>",
"   <p>",
"    High-flux dialysis, compared to low-flux dialysis, has no beneficial effect on the removal of these toxins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/21,71\">",
"     21,71",
"    </a>",
"    ]. However, compared with peritoneal dialysis, p-cresol is cleared better with high-flux hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/75\">",
"     75",
"    </a>",
"    ]. Nevertheless, the plasma concentrations of protein-bound toxins is lower in patients on peritoneal dialysis compared with those on hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]; these findings cannot be explained by differences in dietary protein intake or residual renal function, suggesting a role for metabolism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intestinal handling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    P-cresol is an end-product of protein catabolism, produced by intestinal bacteria that metabolize tyrosine and phenylalanine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/78\">",
"     78",
"    </a>",
"    ]. Environmental sources of p-cresol are toluene, menthofuran, and cigarette smoke. Specific concern is warranted regarding menthofuran, which is present in several herbal medicines, flavoring agents, and psychedelic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/79\">",
"     79",
"    </a>",
"    ]. In view of the known role of the intestine in the generation of p-cresol and its conjugates, several approaches that interfere with intestinal generation of these toxins have been studied and shown to decrease their concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'General removal strategies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In several studies, p-cresol concentration was related to parameters of clinical outcome, including hospitalization rate (particularly due to infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/74\">",
"     74",
"    </a>",
"    ], clinical symptoms of the uremic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/73\">",
"     73",
"    </a>",
"    ], mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/81\">",
"     81",
"    </a>",
"    ], and cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The same associations were also demonstrated with p-cresylsulfate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/84,85\">",
"     84,85",
"    </a>",
"    ], and existed among patients with earlier stages of CKD (2 to 4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/86\">",
"     86",
"    </a>",
"    ]. The latter observation suggests that protein-bound solutes may exert a toxic effect on the general population or at least those not affected by marked kidney disease. In a prospective observational analysis, p-cresylsulfate and indoxyl sulfate were independently associated with progression of CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a paucity of data on the biochemical effect of the conjugates. In one study, it was demonstrated that p-cresylsulfate stimulated baseline leukocyte activity, thereby pointing to a pro-inflammatory effect, whereas the parent compound p-cresol essentially inhibits activated leukocyte function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/88\">",
"     88",
"    </a>",
"    ]. Another report found that retained p-Cresol and p-cresyl sulfate altered endothelial function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the conjugates are present in the blood stream, it remains unclear whether, under some conditions, they may not be reconverted to p-cresol intracellularly, especially since certain cell types such as the leukocytes contain sulfatases and glucuronidases.",
"   </p>",
"   <p>",
"    Previously, only a few studies that examined how to improve removal of the phenols by extracorporeal strategies were performed. One study showed superior dialytic clearance of p-cresol by high-flux hemodialysis compared to peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/75\">",
"     75",
"    </a>",
"    ], although, as noted previously, plasma concentrations were lower in PD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/77\">",
"     77",
"    </a>",
"    ]. Among dialysis strategies, convective approaches were more efficient compared with diffusive ones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By applying combined fractionated plasma separation and adsorption, removal of p-cresol could be markedly enhanced, a strategy currently used as an artificial liver (Prometheus&reg;, Fresenius Medical Care) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/92\">",
"     92",
"    </a>",
"    ]. Unfortunately, the approach applied in this study resulted in major coagulation disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/93\">",
"     93",
"    </a>",
"    ]. However, the study offers proof that adsorption may become an additional asset in the removal of this type of compound.",
"   </p>",
"   <p>",
"    As far as convective strategies are concerned, it was shown that postdilution and predilution hemodiafiltration were not different regarding removal of p-cresylsulfate. Both hemodiafiltration strategies were superior to predilution hemodiafiltration for p-cresylsulfate and other protein-bound compounds, whereas postdilution hemodiafiltration was superior to predilution hemodiafiltration for all other types of uremic retention solutes (ie, the small water soluble compounds and the larger \"middle molecules\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are studies in animals suggesting that intestinal bacterial production and intestinal uptake of p-cresol can be altered. As an example, prevention of the intestinal absorption of p-cresol by administration of oral sorbents decreased its serum concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/95\">",
"     95",
"    </a>",
"    ]. In a mouse model of CKD,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    hydrochloride administration had no impact on the concentration of any of the protein-bound compounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/96\">",
"     96",
"    </a>",
"    ] and the same was observed in a subsequent study in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/97\">",
"     97",
"    </a>",
"    ]. Dietary intake may alter the generation of p-cresylsulfate. In one study of 26 individuals with normal renal function, the average p-cresylsulfate excretion (reflecting generation) was 62 percent lower among vegetarians than among participants on an unrestricted diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Homocysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homocysteine (Hcy) is a sulphur-containing amino acid produced by the demethylation of methionine. Its retention with uremia results in the cellular accumulation of S-adenosyl homocysteine (AdoHcy), an extremely toxic compound that competes with S-adenosyl-methionine (AdoMet) and inhibits methyltransferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/99\">",
"     99",
"    </a>",
"    ]. Hyperhomocysteinemia also disturbs epigenetic control of gene expression by inducing macromolecule hypomethylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/100\">",
"     100",
"    </a>",
"    ]. Guanidino compounds modify serum albumin in a way that protein binding of homocysteine is decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with chronic renal failure have total serum Hcy levels two- to fourfold above those observed in normal individuals. In addition to the degree of renal failure, its serum concentration also depends upon nutritional intake (eg, of methionine), vitamin status (eg, of folate), and genetic factors.",
"   </p>",
"   <p>",
"    Moderate hyperhomocysteinemia is an independent risk factor for cardiovascular disease in the general population and is a prevalent cardiovascular risk factor in patients with ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=see_link\">",
"     \"Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .) It may also be present at increased concentrations in kidney transplant recipients with cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/5/37977?source=see_link\">",
"     \"Risk factors for cardiovascular disease in the renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hcy increases the proliferation of vascular smooth muscle cells, one of the most prominent hallmarks of atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/104\">",
"     104",
"    </a>",
"    ]. The administration of excess quantities of the Hcy precursor methionine to rats induces atherosclerosis-like alterations in the aorta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/105\">",
"     105",
"    </a>",
"    ]. Hcy also disrupts several vessel wall-related anticoagulant functions, resulting in enhanced thrombogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/106\">",
"     106",
"    </a>",
"    ]. A detailed discussion of the proatherogenic effects of hyperhomocysteinemia is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hcy levels can be moderately reduced by the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , vitamin B6,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin B12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/107\">",
"     107",
"    </a>",
"    ]. To reduce Hcy, patients with ESRD may require higher quantities of vitamins than the nonuremic population.",
"   </p>",
"   <p>",
"    Direct clinical proof of the benefit of decreasing Hcy concentration in uremia was not previously available. In addition, low rather than high levels of Hcy were associated with poor outcome in two large observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. However, one study found that correction for poor nutritional status and inflammation as confounders permitted the demonstration that homocysteine was directly related to mortality in the population without chronic inflammation-malnutrition state (CIMS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/110\">",
"     110",
"    </a>",
"    ]. This relationship was masked in patients with CIMS. Vascular events were not reduced in two large randomized controlled trials that effectively lowered homocysteine by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and B vitamins in patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/111,112\">",
"     111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the HOST trial, a randomized double blind evaluation in approximately 2000 patients, active homocysteine lowering therapy also appeared to have no different impact on outcome compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/111\">",
"     111",
"    </a>",
"    ]. However, the placebo group was allowed to take",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplements at their discretion, which casts some doubt on the purity of the placebo group. In addition, only one-third of patients had their homocysteine levels normalized. A German trial that included more than 600 patients, demonstrated no benefit with increased intake of folic acid, vitamin B6 and vitamin B12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/113\">",
"     113",
"    </a>",
"    ]. However, a meta-analysis by the same authors suggested a benefit in reducing cardiovascular disease associated with the vitamin preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/114\">",
"     114",
"    </a>",
"    ]. Many studies were small in this meta-analysis, which detracted slightly from the credibility of the final analysis.",
"   </p>",
"   <p>",
"    Dialytic removal of Hcy is thought to be hampered in a similar way as the other protein-bound uremic toxins. Dialysis with the extremely open (\"super flux\") dialysis membranes, however, could decrease homocysteine concentrations, possibly due to a modification of metabolism, rather than to direct removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Indoles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indoxyl sulfate is metabolized by the liver from indole, which is produced by the intestinal flora as a metabolite of tryptophan. Indoxyl sulfate, which is secreted in the normal kidney by organic anion transporter 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/116\">",
"     116",
"    </a>",
"    ], enhances drug toxicity by competition with acidic drugs at protein binding sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/117\">",
"     117",
"    </a>",
"    ] and inhibits the active tubular secretion of these compounds as well as the deiodination of thyroxine 4 (T4) by cultured hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/118,119\">",
"     118,119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uremic retention solutes induce glomerular sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/120\">",
"     120",
"    </a>",
"    ], with their removal by peritoneal dialysis or by oral sorbent administration retarding the progression of intact nephron loss. Indoxyl sulfate may be one of these possible uremic toxins. The oral administration of indole or of indoxyl sulfate to uremic rats causes a faster progression of glomerular sclerosis and renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. In renal tubular cells, indoxyl sulfate induces free radical production, NF-kappaB activation, and upregulation of plasminogen activator inhibitor-1 (PAI-1) expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/123\">",
"     123",
"    </a>",
"    ]. Among patients on peritoneal dialysis, indoxyl sulfate was correlated with interleukin-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/124\">",
"     124",
"    </a>",
"    ]. Risk factors of atherosclerosis are associated with indoxyl sulfate concentration in hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/125\">",
"     125",
"    </a>",
"    ]. In a study that included patients with CKD stages 2 to 5, serum indoxyl sulfate was predictive of mortality, even after adjustment for major cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelial cell dysfunction is common in uremia. Indoxyl sulfate may play a role by inhibiting endothelial cell proliferation and repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/127\">",
"     127",
"    </a>",
"    ], while it induces a significant production of free radical species in endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/128\">",
"     128",
"    </a>",
"    ]. Endothelial dysfunction induced by indoxyl sulfate is also illustrated by an increase in microparticle release by cultured endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/129\">",
"     129",
"    </a>",
"    ]. In a rat model, indoxyl sulfate was demonstrated to stimulate vascular smooth muscle cell proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/130\">",
"     130",
"    </a>",
"    ]. Indoxyl sulfate also has direct pro-fibrotic, pro-hypertrophic and pro-inflammatory effects on cardiac fibroblasts and myocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that indoxyl sulfate plays a role in aortic calcification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/132\">",
"     132",
"    </a>",
"    ],and elements of bone dysfunction, such as resistance to PTH, osteoblast dysfunction and downregulation of pathways of parathyroid hormone gene expression and low turn-over bone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/133-135\">",
"     133-135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indoles are found in various plants and herbs, and some are also produced by the intestinal flora. Several metabolites are retained in uremia, and kinetic behavior appears to differ among the indoles. Some of these substances do not even conform to the definition of uremic retention solutes, as their concentration is low in patients with stage 5 (ESRD) (eg, tryptophan, melatonin).",
"   </p>",
"   <p>",
"    Removal of protein-bound indoles is hampered during dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/21\">",
"     21",
"    </a>",
"    ]. It does not correlate with that of urea or creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/22\">",
"     22",
"    </a>",
"    ]. In conventional hemodialysis, super-flux triacetate membrane was superior to low flux cellulose triacetate regarding removal of indoxyl sulfate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/136\">",
"     136",
"    </a>",
"    ]. In a group of CKD patients not yet on dialysis, the adsorbent AST-120 (Kremezin R) actively decreased indoxyl sulfate in a dose dependent way, as appreciated from a short-term prospective dose finding study. There were no differences in decline of kidney function, however, possibly due to the short observation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, in a prospective observational analysis, p-cresylsulfate and indoxyl sulfate were independently associated with progression of CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/87\">",
"     87",
"    </a>",
"    ]. In controlled studies with a long follow-up period, the group on AST-120 showed a slower decline of eGFR, was started later on dialysis, and survived longer once dialysis was started [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/138-140\">",
"     138-140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral administration of bifidobacteria in gastro-resistant capsules modifying intestinal flora to hemodialysis patients reduces serum levels of indoxyl sulfate by correcting gastrointestinal flora [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/141\">",
"     141",
"    </a>",
"    ]. Dietary intake may also alter serum levels of indoxyl sulfate. In the study cited above of 26 individuals with normal renal function, the average indoxyl sulfate excretion (reflecting generation) was 58 percent lower among vegetarians than among participants on an unrestricted diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Furanpropionic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF), a urofuranic fatty acid, is a strongly lipophilic uremic solute and a major inhibitor of drug protein binding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/118\">",
"     118",
"    </a>",
"    ]. This toxin inhibits the renal uptake of para-amino hippuric acid (PAH) in rat kidney cortical slices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/142\">",
"     142",
"    </a>",
"    ] and causes a decrease in renal excretion of various drugs, metabolites, and endogenously produced organic acids that are removed via the PAH pathway. In vivo renal CMPF clearance in the rat is inhibited by PAH and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/143\">",
"     143",
"    </a>",
"    ]. CMPF also inhibits hepatic glutathione-S-transferase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/144\">",
"     144",
"    </a>",
"    ], deiodination of T4 by cultured hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/119\">",
"     119",
"    </a>",
"    ], and ADP-stimulated oxidation of NADH-linked substrates in isolated mitochondria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a correlation between neurologic abnormalities and the plasma concentration of CMPF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/146\">",
"     146",
"    </a>",
"    ]. Since CMPF is virtually 100 percent protein-bound, its removal by hemodialysis strategies is virtually nonexistent. CMPF levels can be lowered substantially only with peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MIDDLE MOLECULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Middle molecules, arbitrarily defined as those of a molecular weight (MW) in excess of 500 D were previously thought responsible for the uremic syndrome. However, at the time of the formulation of the middle molecule hypothesis, it was extremely difficult to isolate specific responsible molecules.",
"   </p>",
"   <p>",
"    Nevertheless, several clinical, metabolic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biochemical disturbances are caused by uremic compounds with MWs in this middle molecule range:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromatographic fractions of uremic ultrafiltrate with a MW between 1 and 5 kD inhibit appetite and suppress food intake in animals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/148\">",
"       148",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 500 to 2000 D subfraction of uremic serum inhibits apolipoprotein (apo) A-I secretion in a human hepatoma cell line [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A compound of MW between 750 and 900 D inhibits osteoblast mitogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/150\">",
"       150",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By now, more than 20 compounds have been identified that conform to the strict definition of middle molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/8\">",
"     8",
"    </a>",
"    ]. Several of those have biological effects, especially a pro-inflammatory impact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dialysis membranes with a capacity to remove middle molecules (high flux membranes) have been related to lower morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/151-155\">",
"     151-155",
"    </a>",
"    ]. However, all these data have been collected in observational studies.",
"   </p>",
"   <p>",
"    In the HEMO study, there was no significant improvement in overall survival with high-flux membranes (removing middle molecules) compared to low-flux membranes (with virtually no removal of middle molecules) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/15\">",
"     15",
"    </a>",
"    ]. Upon secondary analysis, however, a benefit for high-flux membranes was found for cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/15\">",
"     15",
"    </a>",
"    ], with the difference especially marked for patients who had been dialyzed for more than 3.7 years prior to enrollment in the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, based on data collected during the HEMO study, it was shown that, independent of the membrane used, beta2-microglobulin concentrations were directly related to mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In another subanalysis of the HEMO study, a decrease in cerebrovascular events was observed for dialysis with high flux compared with low flux membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent to the HEMO study, two other studies showed superiority of high flux regarding outcome. Although both analyses were based on prospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/157,158\">",
"     157,158",
"    </a>",
"    ], the evaluation of flux was performed by secondary analysis and results are therefore less robust, since the primary endpoints in those studies were not directly related to dialysis. In both studies, the superiority of high flux was demonstrated.",
"   </p>",
"   <p>",
"    The next study in this context is the membrane permeability outcome (MPO) study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/28,159\">",
"     28,159",
"    </a>",
"    ]. This study compares high flux versus low flux in European hemodialysis patients. A superior outcome for the high flux membrane was shown in patients with a serum albumin below 4",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    the subgroup of dialysis patients for whom the study protocol originally had been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/28,159\">",
"     28,159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As yet, there are no large randomized controlled trials evaluating impact on outcome of further increasing middle molecule removal by convective strategies, although RCTs are pending [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/160\">",
"     160",
"    </a>",
"    ]. In an observational analysis of a Dialysis Outcome Practice Patterns Study (DOPPS) cohort, superiority of high volume hemodiafiltration was suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/161\">",
"     161",
"    </a>",
"    ]. A limited controlled trial showed borderline survival superiority for on-line hemofiltration over low flux hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/162\">",
"     162",
"    </a>",
"    ]. An Italian multicentric study showed superiority of convective strategies with regards to intra-dialytic hemodynamic stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Beta2-microglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta2-microglobulin (&szlig;2M) (MW of approximately 12,000 D) is a component of the major histocompatibility antigen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .) Dialysis-related amyloid, which can be observed in patients being maintained on long-term dialysis, is to a large extent composed of &szlig;2M. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .) Nevertheless, some patients may suffer from amyloidosis after only one to two years of dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/164,165\">",
"     164,165",
"    </a>",
"    ]. Since the last 15 years, a decline in incidence of dialysis-related amyloidosis has been recorded, at least in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/166\">",
"     166",
"    </a>",
"    ], likely reflecting an improvement of dialysis quality, especially of dialysis water.",
"   </p>",
"   <p>",
"    Advanced glycosylation end products may affect the pathophysiologic impact of &szlig;2M. AGE-modified &szlig;2M has been identified in amyloid of hemodialyzed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/167\">",
"     167",
"    </a>",
"    ]; it also enhances monocytic migration and cytokine secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/168\">",
"     168",
"    </a>",
"    ], suggesting that foci containing AGE-&szlig;2M may initiate inflammatory response, leading to",
"    <span class=\"nowrap\">",
"     bone/joint",
"    </span>",
"    destruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/167,168\">",
"     167,168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum &szlig;2M levels may be lower in peritoneal dialysis (PD) patients than in hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/169\">",
"     169",
"    </a>",
"    ]. This may be due to a better conservation of endogenous residual renal function with PD, since PD alone poorly clears &szlig;2-microglobulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/75\">",
"     75",
"    </a>",
"    ]. Although the clinical expression of dialysis-related amyloidosis disappears after kidney transplantation, the underlying pathological processes, such as bone cysts and tissue &szlig;2M deposits, remain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/170\">",
"     170",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In prospective studies, a progressive decline of predialysis &szlig;2M-levels has frequently been demonstrated in patients dialyzed with membranes with a larger pore size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/171\">",
"     171",
"    </a>",
"    ]. The question arises whether this removal is sufficient to prevent the development of &szlig;2M-amyloid. In a retrospective study, AN69 dialyzers with a large pore size were associated with a lower prevalence of amyloid disease than small pore cuprophane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/172\">",
"     172",
"    </a>",
"    ]. However, cuprophane also induces a more profound inflammatory reaction, which is known to enhance the development of amyloid disease.",
"   </p>",
"   <p>",
"    Because &szlig;2M is only removed by dialyzers with large pore size, it may be representative of other large molecules in its kinetic behavior. Apart from its role in amyloidosis, the biological impact of &szlig;2M seems minor.",
"   </p>",
"   <p>",
"    Finally, a post-hoc analysis of the HEMO study found that serum &szlig;2M levels correlated with mortality, with each 10",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    increase in predialysis level being associated with an 11 percent increase for all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/26\">",
"     26",
"    </a>",
"    ]. Later analysis revealed that this mortality was related to infectious causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/27\">",
"     27",
"    </a>",
"    ]. This result may lend support to using &szlig;2M levels as a marker for middle molecule clearance.",
"   </p>",
"   <p>",
"    Theoretically, long daily hemodiafiltration may provide optimal clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/173\">",
"     173",
"    </a>",
"    ]. Prolonging only high flux dialysis time, however, already causes a significant increase in removal of &szlig;2M [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid hormone (PTH), a middle molecule with a MW of approximately 9000 D, is generally recognized as a major uremic toxin. However, its increase in concentration during ESRD is attributable to enhanced glandular secretion, rather than to decreased removal by the kidneys. Excess PTH gives rise to an increase in intracellular calcium, resulting in disturbances in the function of virtually every organ system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A downregulation of",
"    <span class=\"nowrap\">",
"     PTH/PTHrP",
"    </span>",
"    receptor mRNA expression is observed in the liver, kidney, and heart of rats with advanced chronic renal failure, thereby blunting the cellular response to excess PTH and creating resistance to PTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/175\">",
"     175",
"    </a>",
"    ]. Parathyroidectomy does not entirely prevent",
"    <span class=\"nowrap\">",
"     PTH/PTHrP",
"    </span>",
"    receptor downregulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/176\">",
"     176",
"    </a>",
"    ], suggesting that this alteration depends on more than elevated PTH alone.",
"   </p>",
"   <p>",
"    The increased PTH concentration in uremia is the result of a number of compensatory homeostatic mechanisms. Hyperparathyroidism results at least in part from phosphate retention, decreased production of calcitriol (1,25-dihydroxyvitamin D), and hypocalcemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Advanced glycosylation end products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose and other reducing sugars react non-enzymatically with free amino groups to be converted after weeks into advanced glycosylation end (AGE) products through chemical rearrangements and dehydration reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/177\">",
"     177",
"    </a>",
"    ]. Several AGE compounds are peptide-linked degradation products (MW 2000 to 6000 D) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/178\">",
"     178",
"    </a>",
"    ]. Among the postulated structures for AGE are imidazolone, pyrrole aldehyde, pentosidine, and N epsilon-(carboxymethyl)lysine.",
"   </p>",
"   <p>",
"    The increased accumulation of AGE is not the result of enhanced glucose levels or reduced removal of modified proteins by glomerular filtration. With uremia, it is more likely due to increased concentrations of small carbonyl precursors. Thus, uremia can be described as a status of increased carbonyl stress, resulting from increased oxidation or decreased detoxification of these carbonyl compounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/179\">",
"     179",
"    </a>",
"    ]. Together, these processes help result in increased levels of AGE products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/179\">",
"     179",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AGE products affect multiple processes. These compounds:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cause an inflammatory reaction in monocytes by the induction of IL-6, TNF-alpha, and interferon-gamma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/180\">",
"       180",
"      </a>",
"      ]. Pro-inflammatory effects had previously been demonstrated with artificially prepared AGEs. A similar pro-inflammatory impact was present with genuine AGEs as they were accumulated in uremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/181\">",
"       181",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Modify &szlig;2M, which (as previously mentioned) may play an important role in the formation of dialysis-related amyloid.",
"     </li>",
"     <li>",
"      React with and chemically inactivate nitric oxide (NO), a potent endothelium-derived vasodilator, antiaggregant, and antiproliferative factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/182\">",
"       182",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Induce oxidative protein modification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/183\">",
"       183",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to renal failure, AGE products are also retained in diabetes mellitus and aging, settings in which they have been implicated in tissue damage and functional disturbances. Specific receptors for AGE products have also been identified (RAGE), with their expression being enhanced during moderate uremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/184\">",
"     184",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is unclear whether all AGE products retained in uremia have a biological impact. It is also unknown whether one AGE product is kinetically representative for the molecules of the group. Pentosidine has been advanced as a marker for these compounds; however, with respect to dialysis, inhomogeneous behavior of pentosidine has been demonstrated, a finding that parallels what is known for uremic toxins in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/185\">",
"     185",
"    </a>",
"    ]. In an observational study, high, rather than low, carboxymethyllysine levels were linked to better outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/186\">",
"     186",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This group of molecules highlights growing interest to dialytically remove more of the larger molecules that are retained in uremia, perhaps including more specific removal via adsorption columns.",
"   </p>",
"   <p>",
"    Removal is also more efficient with membranes with a larger pore size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/187\">",
"     187",
"    </a>",
"    ]. This includes protein-leaking dialyzers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/188\">",
"     188",
"    </a>",
"    ]. This was shown in one study in which two groups of 13 hemodialysis patients were treated for six months with protein-leaking and non-protein-leaking dialyzers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/188\">",
"     188",
"    </a>",
"    ]. A significant decrease in total pentosidine values was observed with protein-leaking dialyzers (-43 percent), a decrease not observed with the other dialyzer.",
"   </p>",
"   <p>",
"    This removal could counterbalance some of the deleterious effects of AGE accumulation (eg, apolipoprotein B production) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/189\">",
"     189",
"    </a>",
"    ]. Whether this removal will be sufficient to neutralize the clinical complications potentially attributed to the AGE is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other middle molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kinetic behavior with dialysis of molecules with a MW above 12 kD should be comparable to that of the somewhat smaller middle molecules. Several peptides of MW above 12 kD, which can be recovered from uremic sera, ultrafiltrate, or PD dwell fluid, dampen various polymorphonuclear cells functions involved in the killing of invading bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/190,191\">",
"     190,191",
"    </a>",
"    ]. The exact concentrations in uremic sera or biological fluids were not reported in these studies.",
"   </p>",
"   <p>",
"    Leptin, a 16 kD plasma protein that suppresses appetite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/192\">",
"     192",
"    </a>",
"    ], and induces weight reduction in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/193\">",
"     193",
"    </a>",
"    ], is retained in renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/194\">",
"     194",
"    </a>",
"    ]. The increase in serum leptin levels is almost entirely due to a rise in free (non-protein-bound) concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/194\">",
"     194",
"    </a>",
"    ]; it has been suggested to play a role in the decreased appetite of uremic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .) However, there are conflicting findings concerning the possible biochemical role of leptin in renal failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased leptin is associated with low protein intake and loss of lean tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/195\">",
"       195",
"      </a>",
"      ]. Data suggest an inverse correlation in uremia between leptin and indices of nutritional status such as serum albumin or lean body mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/196\">",
"       196",
"      </a>",
"      ] and a direct correlation with C-reactive protein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/197\">",
"       197",
"      </a>",
"      ] (CRP).",
"     </li>",
"     <li>",
"      However, leptin levels are also elevated in obese people and are not necessarily related to reduced appetite. Body fat and serum leptin correlate positively in uremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/197\">",
"       197",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33591?source=see_link\">",
"     \"Leptin and end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dinucleoside polyphosphates are molecules characterized by the presence of two nucleotides at the extremes, linked by a variable number (mostly 2 to 6) of phosphates. They have a molecular weight of approximately 1000 Dalton, and are protein-bound. The diadenosine polyphosphates induce proliferation of smooth muscle cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/198,199\">",
"     198,199",
"    </a>",
"    ] and enhance free radical production by leukocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/200\">",
"     200",
"    </a>",
"    ]. Uridine adenosine tetraphosphate is a strong vasoconstrictor, which is released by endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/201\">",
"     201",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further middle molecules of potential importance are complement factor D, adrenomedullin, atrial natriuretic peptide (ANP), ghrelin, resistin, immunoglobulin light chains, neuropeptide Y, and various cytokines. Plasma interleukin-6 is independently associated with mortality in patients with CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/202\">",
"     202",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     GENERAL REMOVAL STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main strategies that have been used up to now to decrease uremic solute concentration are conventional hemodialysis and peritoneal dialysis. However, dialysis is nonspecific and also removes essential compounds. In addition, lipophilic compounds, which may be responsible at least in part for functional alterations in uremia, are inadequately removed by current dialysis strategies.",
"   </p>",
"   <p>",
"    With maintenance hemodialysis, treatment with high flux membranes was suggested to provide superior removal of middle molecules, possibly resulting in improved survival. However, the HEMO study found no overall survival difference with high versus low flux membranes at primary analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/15\">",
"     15",
"    </a>",
"    ]. However, differences were found for the entire cohort in cardiovascular mortality, and in the subgroup treated for &gt;3.7 years upon enrollment, for overall mortality with secondary analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/25\">",
"     25",
"    </a>",
"    ]. In the same database, a direct relation between &szlig;2-microglobulin concentration and mortality was also demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, the MPO trial described above subsequently demonstrated better outcomes associated with high flux compared with low flux membranes in the population with serum albumin &lt;4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/28\">",
"     28",
"    </a>",
"    ]. Of note, this low serum albumin group composes a large section of the current population on dialysis.",
"   </p>",
"   <p>",
"    Adding convection by increasing ultrafiltration and equivoluminous substitution with sterile saline or ultrapure dialysate (hemodiafiltration), further adds to middle molecule removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/203-205\">",
"     203-205",
"    </a>",
"    ]. In an observational analysis of the DOPPS database, a survival advantage for convection was found, at least if sufficient exchange volumes were pursued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/161\">",
"     161",
"    </a>",
"    ]. Large exchange volumes can be obtained if ultrapure dialysate is used for substitution (on-line hemodiafiltration). A study comparing convective strategies at strictly identical conditions showed superiority of post-dilution hemodiafiltration and predilution hemofiltration as far as &szlig;2M removal was concerned. Post-dilution hemodiafiltration was superior when considering other aspects of solute removal (small water soluble and protein-bound compounds) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/94\">",
"     94",
"    </a>",
"    ]. At present, there are no large controlled studies showing better survival with this strategy. A limited Italian study showed better outcomes associated with on line hemofiltration compared with low flux dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/162\">",
"     162",
"    </a>",
"    ]. A larger Italian multicenter study showed superiority of convective strategies with regards to hemodynamic stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/163\">",
"     163",
"    </a>",
"    ]. A large controlled Dutch outcome study is under way [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A previously ignored component of adequate dialysis is the treatment time. Lower morbidity and mortality are observed in patients submitted to long dialysis sessions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/206,207\">",
"     206,207",
"    </a>",
"    ]. Compounds may be cleared more efficiently with continuous or long-lasting strategies, because removal is more gradual. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .) In a strictly comparable setting for all dialysis parameters except treatment length, prolonging high flux hemodialysis from four to eight hours resulted in a time-dependent increase in beta2M removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/67\">",
"     67",
"    </a>",
"    ]. However prolonging hemodialysis did not decrease protein bound solutes in a similar study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/208\">",
"     208",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimal removal for each type of molecule may be obtained with a different type of extracorporeal treatment, eg, by using large pore membranes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dialyzers or devices with a high adsorptive capacity for some or several of the uremic toxins. This includes, for example, protein-leaking membranes, which are designed to allow passage of albumin, other similarly-sized proteins, and uremic toxins in the 35 to 60 kD size range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/209\">",
"     209",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Removal is also influenced by intestinal intake (especially for the protein bound solutes) and preservation of renal function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal uptake can be reduced by influencing dietary uptake, or by oral administration of absorbents. Approaches that have been shown to result in a decrease in concentration include a low protein diet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/98,210\">",
"       98,210",
"      </a>",
"      ], administration of prebiotics such as resistant starch [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/211\">",
"       211",
"      </a>",
"      ], or probiotics such as bifidobacterium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/80,212\">",
"       80,212",
"      </a>",
"      ]. The active intestinal sorbent AST-120 (Kremezin R) has essentially been associated with absorption of indoxyl sulfate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/137\">",
"       137",
"      </a>",
"      ], and subsequent preservation of renal function, but this substance also absorbs p-cresol as well as other compounds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/95,213\">",
"       95,213",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preservation of residual renal function may also be an important manner to pursue additional removal of retention solutes. Residual renal function was better preserved after administering the sorbent AST-120 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/87,138,139\">",
"       87,138,139",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, it should be considered that in uremia, not only strategies decreasing solute concentration are important, but interventions countering their biological impact also play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/6\">",
"     6",
"    </a>",
"    ]. Typically, this can be obtained with already developed drugs, such as ACE inhibitors in neutralizing Ca-influx due to SDMA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/214\">",
"     214",
"    </a>",
"    ], but also with drugs still to be developed, and reaches a much broader population than with removal strategies, ie, not only the 0.1 to 0.2 percent of the global population with stage 5 CKD, but all those with stage 3 CKD or more (5 to 10 percent). Similarly, interventions increasing metabolic degradation of toxic solutes may be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uremic syndrome is a complex mosaic of clinical alterations that may be attributable to one or more of these different solutes. Knowledge about the nature and kinetic behavior of the responsible compounds may help when new therapeutic options are considered in the future.",
"   </p>",
"   <p>",
"    The following factors, which have frequently been neglected, may interfere with uremic solute concentrations and their impact on biological functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to classical sources of uremic solutes such as dietary protein breakdown, alternative sources such as environmental contact, food additives, natural stimulants (coffee, tea), intake of herbal medicines, or addiction to psychedelic drugs may play a role in uremic toxicity.",
"     </li>",
"     <li>",
"      Many solutes with toxic capacity enter the body through the intestine. Changes in the composition of intestinal flora, or changes in intestinal production, absorption, transfer, and metabolization may alter serum concentration of these toxins.",
"     </li>",
"     <li>",
"      Some uremic solutes interfere with functions that directly affect the biochemical action of other solutes: eg, the expression of PTH receptors, the response to 1,25(OH)2 vitamin D3, as well as the protein binding and break-down of several other solutes.",
"     </li>",
"     <li>",
"      Most patients with renal failure use multiple medications. Interference of drugs with protein binding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tubular secretion of uremic solutes influences their biological effect.",
"     </li>",
"     <li>",
"      Lipophilic compounds may be responsible at least in part for functional alterations in uremia; they are inadequately removed by current dialysis strategies.",
"     </li>",
"     <li>",
"      The main strategy that has been used up to now to decrease uremic solute concentration is dialysis. However, dialysis is nonspecific and also removes essential compounds.",
"     </li>",
"     <li>",
"      Uremic solutes accumulate not only in the plasma but also in the cells, where most of the biological activity is exerted. Removal of intracellular compounds during dialysis through the cell membrane may be hampered, resulting in multicompartmental kinetics and inadequate detoxification, unless dialysis length",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      frequency are increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lower morbidity and mortality are observed in patients submitted to long dialysis sessions, although the data mentioned have been obtained in an uncontrolled setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/206,207\">",
"     206,207",
"    </a>",
"    ]. A controlled trial demonstrated a positive impact of frequent nocturnal hemodialysis versus conventional dialysis on left ventricular mass and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/215\">",
"     215",
"    </a>",
"    ]. A randomized controlled trial compared six times weekly to thrice weekly hemodialysis over a 12 month follow-up period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/216\">",
"     216",
"    </a>",
"    ]. Six times weekly dialysis was associated with a decrease in the primary outcome which was a composite of death or change in left ventricular mass, and with improved control of hypertension. Compounds may be cleared more efficiently with continuous or long-lasting low efficiency strategies, because removal is more gradual. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biochemical alterations are provoked by a broad spectrum of compounds:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some are small and water-soluble (eg, urea, the guanidines, phosphate, oxalate)",
"     </li>",
"     <li>",
"      Some are lipophilic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      protein-bound (eg, p-cresylsulfate, CMPF, homocysteine, indoles)",
"     </li>",
"     <li>",
"      Some are larger and in the middle molecule range (eg, &szlig;2M, PTH, AGE products).",
"     </li>",
"     <li>",
"      Some compounds from one group may impact generation and behavior of compounds from another group (eg, guanidines increasing generation of tumor necrosis factor-alpha (TNF-a)) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/24/37258/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Optimal removal for each type of molecule may be obtained with a different type of extracorporeal treatment, eg, by using large pore membranes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dialyzers or devices with a high adsorptive capacity for some or several of the uremic toxins. Adsorption with the dialysis devices currently available is of little importance. More specific devices with large surface areas must be developed before adequate adsorption can be obtained.",
"   </p>",
"   <p>",
"    Removal is also influenced by intestinal intake and preservation of renal function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal uptake can be reduced by influencing dietary uptake, by oral administration of absorbents, or by influencing intestinal flora by administration of prebiotics or probiotics.",
"     </li>",
"     <li>",
"      Preservation of residual renal function may also be an important manner to pursue additional removal of retention solutes.",
"     </li>",
"     <li>",
"      Therapeutic intervention includes administration of drugs countering biological impact of uremic solutes and reaching a much larger population than with removal strategies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, the choice of marker molecules for uremic retention and dialytic removal should be reconsidered. It has become increasingly evident that the current markers, which are all small water-soluble compounds (urea, creatinine), are not always representative in their kinetic behavior for middle molecules,",
"    <span class=\"nowrap\">",
"     lipophilic/protein-bound",
"    </span>",
"    compounds, and even some other hydrosoluble compounds.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/1\">",
"      Vanholder R, De Smet R, Hsu C, et al. Uremic toxicity: the middle molecule hypothesis revisited. Semin Nephrol 1994; 14:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/2\">",
"      Vanholder R, Argil&eacute;s A, Baurmeister U, et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001; 24:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/3\">",
"      Vanholder R, Glorieux G, De Smet R, et al. New insights in uremic toxins. Kidney Int Suppl 2003; :S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/4\">",
"      Yavuz A, Tetta C, Ersoy FF, et al. Uremic toxins: a new focus on an old subject. Semin Dial 2005; 18:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/5\">",
"      Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007; 357:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/6\">",
"      Vanholder R, Baurmeister U, Brunet P, et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008; 19:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/7\">",
"      Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/8\">",
"      Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/9\">",
"      Vanholder R, De Smet R, Lameire NH. Redesigning the map of uremic toxins. Contrib Nephrol 2001; :42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/10\">",
"      Lim J, Gasson C, Kaji DM. Urea inhibits NaK2Cl cotransport in human erythrocytes. J Clin Invest 1995; 96:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/11\">",
"      Prabhakar SS, Zeballos GA, Montoya-Zavala M, Leonard C. Urea inhibits inducible nitric oxide synthase in macrophage cell line. Am J Physiol 1997; 273:C1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/12\">",
"      Kraus LM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001; 78:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/13\">",
"      Lee JA, Lee HA, Sadler PJ. Uraemia: is urea more important than we think? Lancet 1991; 338:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/14\">",
"      Johnson WJ, Hagge WW, Wagoner RD, et al. Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 1972; 47:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/15\">",
"      Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/16\">",
"      Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/17\">",
"      Vanholder RC, Ringoir SM. Adequacy of dialysis: a critical analysis. Kidney Int 1992; 42:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/18\">",
"      Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1982; 21:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/19\">",
"      Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/20\">",
"      Fagugli RM, De Smet R, Buoncristiani U, et al. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002; 40:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/21\">",
"      Lesaffer G, De Smet R, Lameire N, et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000; 15:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/22\">",
"      Vanholder RC, De Smet RV, Ringoir SM. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992; 38:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/23\">",
"      Eloot S, Torremans A, De Smet R, et al. Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis 2007; 50:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/24\">",
"      Eloot S, Torremans A, De Smet R, et al. Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int 2005; 67:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/25\">",
"      Cheung AK, Levin NW, Greene T, et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003; 14:3251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/26\">",
"      Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/27\">",
"      Cheung AK, Greene T, Leypoldt JK, et al. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/28\">",
"      Locatelli F, Martin-Malo A, Hannedouche T, et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/29\">",
"      Hirayama A, Noronha-Dutra AA, Gordge MP, et al. Inhibition of neutrophil superoxide production by uremic concentrations of guanidino compounds. J Am Soc Nephrol 2000; 11:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/30\">",
"      Glorieux GL, Dhondt AW, Jacobs P, et al. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004; 65:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/31\">",
"      Schepers E, Glorieux G, Dou L, et al. Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation. Blood Purif 2010; 30:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/32\">",
"      De Deyn PP, Macdonald RL. Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture. Ann Neurol 1990; 28:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/33\">",
"      Asaka M, Iida H, Izumino K, Sasayama S. Depressed natural killer cell activity in uremia. Evidence for immunosuppressive factor in uremic sera. Nephron 1988; 49:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/34\">",
"      Perna AF, Ingrosso D, Satta E, et al. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. J Am Soc Nephrol 2004; 15:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/35\">",
"      Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/36\">",
"      MacAllister RJ, Rambausek MH, Vallance P, et al. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996; 11:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/37\">",
"      Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269:H1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/38\">",
"      Anderstam B, Katzarski K, Bergstr&ouml;m J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997; 8:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/39\">",
"      Zoccali C, Bode-B&ouml;ger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/40\">",
"      Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/41\">",
"      Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/42\">",
"      Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/43\">",
"      Kielstein JT, B&ouml;ger RH, Bode-B&ouml;ger SM, et al. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004; 62:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/44\">",
"      Bode-B&ouml;ger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/45\">",
"      Glorieux G, Schepers E, Schindler R, et al. A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test. Nephrol Dial Transplant 2009; 24:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/46\">",
"      Levillain O, Marescau B, de Deyn PP. Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy. Kidney Int 1995; 47:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/47\">",
"      De Deyn PP, Robitaille P, Vanasse M, et al. Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. Correlations between nerve conduction velocities and altered guanidino compound concentrations. Nephron 1995; 69:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/48\">",
"      Eloot S, van Biesen W, Dhondt A, et al. Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis. Nephrol Dial Transplant 2009; 24:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/49\">",
"      Tanaka M, Sydow K, Gunawan F, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/50\">",
"      Koyama K, Ito A, Yamamoto J, et al. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. Am J Kidney Dis 2010; 55:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/51\">",
"      Marangella M, Petrarulo M, Cosseddu D, et al. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis 1992; 19:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/52\">",
"      Marangella M, Vitale C, Petrarulo M, et al. Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int 1995; 48:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/53\">",
"      Salyer WR, Hutchins GM. Cardiac lesions in secondary oxalosis. Arch Intern Med 1974; 134:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/54\">",
"      Wolfson M, Cohen AH, Kopple JD. Vitamin B-6 deficiency and renal function and structure in chronically uremic rats. Am J Clin Nutr 1991; 53:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/55\">",
"      Morgan SH, Maher ER, Purkiss P, et al. Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine. Nephrol Dial Transplant 1988; 3:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/56\">",
"      Marangella M, Bagnis C, Bruno M, et al. Determinants of oxalate balance in patients on chronic peritoneal dialysis. Am J Kidney Dis 1993; 21:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/57\">",
"      Coburn JW, Salusky IB. Control of serum phosphorus in uremia. N Engl J Med 1989; 320:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/58\">",
"      Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis 1995; 25:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/59\">",
"      Imanishi Y, Koyama H, Inaba M, et al. Phosphorus intake regulates intestinal function and polyamine metabolism in uremia. Kidney Int 1996; 49:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/60\">",
"      Loghman-Adham M. Role of phosphate retention in the progression of renal failure. J Lab Clin Med 1993; 122:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/61\">",
"      Combe C, Aparicio M. Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 1994; 46:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/62\">",
"      Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/63\">",
"      Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989; 320:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/64\">",
"      Verbeke F, Van Biesen W, Honkanen E, et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol 2011; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/65\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/66\">",
"      Haas T, Hillion D, Dongradi G. Phosphate kinetics in dialysis patients. Nephrol Dial Transplant 1991; 6 Suppl 2:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/67\">",
"      Eloot S, Van Biesen W, Dhondt A, et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008; 73:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/68\">",
"      Lefebvre A, de Vernejoul MC, Gueris J, et al. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989; 36:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/69\">",
"      Boirie Y, Broyer M, Gagnadoux MF, et al. Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure. Kidney Int 2000; 58:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/70\">",
"      Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16:3430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/71\">",
"      Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004; 44:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/72\">",
"      de Loor H, Bammens B, Evenepoel P, et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/73\">",
"      Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/74\">",
"      De Smet R, Van Kaer J, Van Vlem B, et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003; 49:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/75\">",
"      Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006; 70:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/76\">",
"      Pham NM, Recht NS, Hostetter TH, Meyer TW. Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 2008; 3:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/77\">",
"      Vanholder R, Meert N, Van Biesen W, et al. Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes? Nat Clin Pract Nephrol 2009; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/78\">",
"      De Smet R, Glorieux G, Hsu C, Vanholder R. p-cresol and uric acid: two old uremic toxins revisited. Kidney Int Suppl 1997; 62:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/79\">",
"      Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 1996; 124:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/80\">",
"      Schepers E, Glorieux G, Vanholder R. The gut: the forgotten organ in uremia? Blood Purif 2010; 29:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/81\">",
"      Bammens B, Evenepoel P, Keuleers H, et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/82\">",
"      Meijers BK, Bammens B, De Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/83\">",
"      Meijers BK, Claes K, Bammens B, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/84\">",
"      Liabeuf S, Barreto DV, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/85\">",
"      Wang CP, Lu LF, Yu TH, et al. Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis 2010; 211:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/86\">",
"      Massy ZA, Barreto DV, Barreto FC, Vanholder R. Uraemic toxins for consideration by the cardiologist-Beyond traditional and non-traditional cardiovascular risk factors. Atherosclerosis 2010; 211:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/87\">",
"      Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011; 26:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/88\">",
"      Schepers E, Meert N, Glorieux G, et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22:592.",
"     </a>",
"    </li>",
"    <li>",
"     Meijers, BK, Van kerckhoven, S, Verbeke, K, et al. The uremic retention solute p-Cresyl Sulfate and markers of endothelial damage.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/90\">",
"      Meert N, Beerenhout C, Schepers E, et al. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009; 22:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/91\">",
"      Meert N, Waterloos MA, Van Landschoot M, et al. Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration. Artif Organs 2010; 34:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/92\">",
"      Meijers BK, Weber V, Bammens B, et al. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs 2008; 32:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/93\">",
"      Meijers BK, Verhamme P, Nevens F, et al. Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant 2007; 7:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/94\">",
"      Meert N, Eloot S, Waterloos MA, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009; 24:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/95\">",
"      Niwa T, Ise M, Miyazaki T, Meada K. Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 1993; 65:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/96\">",
"      Phan O, Ivanovski O, Nguyen-Khoa T, et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/97\">",
"      Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010; 25:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/98\">",
"      Patel KP, Luo FJ, Plummer NS, et al. The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol 2012; 7:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/99\">",
"      Perna AF, Ingrosso D, De Santo NG, et al. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995; 47:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/100\">",
"      van Guldener C, Stehouwer CD. Hyperhomocysteinaemia and vascular disease--a role for DNA hypomethylation? Lancet 2003; 361:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/101\">",
"      Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/102\">",
"      Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/103\">",
"      Massy ZA, Chadefaux-Vekemans B, Chevalier A, et al. Hyperhomocysteinaemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994; 9:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/104\">",
"      Tsai, C, Perrella, MA, Yoshizumi, M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1992; 91:10193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/105\">",
"      Matthias D, Becker CH, Riezler R, Kindling PH. Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 1996; 122:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/106\">",
"      Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr 1996; 126:1285S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/107\">",
"      Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/108\">",
"      Kalantar-Zadeh K, Block G, Humphreys MH, et al. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/109\">",
"      Busch M, Franke S, M&uuml;ller A, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004; 66:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/110\">",
"      Ducloux D, Klein A, Kazory A, et al. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006; 69:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/111\">",
"      Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 298:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/112\">",
"      Mann JF, Sheridan P, McQueen MJ, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. Nephrol Dial Transplant 2008; 23:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/113\">",
"      Heinz J, Kropf S, Domr&ouml;se U, et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010; 121:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/114\">",
"      Heinz J, Kropf S, Luley C, Dierkes J. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis 2009; 54:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/115\">",
"      De Vriese AS, Langlois M, Bernard D, et al. Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. Nephrol Dial Transplant 2003; 18:2596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/116\">",
"      Deguchi T, Ohtsuki S, Otagiri M, et al. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int 2002; 61:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/117\">",
"      Vanholder R, Van Landschoot N, De Smet R, et al. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 1988; 33:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/118\">",
"      Depner TA. Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. Kidney Int 1981; 20:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/119\">",
"      Lim CF, Bernard BF, de Jong M, et al. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993; 76:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/120\">",
"      Motojima M, Nishijima F, Ikoma M, et al. Role for \"uremic toxin\" in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/121\">",
"      Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/122\">",
"      Enomoto A, Takeda M, Tojo A, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002; 13:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/123\">",
"      Motojima M, Hosokawa A, Yamato H, et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003; 63:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/124\">",
"      Lee CT, Kuo CC, Chen YM, et al. Factors associated with blood concentrations of indoxyl sulfate and p-cresol in patients undergoing peritoneal dialysis. Perit Dial Int 2010; 30:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/125\">",
"      Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007; 27:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/126\">",
"      Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/127\">",
"      Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/128\">",
"      Dou L, Jourde-Chiche N, Faure V, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007; 5:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/129\">",
"      Faure V, Dou L, Sabatier F, et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost 2006; 4:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/130\">",
"      Yamamoto H, Tsuruoka S, Ioka T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006; 69:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/131\">",
"      Lekawanvijit S, Adrahtas A, Kelly DJ, et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/132\">",
"      Adijiang A, Goto S, Uramoto S, et al. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008; 23:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/133\">",
"      Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, et al. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 2005; 20:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/134\">",
"      Iwasaki Y, Yamato H, Nii-Kono T, et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006; 21:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/135\">",
"      Nii-Kono T, Iwasaki Y, Uchida M, et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007; 71:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/136\">",
"      De Smet R, Dhondt A, Eloot S, et al. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 2007; 22:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/137\">",
"      Schulman G, Agarwal R, Acharya M, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/138\">",
"      Akizawa T, Asano Y, Morita S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009; 54:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/139\">",
"      Ueda H, Shibahara N, Takagi S, et al. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007; 11:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/140\">",
"      Ueda H, Shibahara N, Takagi S, et al. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008; 30:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/141\">",
"      Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 2003; 41:S142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/142\">",
"      Henderson SJ, Lindup WE. Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 1992; 263:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/143\">",
"      Costigan MG, Lindup WE. Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. Kidney Int 1996; 49:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/144\">",
"      Mabuchi H, Nakahashi H. Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. Nephron 1988; 49:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/145\">",
"      Niwa T, Aiuchi T, Nakaya K, et al. Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. Clin Nephrol 1993; 39:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/146\">",
"      Costigan MG, Callaghan CA, Lindup WE. Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4- methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron 1996; 73:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/147\">",
"      Niwa T, Yazawa T, Kodama T, et al. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 1990; 56:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/148\">",
"      Anderstam B, Mamoun AH, S&ouml;dersten P, Bergstr&ouml;m J. Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat. J Am Soc Nephrol 1996; 7:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/149\">",
"      Kamanna VS, Kashyap ML, Pai R, et al. Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol 1994; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/150\">",
"      Andress DL, Howard GA, Birnbaum RS. Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. Kidney Int 1991; 39:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/151\">",
"      Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/152\">",
"      Chandran PK, Liggett R, Kirkpatrick B. Patient survival on PAN/AN69 membrane hemodialysis: a ten year analysis. Kidney Int Suppl 1993; 41:S287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/153\">",
"      Koda Y, Nishi S, Miyazaki S, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/154\">",
"      Leypoldt JK, Cheung AK, Carroll CE, et al. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999; 33:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/155\">",
"      Port FK, Wolfe RA, Hulbert-Shearon TE, et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the usrds dialysis morbidity and mortality study. Am J Kidney Dis 2001; 37:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/156\">",
"      Delmez JA, Yan G, Bailey J, et al. Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Am J Kidney Dis 2006; 47:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/157\">",
"      Krane V, Krieter DH, Olschewski M, et al. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 2007; 49:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/158\">",
"      Chauveau P, Nguyen H, Combe C, et al. Dialyzer membrane permeability and survival in hemodialysis patients. Am J Kidney Dis 2005; 45:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/159\">",
"      Locatelli F, Hannedouche T, Jacobson S, et al. The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. J Nephrol 1999; 12:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/160\">",
"      Penne EL, Blankestijn PJ, Bots ML, et al. Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients - the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]. Curr Control Trials Cardiovasc Med 2005; 6:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/161\">",
"      Canaud B, Bragg-Gresham JL, Marshall MR, et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/162\">",
"      Santoro A, Mancini E, Bolzani R, et al. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial. Am J Kidney Dis 2008; 52:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/163\">",
"      Locatelli F, Altieri P, Andrulli S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 2010; 21:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/164\">",
"      Jadoul M, Garbar C, No&euml;l H, et al. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Kidney Int 1997; 51:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/165\">",
"      Jadoul M, Garbar C, Vanholder R, et al. Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int 1998; 54:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/166\">",
"      Schwalbe S, Holzhauer M, Schaeffer J, et al. Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis? Kidney Int 1997; 52:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/167\">",
"      Niwa T, Sato M, Katsuzaki T, et al. Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 1996; 50:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/168\">",
"      Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994; 93:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/169\">",
"      Assounga A, Canaud B, Flavier JL, et al. [What does circulating beta 2 microglobulin signify in uremic patients on maintenance dialysis?]. Nephrologie 1987; 8:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/170\">",
"      Mourad G, Argil&eacute;s A. Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol 1996; 7:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/171\">",
"      Locatelli F, Mastrangelo F, Redaelli B, et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/172\">",
"      van Ypersele de Strihou C, Jadoul M, Malghem J, et al. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991; 39:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/173\">",
"      Raj DS, Ouwendyk M, Francoeur R, Pierratos A. beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 2000; 15:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/174\">",
"      Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994; 14:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/175\">",
"      Ure&ntilde;a P, Kubrusly M, Mannstadt M, et al. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 1994; 45:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/176\">",
"      Ure&ntilde;a P, Mannstadt M, Hruby M, et al. Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kidney Int 1995; 47:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/177\">",
"      Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/178\">",
"      Papanastasiou P, Grass L, Rodela H, et al. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/179\">",
"      Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of \"carbonyl stress\" in long-term uremic complications. Kidney Int 1999; 55:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/180\">",
"      Imani F, Horii Y, Suthanthiran M, et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993; 178:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/181\">",
"      Glorieux G, Helling R, Henle T, et al. In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 2004; 66:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/182\">",
"      Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/183\">",
"      Witko-Sarsat V, Friedlander M, Capeill&egrave;re-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/184\">",
"      Abel M, Ritthaler U, Zhang Y, et al. Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant 1995; 10:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/185\">",
"      Henle T, Deppisch R, Beck W, et al. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999; 14:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/186\">",
"      Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/187\">",
"      Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/188\">",
"      Galli F, Benedetti S, Floridi A, et al. Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 2005; 67:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/189\">",
"      Fishbane S, Bucala R, Pereira BJ, et al. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 1997; 52:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/190\">",
"      H&ouml;rl WH, Haag-Weber M, Georgopoulos A, Block LH. Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci U S A 1990; 87:6353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/191\">",
"      Tschesche H, Kopp C, H&ouml;rl WH, Hempelmann U. Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 1994; 269:30274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/192\">",
"      Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/193\">",
"      Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/194\">",
"      Sharma K, Considine RV, Michael B, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/195\">",
"      Young GA, Woodrow G, Kendall S, et al. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition? Nephrol Dial Transplant 1997; 12:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/196\">",
"      Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 1998; 9:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/197\">",
"      Heimb&uuml;rger O, L&ouml;nnqvist F, Danielsson A, et al. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997; 8:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/198\">",
"      Jankowski J, Hagemann J, Yoon MS, et al. Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int 2001; 59:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/199\">",
"      Jankowski V, Karadogan S, Vanholder R, et al. Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells. Kidney Int 2007; 71:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/200\">",
"      Schepers E, Glorieux G, Jankowski V, et al. Dinucleoside polyphosphates: newly detected uraemic compounds with an impact on leucocyte oxidative burst. Nephrol Dial Transplant 2010; 25:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/201\">",
"      Jankowski V, T&ouml;lle M, Vanholder R, et al. Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med 2005; 11:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/202\">",
"      Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010; 77:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/203\">",
"      Lornoy W, Becaus I, Billiouw JM, et al. Remarkable removal of beta-2-microglobulin by on-line hemodiafiltration. Am J Nephrol 1998; 18:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/204\">",
"      Maduell F, del Pozo C, Garcia H, et al. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999; 14:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/205\">",
"      Ward RA, Schmidt B, Hullin J, et al. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000; 11:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/206\">",
"      Charra B, Calemard M, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol 1996; 16:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/207\">",
"      Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/208\">",
"      Basile C, Libutti P, Di Turo AL, et al. Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slow-flow bicarbonate haemodialysis. Nephrol Dial Transplant 2011; 26:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/209\">",
"      Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol 2005; 16:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/210\">",
"      Ling WH, H&auml;nninen O. Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. J Nutr 1992; 122:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/211\">",
"      Birkett A, Muir J, Phillips J, et al. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 1996; 63:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/212\">",
"      Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 2005; 15:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/213\">",
"      Kikuchi K, Itoh Y, Tateoka R, et al. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/214\">",
"      Schepers E, Glorieux G, Dhondt A, et al. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 2009; 24:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/215\">",
"      Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/24/37258/abstract/216\">",
"      FHN Trial Group, Chertow GM, Levin NW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363:2287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1916 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-6DBE490E2D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37258=[""].join("\n");
var outline_f36_24_37258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SMALL WATER-SOLUBLE COMPOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Urea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Marker of dialysis adequacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Guanidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nitric oxide and guanidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Removal of guanidines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oxalate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Phosphorus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Creatinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Polyamines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROTEIN-BOUND COMPOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      P-cresol and p-cresylsulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Homocysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Indoles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Furanpropionic acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MIDDLE MOLECULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Beta2-microglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Advanced glycosylation end products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other middle molecules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      GENERAL REMOVAL STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1916\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1916|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/13/18652\" title=\"table 1\">",
"      Concentration of uremic solutes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11657?source=related_link\">",
"      Chapter 12B: Renal potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26822?source=related_link\">",
"      Chapter 6G: Calcium and phosphate metabolism in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33591?source=related_link\">",
"      Leptin and end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/0/29703?source=related_link\">",
"      Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/5/37977?source=related_link\">",
"      Risk factors for cardiovascular disease in the renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_24_37259="Antimicrobial treatment erysipelas";
var content_f36_24_37259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial therapy for erysipelas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        For adults",
"       </td>",
"       <td class=\"subtitle1\">",
"        For children age &gt;28 days*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Oral therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin",
"       </td>",
"       <td>",
"        500 mg orally every 6 hours",
"       </td>",
"       <td>",
"        25 to 50 mg/kg per day orally in 3 or 4 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amoxicillin",
"       </td>",
"       <td>",
"        500 mg orally every 8 hours",
"       </td>",
"       <td>",
"        25 to 50 mg/kg per day orally in 3 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        250 mg orally every 6 hours",
"       </td>",
"       <td>",
"        30 to 50 mg/kg per day orally in 2 to 4 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Parenteral therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        1 g intravenously every 24 hours",
"       </td>",
"       <td>",
"        50 to 75 mg/kg per day intravenously in 1 or 2 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefazolin",
"       </td>",
"       <td>",
"        1 to 2 g intravenously every 8 hours",
"       </td>",
"       <td>",
"        100 mg/kg per day intravenously in 3 doses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Maximum single dose should not exceed dose for adults.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     May not be adequate therapy in areas with relatively high resistance rates among beta-hemolytic streptococci.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37259=[""].join("\n");
var outline_f36_24_37259=null;
var title_f36_24_37260="PFT interpretation in children";
var content_f36_24_37260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guide for pulmonary function interpretation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Restrictive",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Obstructive",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Combined",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Lung",
"volumes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total lung capacity (TLC)",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        Normal or &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vital capacity",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        Normal or &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Residual volume (RV)",
"       </td>",
"       <td>",
"        Normal or &darr;",
"       </td>",
"       <td>",
"        Normal or &uarr;",
"       </td>",
"       <td>",
"        Normal or &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        RV/TLC ratio",
"       </td>",
"       <td>",
"        Normal or &uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Maximal",
"expiratory flow rates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FEV1",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FEV1:FVC",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FEF 25%-75%",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peak expiratory flow",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flow-volume curve",
"       </td>",
"       <td>",
"        &darr; Volume",
"       </td>",
"       <td>",
"        &darr; Flows",
"       </td>",
"       <td>",
"        &darr; Flows and volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchodilator response",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        &uarr; Flows",
"       </td>",
"       <td>",
"        Normal or &uarr; flows",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Gas",
"exchange",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DLCO",
"       </td>",
"       <td>",
"        Normal or &darr;",
"       </td>",
"       <td>",
"        Normal or &uarr;",
"       </td>",
"       <td>",
"        Normal, &uarr;, or &darr;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; FEF 25%-75%: forced expiratory flow rate between 25 percent and 75 percent of the exhaled vital capacity; DLCO: carbon monoxide-diffusing capacity.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Fraire, JA, Keens, TG. Pulmonary function tests in children: Guidelines for interpretation. J Respir Dis Pediatricians 2003; 5:211. Copyright &copy; 2003 Cliggott Publishing Group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37260=[""].join("\n");
var outline_f36_24_37260=null;
var title_f36_24_37261="Ventilation in pregnancy";
var content_f36_24_37261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Changes in ventilation during pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 227px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time course of percent increases in minute ventilation, oxygen uptake, and basal metabolism during pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Prowse, CM, Gaensler, EA, Anesthesiology 1965; 26:381.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37261=[""].join("\n");
var outline_f36_24_37261=null;
var title_f36_24_37262="Causes nonimmune hydrops";
var content_f36_24_37262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with nonimmune hydrops",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cardiovascular",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Malformation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Left heart hypoplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Atrioventricular canal defect",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Right heart hypoplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Closure of foramen ovale",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Single ventricle",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Transposition of the great arteries",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Ventricular septal defect",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Atrial septal defect",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Tetralogy of Fallot",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Ebstein's anomaly",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Premature closure of ductus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Truncus arteriosus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Aortic or pulmonary stenosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Valvular insufficiency",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          AV canal defect",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Tachyarrhythmia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Atrial flutter",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Paroxysmal atrial tachycardia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Wolff-Parkinson-White",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Supraventricular tachycardia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bradyarrhythmia including complete heart block",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Other arrhythmia (eg, long QT)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          High-output failure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Neuroblastoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Sacrococcygeal teratoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Large fetal angioma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Placental chorioangioma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Umbilical cord hemangioma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cardiac tumors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Other cardiac neoplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cardiomyopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cardiosplenic syndromes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Aneuploidy and structural abnormalities of chromosomes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          45, X",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trisomy 21",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trisomy 18",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trisomy 13",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          18q +",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          13q -",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          45,X mosaic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Triploidy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          17q -",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Duplicated 11p",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chondrodysplasias",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thanatophoric dysplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Short rib polydactyly",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypophosphatasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Osteogenesis imperfecta",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Achondrogenesis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Camptomelic dysplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lethal chondroplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Homozygous achondroplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Twin pregnancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Twin-twin transfusion syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acardiac twin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Hematologic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Alpha-thalassemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fetomaternal transfusion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Parvovirus B19 infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          In utero hemorrhage",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glucose-6-phosphate dehydrogenase (G6PD) deficiency",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Red cell enzyme deficiencies",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thrombosis of major vessels",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Leukemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Red cell aplasias",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pyruvate kinase deficiency",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Thoracic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Congenital cystic adenomatoid malformation of lung",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diaphragmatic hernia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intrathoracic mass",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary sequestration",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chylothorax",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Airway obstruction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary lymphangiectasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary neoplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bronchogenic cyst",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Infections",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytomegalovirus (CMV)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Toxoplasmosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Parvovirus B19 (fifth disease)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Syphilis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Herpes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rubella",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Coxsackievirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Leptospirosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trypanosoma cruzi",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Malformation sequences and genetic syndromes",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Congenital lymphedema, eg, Noonan's syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Arthrogryposis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Multiple pterygium syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neu-Laxova syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pena-Shokeir syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Myotonic dystrophy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Saldino-Noonan syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Francois syndrome, type III",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Familial Nuchal Bleb",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acrocephalopolydactylous dysplasia (Elejalde syndrome)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thoracoabdominal syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lymphedema distichiasis syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Metabolic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gaucher's disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          GM",
"          <sub>",
"           1",
"          </sub>",
"          gangliosidosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sialidosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hurler syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mucopolysaccharide (MPS) IVa",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mucolipidosis type I+II",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Galactosialidosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Urinary",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Urethral stenosis or atresia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Posterior urethral valves",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Congenital nephrosis (Finnish type)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Prune belly syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Gastrointestinal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Midgut volvulus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Malrotation of the intestines",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Duplication of the intestinal tract",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Meconium peritonitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hepatic fibrosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cholestasis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Biliary atresia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hepatic vascular malformations",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hepatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hepatic necrosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Liver tumors or cysts",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37262=[""].join("\n");
var outline_f36_24_37262=null;
var title_f36_24_37263="Hypoechoic nodule";
var content_f36_24_37263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypoechoic nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a transverse view of the thyroid gland (T) that shows a 3.2 X 1.2 cm hypoechoic, pre-tracheal nodule (+ --- +) in the right lobe/isthmus (I). A tracheal cartilage (TC) is seen anterior to air-artifact in the trachea, which obscures the image and the structures deep to it. Muscles are seen (M). A 14.0 MHz transducer was used.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_24_37263=[""].join("\n");
var outline_f36_24_37263=null;
